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Abstract 
Group A Streptococcus (GAS; group A streptococci; Streptococcus pyogenes) is a 
globally significant bacterial pathogen. The primary biological host for GAS is 
humans, and GAS is responsible for a plethora of non-invasive and invasive 
infections. Generally, GAS colonisation of superficial tissue sites, including the 
epidermal surface of the skin or the mucosal epithelium of the upper respiratory 
tract, results in non-invasive conditions such as impetigo and pharyngitis. Less 
commonly, GAS can gain access and disseminate into more sterile tissue areas. This 
leads to invasive life-threatening conditions, including necrotising fasciitis and 
streptococcal toxic shock syndrome, which involve destruction of the skin and soft 
tissue. Infection with GAS can also give rise to delayed nonsuppurative sequelae, 
such as rheumatic fever and acute glomerulonephritis, which are responsible for high 
rates of morbidity and mortality worldwide. The last comprehensive study assessing 
the global impact of diseases attributable to GAS estimated over 500,000 deaths per 
annum, placing this bacterium among the world’s most significant human pathogens. 
In the past few decades, there has been an increase in the severity and incidence of 
invasive GAS disease in Western countries, though currently it remains endemic in 
developing nations and Indigenous populations.  
Subversion of the host plasminogen activation system is critical for streptococcal 
virulence. Central to this system is the blood-circulating zymogen plasminogen, that 
is activated to plasmin by host activators, urokinase plasminogen activator (uPA) or 
tissue plasminogen activator (tPA), as well as by bacterial activators, including the 
secreted GAS protein streptokinase. GAS recruits plasminogen to the bacterial cell 
surface via multiple cell surface receptors, and activation of bound plasminogen 
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results in plasmin-coated GAS. Under physiological conditions, plasmin is strictly 
regulated by circulating inhibitors such as 2-antiplasmin, however under certain 
circumstances, plasmin localised at the GAS cell surface is protected from inhibition. 
Consequently, GAS can acquire an unregulated source of potent proteolytic activity 
at its cell surface, which is believed to facilitate the breakdown of host tissue barriers 
and extracellular matrix components (ECM). The human innate immune system 
serves as a protective shield against invading microbes during the early stages of 
infection. Plasmin-mediated immune evasion has recently emerged as a key 
mechanism in bacterial pathogenesis. In order to establish systemic infection, GAS 
must overcome the bactericidal effects of complement, a fundamental component of 
the innate immune response. A number of human pathogens have thwarted the 
complement system via either binding plasminogen directly to the cell surface or 
expressing plasminogen activators; both mechanisms result in proteolytic plasmin 
activity. Bacterial-generated plasmin has been shown to degrade essential 
components of the complement system, thereby preventing complement-driven 
phagocytosis, and enhancing the survival of the organism. However, there is limited 
knowledge on the impact of plasminogen activation and plasmin acquisition by GAS 
on host innate immunity. Furthermore, for a wide range of pathogenic 
microorganisms, surface bound plasminogen can be converted to plasmin by uPA 
and tPA, with the resulting plasmin activity facilitating host invasion by the 
bacterium. Streptokinase-generated plasmin activation has been thoroughly studied, 
however, the contribution of host activators to GAS pathogenesis has yet to be 
explored. To further clarify the role of the fibrinolytic system in GAS virulence, this 
project used two clinically important GAS isolates to investigate the impact of 
plasminogen activation and cell surface plasmin acquisition on the host innate 
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immune response to GAS, and elucidate the contribution of uPA and tPA to invasive 
GAS disease. 
Several bacterial species have demonstrated the ability to modulate the functions of 
C3b, a key opsonin. One consequence of C3b deposition on the bacterial cell surface 
is complement-mediated neutrophil killing. We demonstrate that the acquisition of 
plasmin to the GAS cell surface results in degradation of C3b, and this was 
correlated with a significant decrease in C3b opsonisation and neutrophil killing in 
vitro. Further, in a transgenic humanised plasminogen mouse model of GAS 
infection, the ability of GAS to accumulate cell surface plasmin was associated with 
reduced C3b deposition, neutrophil phagocytosis, and increased bacterial survival in 
vivo. Our findings highlight a significant role for cell-bound plasmin in protecting 
GAS from complement-mediated neutrophil killing, and provide new insight for the 
mechanisms involved during the early phases of invasive GAS infection.  
We next assessed the role of uPA-mediated plasminogen activation in GAS 
pathogenesis. In the absence of streptokinase, uPA can facilitate GAS cell surface 
plasmin acquisition during incubation with human plasminogen in vitro, and in 
human plasma ex vivo. Using a newly described transgenic humanised plasminogen 
uPA-knockout mouse model, the absence of host uPA significantly increased mice 
survival compared to wild-type mice following subcutaneous GAS infection. This 
correlated with the reduced ability of GAS to disseminate in vivo, and accumulate 
cell surface plasmin ex vivo in the absence of uPA. Given the key contribution of 
uPA in GAS virulence, we explored the therapeutic potential of commercial and 
previously undescribed uPA inhibitors to block uPA-mediated plasminogen 
activation. Minimal inhibitory concentration data demonstrated that these inhibitors 
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displayed antimicrobial activity against GAS, and enhanced potency against uPA 
activity in vitro. However, treatment with these inhibitors did not delay or prevent 
the progression of invasive GAS disease in this particular mouse model of infection.  
The absence of uPA and streptokinase did not completely abrogate GAS virulence in 
the humanised mouse plasminogen infection model, suggesting a potential role for 
tPA in GAS disease. Whilst we confirmed that tPA can facilitate plasminogen 
activation at the bacterial cell surface in vitro, the absence of tPA did not have an 
impact on bacterial dissemination, or mice survival in humanised plasminogen tPA-
knockout mice compared to wild-type mice post-GAS infection. Similarly, no 
differences were observed in skin lesion size, or the pathology of GAS infection in 
the absence of tPA. While we cannot completely dismiss the role of tPA during GAS 
virulence, these data suggest that tPA plays a limited role in this particular mouse 
model of infection, and further highlights the significance of uPA and streptokinase 
during the course of GAS infection.  
The findings in this project define a new role for the acquisition of plasmin(ogen) in 
evasion of the host innate immune response, and establishes a role for uPA, but not 
tPA, in a mouse model of invasive GAS disease. These data further extend our 
knowledge of the complex interactions between GAS and the host fibrinolytic 
system, and the critical role that plasmin(ogen) plays during GAS pathogenesis.  
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1.1 Overview 
Subversion of the human plasminogen activation system is critical for initiation of 
invasive disease by many pathogenic bacteria. Plasminogen is the central mediator of 
the plasminogen activation system, and its activation to the broad spectrum protease 
plasmin is facilitated by urokinase (uPA) and tissue (tPA) plasminogen activators. 
Plasmin has wide substrate recognition and is physiologically important in a number 
of roles. Primarily, plasmin degrades fibrin blood clots, but is also involved in the 
breakdown of extracellular matrix (ECM) components, blood coagulation, immune 
factors and matrix prometalloproteinases (Collen and Lijnen 1991; Lahteenmaki et 
al. 2000; Aisina and Mukhametova 2014). Plasmin is also implicated in other 
biological processes such as cell migration, wound healing and infiltration of 
immune cells to sites of infection (Vassalli et al. 1991; Del Rosso et al. 2008). 
Consequently, the plasminogen activation system is an attractive target for 
exploitation by microorganisms including the Gram-positive pathogen, Group A 
Streptococcus (GAS; group A streptococci; Streptococcus pyogenes). GAS is a 
significant pathogen, with humans the only natural reservoir identified to date. The 
heavy global burden of GAS disease is attributable to the plethora of virulence 
factors that result in clinically diverse manifestations. Localised and superficial GAS 
infections may result in pharyngitis, scarlet fever and impetigo, which can further 
progress into life-threatening invasive diseases such as bacteremia, streptococcal 
toxic shock syndrome (STSS) and the ‘flesh-eating disease’, necrotising fasciitis 
(Bisno and Stevens 1996; Cunningham 2000). The severity of invasive GAS 
infections has resurged in recent decades, and over 700 million cases of GAS 
infection worldwide are estimated each year (Carapetis et al. 2005). The acquisition 
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of the host protease plasmin has been shown to be a pre-requisite for a subset of 
GAS isolates for full virulence in a mouse model of infection (Sun et al. 2004; Cole 
et al. 2006; Sanderson-Smith et al. 2008). There is some evidence that pathogens 
hijack plasmin to resist host innate immunity by targeting the complement system 
(Rooijakkers et al. 2005). Additionally, host uPA- and tPA-mediated plasminogen 
activation at the cell surface of a number of pathogenic bacteria results in localised 
plasmin activity that leads to bacterial host invasion (Rooijakkers and van Strijp 
2007). Despite intensive research efforts, the molecular mechanisms governing GAS 
pathogenesis are yet to be fully characterised. Understanding of host-GAS 
interactions is vital for identifying key virulence factors and pathways. Presented 
here is work further investigating the role of the host fibrinolytic system in GAS 
pathogenesis. Two clinically important GAS isolates were employed to explore the 
impact of plasminogen acquisition and activation by GAS on evasion of 
complement-mediated neutrophil phagocytosis during the early stages of infection, 
and to elucidate the roles of host activators uPA and tPA in GAS virulence in vivo.  
1.2 Classification of streptococci 
1.2.1 Lancefield classification  
The genus Streptococcus is a diverse group comprised of 50 species originating from 
both human and domesticated animals (Innings et al. 2005). Rebecca Lancefield first 
described a serological classification system based on the antigenic variation in 
polysaccharides located in the bacterial cell walls of Groups A, B, C, F and G 
streptococci, or lipoteichoic acids in Group D streptococci (Cunningham 2000). 
Among these streptococci, GAS is considered one of the most virulent species 
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causing human infections (Facklam 2002). Accurate identification of Group A 
streptococci is fundamental to epidemiological and pathogenic studies of 
streptococcal diseases. Characterisation of GAS has been highly dependent on the M 
protein, an important virulence factor of GAS. M protein evokes a type-specific host 
immune response, and antibodies directed against the M protein confer protective 
immunity (Smeesters et al. 2010). This has led to the development of the traditional 
M-serotyping method, which has now been replaced by a technique termed emm-
sequencing.  
1.2.2 M-serotyping 
The surface-exposed M protein is one of the most extensively studied streptococcal 
proteins. Encoded by the emm gene, M proteins are dimeric α-helical, coiled-coil in 
structure and are tethered to the cell membrane via the conserved carboxy-terminal 
region (Figure 1.1). The N-terminus of the M protein faces the extracellular mileu 
and is extremely hypervariable (Figure 1.1) (Phillips et al. 1981). Antigenic variation 
in this hypervariable region marks the foundation of M-serotyping, and antibodies 
raised against this region are serotype specific (Smeesters et al. 2009). The 
hypervariable region of the M protein is considered one of the most important 
epidemiological markers for characterising GAS (Vitali et al. 2002). However, the 
M-serotyping method has major shortcomings that have limited its use. With an 
increasing discovery rate of GAS isolates, providing type-specific antisera for all 
known and newly encountered serotypes is difficult. Additionally, many GAS 
isolates are non-typeable, particularly those found in tropical regions, due to the lack 
of reactivity against available standard antisera (Relf et al. 1992). These deficiencies 
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challenged the continued use of this M-serotyping and were overcome by the 









Figure 1.1 Schematic of the GAS M protein. The M protein is a key virulence factor of GAS. M 
proteins extend approximately 50-60 nm from the bacterial surface and are anchored via the highly 
conserved carboxy (COOH) terminal region. They are coiled-coil, α-helical structures that form 
dimers stabilised by intermolecular interactions with neighboring M protein molecules. The 
hypervariable region is found at the amino (NH2) terminus and is highly variable among GAS 
isolates. The M protein contains multiple repeat regions (not shown) which bind to a diverse number 
of host molecules, contributing to the virulence of this pathogen. Adapted from Fischetti (1989) and 
Georgousakis et al. (2009). 
 
1.2.3 emm-sequence typing 
The emm-sequence typing method is a widely used and accepted genotyping scheme 
for characterising GAS isolates. This simple method is based on sequence analysis of 
polymerase chain reaction (PCR) products comprising the first 160 bases of the 
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protein (Figure 1.1) (Facklam 2002). This typing system has led to the detection of 
previously unidentified emm types, and differentiation between M-nontypeable 
strains. Virtually all GAS isolates are epidemiologically defined by their emm type, 
and to date, 234 different emm types have been documented worldwide (McMillan et 
al. 2013). 
1.3 Clinical spectrum of GAS disease and epidemiology 
GAS is among the most common and versatile of human-adapted pathogens. An 
analysis of deaths attributable to infectious disease indicated that the number of 
GAS-associated deaths is only exceeded by HIV, Mycobacterium tuberculosis, 
Plasmodium falciparum and Streptococcus pneumoniae (WHO 2005). A plethora of 
host and GAS proteins contribute to the diversity of clinical GAS manifestations, 
ranging from pyogenic infections to necrotising fasciitis, as well as post-infectious 
immune-mediated sequelae (Walker et al. 2014). A summary of GAS disease and 
epidemiology is provided in Table 1.1. 
1.3.1 Superficial GAS infections 
The epithelium of the throat and skin are the main physiological niches of GAS, and 
as such, is the most common bacterial cause of acute pharyngitis, accounting for 15-
30% of childhood cases and 10% of adult cases (Carapetis et al. 2005). Individuals 
in developed countries are more likely to experience pharyngitis at least once a year, 
whilst this rate is increased by 5 to 10 times in developing regions (Carapetis et al. 
2005; Henningham et al. 2012). In some cases, scarlet fever has been known to 
accompany GAS pharyngitis (Wessels 2011). Cases of scarlet fever have remained 
low during the twentieth century, but the disease burden has reappeared in the past 
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decade and currently remains problematic (Wong and Yuen 2012; Walker et al. 
2014). Localised skin infection caused by GAS can also result in impetigo, a 
contagious skin infection. The global burden of superficial GAS infection is 
significant; over 616 million cases of GAS pharyngitis, and 111 million cases of 
GAS pyoderma are reported each year (Carapetis et al. 2005). 
1.3.2 Invasive GAS disease 
Although less frequent than superficial infections, systemic GAS disease can 
develop from any streptococcal infection. Penetration of host epithelial barriers via 
skin or mucous membranes provides an invasive pathway for GAS and facilitates 
bacterial dissemination into distant, sterile organs. For a substantial number of 
invasive GAS infections however, the portal of bacterial entry is unknown, although 
several studies have associated previous blunt trauma with invasive GAS infections 
(Stevens et al. 1989; Kaul et al. 1997; Johansson et al. 2010). Up to 23% of patients 
with invasive disease die within seven days of GAS infection (Walker et al. 2014). 
The most common forms of invasive streptococcal disease are cellulitis and 
bacteremia; each accounting for approximately 20-40% of invasive GAS disease 
(O'Loughlin et al. 2007; Lamagni et al. 2008). Further progression of these 
infections may lead to necrotising fasciitis that often occurs in combination with 
streptococcal toxic shock syndrome (STSS), a systemic inflammatory disease. 
Necrotising fasciitis and STSS are considered the most severe manifestations of 
GAS infection, with a staggering 85.7% case-fatality rate resulting from patients 
with necrotising fasciitis that do not receive any surgical treatment (Johansson et al. 
2010; Walker et al. 2014). 
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1.3.3 Post-immune sequelae 
Post-infectious complications can result from prior GAS infections. Rheumatic fever 
(RF) is the leading cause of heart disease amongst school-aged children, and is the 
most significant contributor to the death toll of GAS disease worldwide, resulting in   
23,300 deaths annually (Ellis et al. 2010; Guilherme and Kalil 2010). Pharyngitis is 
classically a precursor for RF, but is not a pre-requisite (Carapetis et al. 2005). The 
disease has also been detected following cases of STSS and is endemic in 
populations which have low incidences of GAS throat colonisation (Carapetis et al. 
2000; McDonald et al. 2004; Smeesters et al. 2010). RF is considered the most 
significant of non-suppurative immune sequelae following GAS infection, but others 
may arise including acute post-streptococcal glomerulonephritis, Sydenham chorea 
and the more controversial, pediatric autoimmune neuropsychiatric disorders 
associated with streptococcal infections (Henningham et al. 2012; Walker et al. 
2014). 
1.3.4 Molecular epidemiology and diversity of emm-types 
Molecular epidemiology studies have highlighted the genetic diversity and varied 
distribution of emm-types, particularly between temperate and tropical environments 
(Smeesters et al. 2009). GAS diseases are most common in areas of poverty, where 
living conditions are poor and inadequate medical assistance facilitates bacterial 
transmission. In low-income settings, the diversity of emm-types far exceeds that 
seen in isolates circulating in high-income settings, where a small subgroup of emm- 
types dominate (Smeesters et al. 2009). Further, emm-types found within
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Table 1.1 Summary of GAS diseases and their current epidemiology. 
 Pathology and/or symptoms Epidemiology References 
Non-invasive 
Pharyngitis 
Sore throat with swollen uvula, fever, malaise, headache, nausea and 
vomiting; often remains benign and self-limiting. 
Predominant in crowded conditions, school-aged children and in 
less-developed countries. 
(Bisno and Stevens 
1996; Cunningham 
2000; Choby 2009; 
Henningham et al. 
2012)  
Scarlet fever 
Characterised by ‘strawberry,’ furry tongue with enlarged papillae that later 
develops into a deep red rash, and can spread from the face down to the 
neck and upper trunk.  
Outbreak in Hong Kong and mainland China. 
(Wong and Yuen 
2012) 
Impetigo 
Epidermal disorder characterised by numerous lesions which transition to 
pustules followed by the formation of thick, honey-coloured crusts.  
Widespread among economically disadvantaged children. 
Prevalent in tropical or subtropical climates.  
(Bisno and Stevens 
1996; Valery et al. 




Soft-tissue infection characterised by rapid inflammation and subsequent 
necrosis of subcutaneous  and deep soft tissue, leading to destruction of 
fascia, connective tissue and fat, usually on the face or extremities. 
Accompanied by local pain, fever and systemic toxicity.  
Invasive GAS diseases occur more commonly in the USA and in 
northern European countries. Primarily targets school-aged 
children who have previously been infected with pharyngitis, 
though it also manifests in young, previously healthy individuals. 
(Bisno and Stevens 
1996; Green et al. 
1996; Olsen et al. 
2009; Henningham et 
al. 2012) Streptococcal toxic 
shock syndrome 
Systemic inflammatory disease caused by the production of toxins that are 
released into the bloodstream. Patients experience myalgia, nausea, 




Erysipelas occurs as an acute, diffuse, spreading infection in superficial 
layers of the skin. Cellulitis occurs deep in subcutaneous tissues, 
characterised by redness and inflammation pain and swelling of the skin. 
Erysipelas occurs in young children and the elderly. Cellulitis is 
most frequent among middle-aged and elderly individuals. 
(Bisno and Stevens 




Characterised by inflammation of the joints, central nervous system, skin 
and subcutaneous nodules, and the heart and heart valves. Delayed sequel 
to pharyngeal infections. 
Highest prevalence in Indigenous communities in the Northern 
Territory of Australia and Pacific Island nations.  
(Carapetis et al. 1996; 




Causes irreversible, chronic renal failure and manifests as discoloured 
urine, edema of the face and extremities, and circulatory congestion. 
Develops from pharyngeal or skin infections. 
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developing countries differ substantially from one another, hampering the 
development of an effective vaccine, and increasing the complexity of characterising 
the virulence mechanisms of the large repertoire of GAS strains (Dey et al. 2005; 
Abdissa et al. 2006; Smeesters et al. 2006; Sanderson-Smith et al. 2014). Vaccines 
targeting common emm types may not be effective in poor-resourced countries, 
highlighting the need for the development of a multivalent vaccine which provides 
coverage against multiple emm-types. A recently developed emm cluster typing 
system that divides GAS emm-types into 48 discrete clusters has enabled better 
analysis of closely related M proteins that share binding and structural properties 
(Sanderson-Smith et al. 2014). This system has added a new dimension to 
identifying not only strains circulating in high-income areas, but also the diverse 
number of emm-types found in low-income settings.  
The reappearance of severe global invasive streptococcal disease in Western 
countries has been associated with circulating emm1 and emm3 GAS (Lynskey et al. 
2011). Whilst emm3 displays cyclic episodes of 4-7 year outbreaks, emm1 has non-
traditionally persisted for over 25 years and remains the most predominantly isolated 
GAS clone from the Western world (Schwartz et al. 1990; Aziz and Kotb 2008). 
This may be explained by the unique feature of the emm1 clone to switch to a 
hypervirulent phenotype during infection, however the exact molecular basis for this 
remains elusive (Cole et al. 2006; Sumby et al. 2006; Walker et al. 2007; Hollands 
et al. 2010). Other emm-types are frequently associated with outbreaks such as 
emm59 and emm81 GAS causing bacteremia and cellulitis, and ecthyma respectively 
(Henningham et al. 2012). 
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1.3.5 Current treatment for GAS infections 
Despite increased research in recent decades, morbidity and mortality due to GAS 
infection continue to be a major problem worldwide. Whilst non-invasive infections 
such as pharyngitis remain susceptible to penicillin, severe invasive diseases are 
limited to extremely high doses of intravenous penicillin or surgical debridement. A 
thorough understanding of the mechanisms governing host-pathogen interactions is 
paramount to developing effective treatments for invasive GAS disease. GAS is still 
sensitive to penicillin, despite being exposed to this antibiotic for over five decades 
(Passali et al. 2007). However, a safe and effective vaccine is still unavailable. 
Currently, vaccine development has largely focused on targeting the M protein, 
which have shown promise as GAS vaccine candidates in animal-based trials 
(Walker et al. 2014). 
1.4 GAS immune evasion 
Multicellular organisms have evolved a complex immune system composed of 
intertwining networks and strategies in order to protect the host organism. The 
human immune system has traditionally been divided into innate and adaptive 
(acquired) immunity, though both systems cooperate to provide efficient defence 
against potential pathogens (Turvey and Broide 2010). The innate immune response 
serves as host protection against the initial stages of bacterial infection. Both the 
ability to elude host defence and produce surface and secreted virulence factors by 
GAS is critical for establishing invasive disease. The role of plasminogen acquisition 
and activation by GAS on evasion of the complement system has yet to be explored, 
and will be a major focus of this thesis. 
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1.4.1 The innate immune system 
While anatomical and physiological barriers offer protection against the initial 
encounter with microbial organisms, the innate immune system represents the first 
line of defence once these barriers are breached. Innate immunity is characterised by 
its rapid response to foreign material and lack of immunological memory. Innate 
immune protection is attributed to a large repertoire of immunocytes that engulf and 
destroy pathogens (Beutler 2004). These myeloid cells include mononuclear 
leukocytes, which consist of macrophages, dendritic cells and natural killer cells, and 
polymorphonuclear leukocytes (PMNs), which can be further subdivided into 
neutrophils, basophils and eosinophils. The complement system is a critical 
component of innate immunity, and together with phagocytic cells, in particular 
neutrophils, plays a major role against controlling GAS infection.  
1.4.1.1 Neutrophils 
Neutrophils are the most abundant circulating leukocytes (Kumar and Sharma 2010). 
They are endowed with numerous cytotoxic granules enriched with powerful and 
lethal antimicrobial molecules (Kumar and Sharma 2010). Neutrophils however, are 
short-lived, surviving in the bloodstream for approximately six hours before 
undergoing apoptosis (Beutler 2004). Neutrophils are synthesised and continuously 
replenished from bone marrow and once matured, are recruited by inflammatory 
mediators and enter the bloodstream to migrate to the site of bacterial infection. 
Neutrophils directly eliminate pathogens via three effective strategies (Figure 1.2). 
Neutrophils can undergo degranulation, where antimicrobial substances are delivered 
to the phagosome or to the exterior of the cell (Brinkmann and Zychlinsky 2007). In 
the phagolysosome, bacteria are killed via the action of reactive oxygen species and 
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antimicrobial peptides which permeabilise the bacterial membrane and lyse microbes 
(Borregaard and Cowland 1997). In addition to their phagocytic properties against 
pathogenic bacteria, activated neutrophils also secrete neutrophil extracellular traps 
(NETs) which further enhance the killing capacity of these cells (Brinkmann et al. 
2004). NETs, composed of a network of fibres containing chromatin, some granular 
and cytoplasmic proteins, are formed as a result of extracellular release of neutrophil 
nuclear contents (Brinkmann et al. 2004). NETs play an important role in 
containment of infection and inflammation, and have been shown to kill GAS, as 
well as other microorganisms such as Staphylococcus aureus (S. aureus), Bacillus 
anthracis and Mycobacterium tuberculosis (Buchanan et al. 2006; Brinkmann and 
Zychlinsky 2007; Fuchs et al. 2007; Ramos-Kichik et al. 2009).  
1.4.2 The complement system 
The complement system is the major arm of innate immunity and functions in 
concert with neutrophils primarily to recognise and destroy invading pathogens 
(Potempa and Potempa 2012). The complement system serves as the first line of 
defence against bacterial invasion and is comprised of a network of over 30 plasma 
proteolytic enzymes that behave in a cascade-like manner. Complement is present in 
the human bloodstream as well as at mucosal surfaces, and its activation is tightly 
regulated by multiple soluble and membrane-bound regulators (Kolev et al. 2014). 
Many bacterial pathogens have evolved mechanisms to manipulate and overcome 
complement activation and evade host defence (Okumura and Nizet 2014). GAS 
interacts with the complement system via a multitude of strategies which target the 
multiple stages of the complement cascade, and will be briefly described below.  
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Figure 1.2 Neutrophil killing mechanisms. Neutrophils employ three effective strategies for the 
eradication of pathogens. Firstly, phagocytosis of bacteria involves the formation of a membrane-
bound compartment called a phagosome which fuses with granules to generate a phagolysosome. In 
the phagolysosome, bacteria are exposed to lethal components, such as reactive oxygen species and 
antimicrobial peptides. Neutrophils can also undergo degranulation, where they employ their granule-
associated arsenal, leading to the release of antimicrobial factors into the extracellular medium, or into 
phagosomes to enrich phagocytic vacuoles. Neutrophils also secrete neutrophil extracellular traps 
(NETs) which entrap and kill bacteria extracellularly.  
 
1.4.2.1 Activation of complement  
Detection of microorganisms that have breached external host barriers leads to 
complement activation via three distinct pathways; the classical, mannose-binding 
lectin or alternate pathways (Figure 1.3). These pathways can be triggered via 
binding of the C1q complex to bacteria either directly or via immunoglobulins 
(classical pathway), recognition of polysaccharides present on microbial surfaces via 
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instability of C3 (alternative pathway) (Gotze and Muller-Eberhard 1971; Potempa 
and Potempa 2012). Combined, these pathways result in either bacterial opsonisation 
for phagocytic uptake, or direct bacterial killing by the membrane attack complex 
(MAC). Although complex, these pathways converge to generate C3 and C5 
convertases, which cleave C3 into fragments C3a and C3b, and C5 into C5a and 
C5b, respectively (Figure 1.3). C3b opsonises bacteria and promotes bacterial uptake 
by phagocytic cells such as neutrophils and macrophages via specific receptors 
(CD35, CD11b/18 and CD11c/18). C3b deposition also facilitates an amplification 
process involving the formation of C3 convertase, leading to the rapid deposition of 
additional C3b on bacterial surfaces (Pangburn et al. 2008). C5a and C3a are 
powerful chemoattractants that recruit immune cells to the site of infection (Peng et 
al. 2009). Deposition of C5b initiates the terminal pathway and assembly of the 
MAC, consisting of components C5-C9. The formation of MAC results in the 
generation of lipophilic, membrane-insertion complexes that initiate cell lysis via 
inducing pores in the bacterial cell membrane (Muller-Eberhard 1986; Potempa and 
Potempa 2012).  
1.4.3 GAS complement evasion strategies 
GAS has evolved a multitude of sophisticated mechanisms for evading complement 
attack. Acquisition of key host complement regulatory proteins and degradation or 
inactivation of complement proteins by proteases are proposed mechanisms 
employed by GAS for impeding complement activation and avoiding 
opsonophagocytosis (Nizet 2007). The ability of GAS to inhibit complement 
functions at multiple levels plays a significant role in overcoming host immunity and 
facilitating GAS survival. Figure 1.4 provides a summary of various streptococcal 
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Figure 1.3 Activation and function of complement. Complement activation occurs via three distinct 
pathways; classical, mannose-binding lectin or alternate pathways. Each pathway activates the 
complement cascade to converge at the formation of C3 convertase, which cleaves C3 to activate C3a 
and C3b fragments. Opsonisation of bacterial surfaces by C3b leads to cell clearance by phagocytes, 
amplification of complement activation via the formation of C3 convertase, and the assembly of C5 
convertases, which generate C5a and C5b. The release of the anaphylatoxins, C3a and C5a, trigger 
chemotactic and pro-inflammatory responses. Terminal complement components (C5b) induce the 
formation of the membrane-attack complex (MAC) which facilitates bacterial cell lysis. Adapted from 
Kolev et al. (2014), Okumura and Nizet (2014) and Barthel et al. (2012a). 
 
1.4.3.1 Acquisition of host complement regulators 
The interaction of microbial pathogens and host complement regulators has been 
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thereby dissociating formation of C3 convertase, as well as functioning as a cofactor 
in the proteolytic inactivation of C4b (Oliver et al. 2008). GAS exhibits high affinity 
binding to C4BP via M protein and M protein family members Sir and Arp (Thern et 
al. 1995; Jarva et al. 2003; Sanderson-Smith et al. 2014). This interaction is 
mediated by the hypervariable N-terminal region of the GAS M protein (Accardo et 
al. 1996). Binding of the M protein to C4BP has been shown to mimic the binding to 
that of C4b, resulting in an overlap in binding site and preventing subsequent C4b 
regulation and down-regulation of complement activation (Berggard et al. 2001). 
The acquisition of C4BP by GAS has also been correlated with evasion of 
phagocytosis (Carlsson et al. 2003; Blom et al. 2009). Acquisition of C4BP is a 
common phenomenon amongst human pathogens and has been demonstrated by 
Neisseria meningitides (Schneider et al. 2007), Escherichia coli (E. coli) (Wooster et 
al. 2006) and Bordetella pertussis (Berggard et al. 1997; Berggard et al. 2001).  
Another mechanism by which GAS subverts complement attack is binding to 
regulators of the alternative pathway such as factor H (FH) and its spliced gene 
product, factor H-related (FHL)-1 proteins. These inhibitors compete with factor B 
for binding with C3b, control the formation of C3 convertase and act as cofactors for 
degradation of C3b (Zipfel et al. 1999). The GAS M protein has been shown to bind 
FH and FHL-1 via the conserved C-repeated domain and hypervariable region 
respectively (Blackmore et al. 1998). Acquisition of both these proteins promotes 
bacterial survival in the bloodstream (Kraiczy and Wurzner 2006). However, GAS 
strains exhibit varying affinities for these proteins; invasive strains M1 and M3 show 
little binding capacity compared to M18, which demonstrates the highest binding 
affinity (Perez-Casal et al. 1995). A recent study has demonstrated that enhanced 
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mouse mortality was observed upon infection with GAS strains that bind C4BP 
and/or FH in a humanised transgenic mouse model expressing human complement 
inhibitors (Ermert et al. 2015). This further emphasises the importance of the 
recruitment of host complement inhibitors by GAS to attenuate complement 
opsonisation and phagocytic killing. 
1.4.3.2 Degradation of complement factors by GAS proteases 
Degradation and inactivation of complement components by bacterial virulence 
factors are key mechanisms for evading complement activation by a number of 
human pathogens. GAS produces a number of virulence factors directed at evading 
complement including those that directly degrade complement components. GAS 
expresses a multidomain surface-bound endopeptidase, C5a peptidase (ScpA) that 
specifically degrades complement factor C5a via limited proteolysis of the C-
terminus, a critical region that is recognised by receptors of polymorphonuclear 
leukocytes (Hynes 2004; Kagawa et al. 2009). Consequently, this leads to impaired 
C5a-mediated pro-inflammatory and chemotactic responses and impedes the 
migration of inflammatory cells to the site of infection. In a mouse model of 
infection, this has been shown to promote increased GAS dissemination (Ji et al. 
1996). Similarly, GAS plasminogen binding anchorless proteins surface -enolase 
(SEN) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (discussed in 
1.8.2.2) have also been shown to capture and inhibit C5a function (Terao et al. 
2006). Furthermore, GAS secretes streptococcal pyrogenic exotoxin B (SpeB), a 
cysteine protease that plays a pivotal role in complement evasion by GAS (Honda-
Ogawa et al. 2013). SpeB directly degrades C3 and C3b, thereby inhibiting all three 
pathways of complement activation at the level of C3 convertase and opsonisation 
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Figure 1.4 Overview of virulence mechanisms employed by GAS to thwart the host innate 
immune response. (1) GAS secreted DNase Sda1 promotes degradation of neutrophil extracellular 
traps (NETs) and resistance to neutrophil killing. (2) Impaired phagocytic activity is also 
accomplished via lysis of neutrophils by streptolysin O (SLO) and streptolysin S (SLS). (3) The 
chemokine interlukin-8 (IL-8) and complement-derived chemoattractant peptide C5a are degraded by 
peptidase ScpC and ScpA, respectively. (4) Deposition of C3b, required for opsonisation on the 
bacterial surface, is inhibited via acquisition of host complement regulators C4-binding protein 
(C4BP) and Factor H (FH) by the GAS M protein. (5) The M protein nonopsonically binds 
immunoglobulin, which is also degraded by the GAS protease, SpeB. (6) Recruitment of host matrix 
proteins by M and M-like proteins, as well as mimicry by the hyaluronic acid capsule provides GAS 
with a protective cloak against opsonin recognition. (7) Impediment of phagocytic uptake is caused by 
inhibition of the membrane-attack complex (MAC) formation as a result of colocalisation of 
streptococcal inhibitor of complement (SIC) with actin cytoskeletal arrangements. (8) Both SpeB and 
SIC also protect GAS against the bactericidal activities of antimicrobial peptides. Adapted from 
Kwinn and Nizet (2007). 
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respectively (Terao et al. 2008). SpeB also degrades properdin, a protein critical for 
maintaining the stability of convertases of the alternative pathway (Tsao et al. 2006). 
Infection with a SpeB-deficient GAS strain results in an influx of neutrophils to the 
site of infection, enhanced neutrophil uptake and bacterial clearance in a mouse 
model of infection (Nelson et al. 2011). 
1.4.3.3 Inhibitors of complement 
GAS also targets the final stage of the complement cascade via expression of the 
streptococcal inhibitor of complement (SIC). SIC binds to the soluble C5b7 and 
C5b8 complexes that are necessary for the assembly of MAC on the target 
membrane, thereby hampering the formation of pores and impairing bacterial 
complement-mediated lysis (Akesson et al. 1996). However in this regard, the 
function of SIC appears to be redundant at least in part as GAS is naturally resistant 
to MAC-mediated cell lysis due to its cell wall structure (Lambris et al. 2008). Other 
functions of SIC have been identified that do not involve complement, which 
indicates that complement inhibition is not the sole function of SIC. These include 
playing a role in altering cellular processes and inactivating antibacterial peptides in 
neutrophils (Hoe et al. 2002; Frick et al. 2003). 
1.4.4 Neutrophils in controlling GAS infection 
The major immune cells contributing to the control of GAS infection are neutrophils, 
macrophages and dendritic cells. As already discussed, neutrophils are one of the 
first immune cells to encounter invading GAS and therefore play an important early 
defence mechanism. Studies have shown that GAS has evolved powerful escape 
mechanisms to the phagocytosis, phagosome maturation, and NETs of neutrophils 
(von Pawel-Rammingen et al. 2002; Carlsson et al. 2003). Furthermore, fewer 
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neutrophils have been reported to migrate to sites of invasive GAS infection, while 
degradation of anaphylatoxins C5a and IL-8 by ScpA and SpyCEP respectively, is 
associated with GAS resistance to neutrophil killing (Wexler and Cleary 1985; 
Brinkmann et al. 2004; Hidalgo-Grass et al. 2004; Zinkernagel et al. 2008). In a 
lethal GAS infection mouse model, a diminished source of bone-marrow derived 
neutrophils led to a decreased infiltration of neutrophils to the site of bacterial 
infection, resulting in high mice mortality (Navarini et al. 2009). The functions of 
neutrophils are therefore critical for host protection in response to GAS invasion.  
1.4.5 Subversion of host proteins to evade complement attack 
Several pathogens over the past decade have been found to subvert host proteases to 
avoid complement attack (Rooijakkers and van Strijp 2007). Hijacking of the human 
plasminogen activation system to convert the endogenous plasminogen into the 
protease plasmin on bacterial surfaces can lead to degradation of key complement 
proteins and host factors. Establishment of severe invasive GAS disease has been 
attributed to its interaction with the host plasminogen activation system, and 
represents one of the most intensively studied mechanisms of GAS virulence 
(Walker et al. 2014). The interaction of GAS and the human plasminogen activation 
system forms the foundation of this thesis, and is described in detail below.  
1.5 The human plasminogen activation system 
Activation and subversion of the human fibrinolytic system is emerging as a 
common mechanism in invasive bacterial infection. The highly regulated 
plasminogen activation system is central to a spectrum of biological processes 
including, but not limited to fibrinolysis, inflammation, matrix remodelling, wound 
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healing, tumor invasion and cell invasion. This system involves the conversion of the 
ubiquitous inactive plasminogen by host uPA and tPA, to the broad spectrum serine 
protease plasmin (Figure 1.5). Regulation of this system is primarily mediated by 
inhibitors of plasminogen activators (PAI-1, PAI-2) and plasmin (α2-antiplasmin, α2-
macroglobulin). 
1.5.1 Plasmin(ogen) 
Plasminogen, the 92 kDa inactive precursor of plasmin, is synthesised in the liver, 
abundant in plasma and circulates at approximate concentrations of 2 µM (Ogston 
1980; Raum et al. 1980). Cleavage of plasminogen by uPA or tPA occurs at the 
single peptide bond Arg561-Val562, and leads to the formation of two-chain plasmin 
that is composed of a heavy and light chain that remain joined by disulphide bridges 
(Figure 1.6) (Rijken and Lijnen 2009). Plasminogen consists of five homologous 
kringle domains with lysine-binding sites, which allows for recognition of substrates 
and plasminogen receptors, and a serine protease domain which contains the 
catalytic triad (His603, Asp643 and Ser741) that is responsible for the proteolytic 
activity of plasmin (Figure 1.6) (Castellino and Ploplis 2005; Law et al. 2013). Two 
conformational states of plasminogen exist in plasma; both display differing binding 
affinities for ligands. Glu-plasminogen is the native form of plasminogen (named 
after the first N-terminal amino acid) and circulates in plasma in a closed 
conformation. It contains an N-terminal 8 kDa activation peptide that, when cleaved 
by plasmin, forms Lys-plasminogen, an 83 kD protein that exhibits a more open and 
relaxed conformation. This truncated form renders plasminogen more accessible for 
higher affinity and faster interactions with receptor and target molecules than the  
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Figure 1.5 Schematic diagram of the mammalian plasminogen activation system. Inactive pro-
uPA binds to the uPA receptor, uPAR, which is then converted to active uPA by plasmin. Host uPA 
and tPA proteolytically convert the proenzyme plasminogen to active protease plasmin. Plasmin 
through its own proteolytic function degrades fibrin clots to produce fibrin degradation products 
(FDPs), and can degrade extracellular matrices (ECM). Alternatively, upon plasmin-mediated 
activation of precursors of matrix metalloproteases (Pro-MMPs), matrix metalloproteases (MMPs) 
degrade collagen and gelatins of basement membranes, and ECM components that form barriers for 
cellular migration. The plasminogen activation system is regulated by plasminogen activator 
inhibitors (PAIs) and the anti-proteases, α2-antiplasmin and α2-macroglobulin, which inhibit 
plasminogen action and plasmin, respectively (dashed arrows). Adapted from Lähteenmäki et al. 
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Figure 1.6 Domain structure of human plasminogen. Plasminogen is cleavaged by plasminogen 
activators (uPA/tPA) at the Arg561-Val562 peptide bond to form the broad spectrum two-chain 
protease plasmin, consisting of a heavy and a light chain. The heavy chain (amino terminal, NH2) 
contains the five kringle domains which primarily mediate fibrin and matrix protein interactions via 
lysine-binding sites. The light chain (carboxy terminal, COOH) harbours the catalytic triad (His603, 
Asp643 and Ser741) which forms the active site of plasmin. Plasmin-mediated cleavage of the N-
terminal activation peptide converts the native and closed form of plasminogen (Glu-plasminogen) 
into a more open conformation (Lys-plasminogen). Cleavage sites for plasminogen activators and 
plasmin are indicated by arrows; disulfide bridges are indicated by dotted lines. Adapted from 
Andreasen (2001).  
 
parent molecule, and also facilitates conversion to plasmin (Ranson and Andronicos 
2003; Castellino and Ploplis 2005; Law et al. 2013). 
1.5.2 Host plasminogen activators 
Two physiologically distinct eukaryotic activators of plasminogen have been 
identified; uPA and tPA. Whilst both activators share the ability to activate 
plasminogen, they differ in their genetic makeup, have distinct structures with tissue-
specific expression and more important, play different biological roles (Vassalli et 
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is highly dependent on the presence of cofactors, such as fibrin, that bind to, and 
alter the conformation of plasminogen (Irigoyen et al. 1999). In contrast, uPA 
doesn’t directly bind fibrin, but rather it is the critical trigger for the generation of 
localised proteolytic plasmin activity during inflammation, wound healing, tissue 
remodelling, metastasis and invasion (Kolev and Machovich 2003). Despite this 
apparent functional distinction, studies using uPA- and tPA-deficient mice suggest 
an overlap in function. In the absence of either activator, the skin wound healing 
process continues normally in mice, suggesting that uPA and tPA can substitute for 
each other in fibrinolysis (Lund et al. 2006). However, inactivation of both genes 
severely impairs this process (Romer et al. 1996), causes rectal prolapse, runting and 
extensive fibrin deposition in multiple organs (Carmeliet et al. 1994). These findings 
clearly demonstrate that uPA and tPA are crucial for thrombolytic and fibinolytic 
processes in the host. 
1.5.2.1 urokinase plasminogen activator (uPA) 
uPA is a 54 kDa multidomain protein consisting of 411 aa. It is synthesised and 
secreted as a single-chain latent pro-enzyme (pro-uPA) by neutrophils, macrophages 
and endothelial and renal epithelial cells (Riccio et al. 1985). uPA contains a growth 
factor domain and one kringle domain homologous to that found in plasminogen and 
tPA at the N-terminus, as well as a serine protease domain containing the catalytic 
triad (His204, Asp255, Ser356) at the C-terminus (Figure 1.7) (Kasai et al. 1985). Pro-
uPA, which exhibits minimal intrinsic plasminogen activating capacity (Lijnen et al. 
1990), is cleaved at Lys158- Ile159 by plasmin or other proteases to yield a two-chain 
uPA molecule connected by a disulphide bond (Figure 1.7). The catalytically active 
two-chain uPA exhibits 250-fold greater activity than pro-uPA in humans, and exists 
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in both high (HMW) and low (LMW) molecular weight forms (Petersen et al. 1988; 
Schmitt et al. 1991; Andreasen et al. 1997; Cesarman-Maus and Hajjar 2005). 
Further proteolysis of two-chain uPA at the peptide bond Lys135-Lys136 results in the 
formation of a fully functional HMW uPA, whilst additional proteolysis at position 
Glu143-Leu144 by specific metalloproteases generates a LMW 33 kDa uPA product 
(Barlow et al. 1981). Although both forms of uPA can activate plasminogen, LMW 
uPA does not bind to uPAR, a well-characterised uPA-specific cell surface receptor 
(Ellis et al. 1989; Ulisse et al. 2009). uPAR is expressed by a wide variety of cells 
including monocytes, macrophages and neutrophils (Blasi and Carmeliet 2002). 
Binding of uPA to uPAR accelerates the plasminogen activation cascade and 
activates plasminogen more efficiently than the fluid phase enzyme. This enhanced 
plasmin formation is a consequence of a phenomenon known as ‘reciprocal zymogen 
activation,’ where a feedback activation loop facilitates pro-uPA activation by 
plasmin and in a reciprocal fashion, uPA catalyses the activation of plasmin, thereby 
enhancing its own production (Blasi and Carmeliet 2002). uPAR is tethered to the 
cell plasma membrane, and as such, the pericellular localisation of uPA and plasmin 
activity is readily available during cell migration and invasion (Ulisse et al. 2009). 
Due to the absence of a lysine binding site in the kringle domain, uPA has low 
affinity for fibrin, however when fibrin is present, plasminogen activation by two-
chain uPA is enhanced by almost 10-fold (Gurewich et al. 1984).  
1.5.2.2 tissue plasminogen activator (tPA) 
tPA is a 70 kDa protein composed of 527 aa and is the principle activator in 
fibrinolysis (Lijnen and Collen 1988). tPA has five functionally distinct domains 
(finger-like domain of fibronectin, epidermal growth factor, two kringle domains and 
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serine protease domain), each with a different role including rapid binding to fibrin, 
fibrin-specific plasminogen activation, rapid clearance in hepatocytes and binding to 
cellular receptors (Figure 1.7) (Cesarman-Maus and Hajjar 2005). The serine 
protease region consists of three residues (His322, Asp371, Ser478) located at the C-
terminus. Plasmin digestion at the specific Arg275-Ile276 peptide bond of tPA yields a 
disulfide-linked, two-chain molecule. However, unlike other single-chain precursors 
of most serine proteases, single-chain tPA is unique in that it also displays enzymatic 
activity (Nienaber et al. 1992). While single-chain tPA shows reduced enzymatic 
activity compared to two-chain tPA, both forms of tPA demonstrate equivalent 
activity in the presence of fibrin (Tate et al. 1987). tPA is primarily produced and 
secreted by endothelial cells, but also by keratinocytes, neurons and melanocytes, 
and it is most abundant in areas that are within close vicinity to fibrin clots (Levin 
1983; Chen et al. 1993; Kooistra et al. 1994; Teesalu et al. 2004). The high affinity 
of tPA for fibrin is due to the combination of the second kringle domain and the 
finger-like amino terminal domain of tPA, that is homologous to the fibrin-binding 
finger domain of fibronectin (Verheijen et al. 1986). The release of tPA is induced 
by various stimuli, some of which include thrombin, histamine, bradykinin and 
adrenalin. Plasminogen activation by tPA is highly dependent on the presence of 
cofactors, such as fibrin (Irigoyen et al. 1999). tPA is also involved in other 
biological functions such as potentiation in the hippocampus and excitotoxic 
damage, as well as participating in physiological and pathological roles in the brain 
(Huang et al. 1996; Lemarchant et al. 2012). To date, a cell-surface receptor which 
exclusively binds tPA, has yet to be identified.  
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Figure 1.7 Schematic domain organisation of human plasminogen activators. tPA is composed of 
five domains; the N-terminal (NH2) finger-like domain of fibronectin responsible for binding fibrin, 
the epidermal growth factor domain, two kringle domains of plasminogen, and the catalytic domain at 
the carboxy terminal region (COOH). Single-chain tPA is cleaved by plasmin at the Arg275-Ile276 
peptide bond to yield two-chain tPA. Both single-chain and two-chain tPA are enzymatically active, 
making tPA a unique protease. Inactive pro-uPA (or single-chain uPA) is comprised of the epidermal 
growth factor domain and a single kringle and catalytic domain. Activation of pro-uPA at Lys158-Ile159 
by plasmin or kallikrein leads to the formation of fully active two-chain uPA. In contrast to tPA, uPA 
has no fibrin binding capacity, but instead interacts with its own receptor, uPAR, that is expressed on 
many cell types. Dotted lines represent disulphide bonds; red arrows indicate cleavage sites where 
two-chain proteases are generated from their single-chain precursors. Adapted from Andreasen 
(2001), and Dobrovolsky and Titaeva (2002). 
 
1.5.3 Regulation of plasmin 
In order to avoid widespread tissue destruction by the action of plasmin, the 
plasminogen activation system is tightly regulated both at the levels of direct enzyme 
binding, plasmin generation, and control of plasmin activator activity (Figure 1.5). 
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Plasmin has two physiological inhibitors in plasma; 2-antiplasmin and 2-
macroglobulin. Inhibition by 2-antiplasmin occurs in two stages; the reversible and 
rapid interaction of 2-antiplasmin with the lysine-binding kringles 1-3 of plasmin, 
followed by the irreversible and slow reaction leading to formation of a covalent 
bond between the inhibitor and the active site serine residue of plasmin 
(Lahteenmaki et al. 2001; Peetermans et al. 2015). Occupation of the lysine-binding 
sites during plasmin(ogen) binding to fibrin and cell surface receptors results in 
plasmin being protected from inhibition by 2-antiplasmin (Longstaff and Gaffney 
1991; Lahteenmaki et al. 2001; Rijken and Lijnen 2009). 2-macroglobulin is a 
proteinase inhibitor with broad specificity, and is more abundant of the two plasmin 
inhibitors. Plasmin inhibition by 2-macroglobulin generally takes place when the 
limited supply of 2-antiplasmin in plasma is significantly decreased (Saksela 1985). 
Plasminogen activators are primarily regulated by plasminogen activator inhibitors 
(PAIs). Whilst uPA is susceptible to inhibition by both PAIs, tPA is more readily 
inhibited by PAI-1. PAI-1 is secreted by multiple cell types, including endothelial 
cells, and is implicated in cell migration, tumour development and cardiovascular 
diseases (Rijken and Lijnen 2009; Peetermans et al. 2015). Comparatively, PAI-2 is 
located in monocytes/macrophages and endothelial cells, and although several 
functions have been ascribed to PAI-2 including a cytoprotective role (Lee et al. 
2015), its exact physiological role remains an enigma (Lee et al. 2011). Other 
alternative inhibitors of uPA and tPA are protease nexin and PAI-3, which have been 
found in tissue and urine, respectively (Potempa et al. 1994; Rijken 1995). Protease 
nexin is a broad spectrum inhibitor, with antagonistic effects against plasmin, 
   
Chapter 1 Review of the Literature 
 
Page | 30 
 
thrombin and uPA, whereas PAI-3 inhibits uPA and tPA, but at a slower rate than 
PAI-1 and PAI-2 (Saksela and Rifkin 1988; Rijken 1995). Of the four plasminogen 
activator inhibitors, PAI-1 accounts for approximately 60% of inhibition of 
plasminogen activators (Correia and Haynes 2006). 
1.5.4 Physiology of the plasminogen activation system 
The plasminogen activation system primarily acts to generate localised cellular 
proteolytic plasmin activity that is implicated in a vast number of biological roles; its 
classical role being fibrinolysis. Fibrin is considered the major target substrate for 
plasmin-mediated degradation, such that binding of plasminogen and tPA to fibrin, 
or plasminogen to the ECM, dramatically enhances plasminogen activation (Ranby 
1982; Knudsen et al. 1986; Lijnen and Collen 1995). The ability of plasmin to digest 
fibrin therefore controls the extent of coagulation and is of central importance for 
solubilisation of blood clots. It is also involved in the breakdown of ECM 
components including laminin, fibronectin, vitronectin and heparin sulphate 
proteoglycans, as well as activating matrix metalloproteases. Indirect plasmin 
activation of procollagenases causes degradation of collagen that is otherwise not 
susceptible to plasmin-mediated cleavage (Murphy et al. 1992). Plasmin-mediated 
activation of the aforementioned ECM substrates is critical for many processes 
including tissue remodeling events and inflammatory cell migration (Vassalli et al. 
1992; Plow et al. 1995; Del Rosso et al. 2008). Additionally, the overexpression of 
plasminogen activators has been linked to tumor cell invasion, and in particular, the 
upregulation of uPA is a hallmark feature of cancer cells (Ulisse et al. 2009; 
Mekkawy et al. 2014). The function of the plasminogen activation system, in 
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particular the broad proteolytic capacity of plasmin, highlights its potential to be 
exploited by pathogenic bacteria during invasive bacterial infections.  
1.6 Interaction of GAS with the human plasminogen activation system 
The ability to recruit and exploit host plasminogen is common amongst many 
virulent bacterial pathogens (Sanderson-Smith et al. 2012). GAS express an array of 
proteins that interact with and activate human plasminogen. Plasminogen acquisition 
and activation at the bacterial cell surface enables GAS to breach tissue and host 
barriers to promote systemic bacterial infection (Walker et al. 2005). Streptococcal 
proteins that are involved in the interaction between GAS and plasminogen include 
(1) secretion of the plasminogen activator, streptokinase; (2) direct binding with 
surface proteins via specialised plasminogen receptors (plasminogen-binding GAS 
M proteins, PAM; PAM-related protein, Prp), or the moonlighting enzymes of the 
glycolytic pathway (GAPDH, SEN); or (3) indirectly by sequential binding of 
fibrinogen and plasminogen via expression of fibrinogen-binding proteins (Figure 
1.8) (Sanderson-Smith et al. 2012; De Oliveira et al. 2015). 
1.6.1 Streptokinase 
Streptokinase is a potent activator of plasminogen and is secreted by Group C and G 
streptococci, and all GAS isolates (Boyle and Lottenberg 1997). Streptokinase is 
encoded by the ska gene, and is a single-chain 414 amino acid, three domain, non-
glycosylated protein (Wang et al. 1998). Streptokinase is a major virulence factor of 
GAS, displays a high level of species specificity, showing little or no interaction 
with plasminogen from other species including murine plasminogen (Sun et al. 
2004). Two main sequence clusters of ska have been phylogenetically established; 
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cluster types 1 and 2, with cluster 2 further subdivided into cluster 2a and 2b 
(McArthur et al. 2008). These clusters display important functional differences; 
cluster 2, but not cluster 1, requires fibrinogen to activate plasminogen (Figure 1.8) 
(McArthur et al. 2008). Streptokinase activates plasminogen non-proteolytically, 
inducing a conformational change in plasmin(ogen) via formation of a 1:1 
stoichiometric complex (Reddy and Markus 1972). The streptokinase-plasmin(ogen) 
complex has the ability to hydrolytically activate other free plasminogen molecules 
to plasmin, or plasminogen already bound to the bacterial surface, resulting in 
localised cell surface plasmin that circumvents regulation by host plasmin inhibitors 
(Lottenberg et al. 1992; Parry et al. 2000).  
1.6.2 GAS plasmin(ogen) receptors 
1.6.2.1 Specialised cell surface plasminogen receptors 
Approximately 15% of all GAS isolates express specialised plasminogen-binding M 
proteins (PAM, Prp). PAM was initially isolated from the M53 GAS serotype, and is 
strongly associated with isolates causing impetigo (Berge and Sjobring 1993; 
Svensson et al. 1999). The plasminogen-binding region of PAM is located in the N-
terminal A1 and A2 hypervariable region containing tandem repeats. In contrast to 
other plasminogen-binding motifs, the high affinity and specificity of PAM with 
plasminogen is dependent on positively charged arginine and histidine residues, but 
not lysine, found within the two internal repeat domains (Wistedt et al. 1995; 
Sanderson-Smith et al. 2006). A unique characteristic of plasminogen-binding M 
proteins is the ability to directly capture plasminogen to the bacterial cell surface, 
which is readily accessible to activation by host activators uPA and tPA, or 
streptokinase (Figure 1.8) (Berge and Sjobring 1993). Furthermore, the resulting 
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surface bound plasmin is protected from inactivation by circulating host plasmin 
inhibitors (Wistedt et al. 1995). Prp is another high affinity plasminogen binding M 
protein isolated from a severe GAS infection (McKay et al. 2004; Sanderson-Smith 
et al. 2008). Plasminogen acquisition by PAM/Prp has been associated with the 
propensity to cause invasive diseases (McKay et al. 2004; Sanderson-Smith et al. 
2007). The susceptibility of human plasminogen transgenic mice was significantly 
abolished following infection with a PAM-negative GAS strain compared to 
littermate controls (Sun et al. 2004). Similarly, abrogation of plasminogen binding 
and plasminogen acquisition by Prp significantly reduced the capacity of GAS to 
cause a lethal infection in a humanised plasminogen mouse model of infection 
(Sanderson-Smith et al. 2008). The ability of plasminogen-binding proteins to 
readily capture plasminogen to the bacterial cell surface therefore significantly 
enhances GAS host invasion.  
1.6.2.2 Glycolytic moonlighting proteins as plasminogen receptors 
Glycolytic pathway enzymes GAPDH and SEN are multifunctional, anchorless 
proteins secreted by GAS and other bacterial species with plasminogen-binding 
capabilities (Pancholi and Fischetti 1998; Knaust et al. 2007; Matta et al. 2010). 
GAPDH, also referred to as streptococcal surface dehydrogenase or plasmin 
receptor, was the first identified streptococcal receptor for plasmin (Winram and 
Lottenberg 1996). It contains a carboxy-terminal lysine residue that is responsible for 
the high binding affinity of GAPDH for plasmin, and to a lesser extent, plasminogen 
(Winram and Lottenberg 1998). Site-directed mutagenesis of this region obliterated 
plasmin binding activity by the protein, but did not affect the capacity of GAS to 
bind plasminogen, strongly suggesting a significant role of other unidentified 
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plasmin receptors of GAS (Winram and Lottenberg 1998). The high affinity of SEN 
for plasminogen was originally thought to be mediated by lysine residues (Lys434 and 
Lys435) located at the C-terminus (Pancholi and Fischetti 1998). However, a later 
study examining the octameric structure of SEN revealed a second plasminogen-
binding motif involving internal lysine residues (Lys252 and Lys255) (Cork et al. 
2009). Abrogation of either binding sites eliminates plasminogen binding (Cork et 
al. 2009), which strongly suggests the critical and concerted role that both motifs 
play in plasminogen acquisition by SEN. The exact role of both enzymes in GAS 
virulence and the mechanism by which these proteins are exported to the cell surface 
are hitherto unknown (Jin et al. 2005). Despite this, these enzymes have been 
discovered on other microbial surfaces (Bergmann et al. 2004; Jin et al. 2005). Due 
to their house keeping functions, deletion of these enzymes has proven difficult. It 
has been suggested however, that in GAS strains binding human plasminogen in a 
non-M protein dependent manner, GAPDH and SEN may play an important role in 
plasmin(ogen) recruitment to the cell surface (Sun et al. 2004; Cole et al. 2006). 
1.6.3 GAS fibrinogen binding proteins 
Human fibrinogen is a 340 kDa plasma glycoprotein synthesised in the liver and 
plays an essential role in blood coagulation. Thrombin cleaves fibrinogen in the last 
step of the coagulation cascade to form insoluble fibrin polymers (Blomback et al. 
1978). For some GAS isolates, cell surface plasmin acquisition is dependent on 
fibrinogen binding as a pre-requisite (Wang et al. 1995a). Streptococcal fibrinogen 
binding proteins are exposed on the bacterial cell surface, and include M and M-
related proteins, PrtF1 and PrtF2 variants, and the lipoprotein Spy_0591 (Sanderson-
Smith et al. 2012; Sanderson-Smith et al. 2014). These proteins provide an anchor 
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for the pre-assembled streptokinase-plasminogen complex that is mediated by lysine-
binding sites. This resulting trimolecular complex composed of streptokinase-
plasminogen-fibrinogen, possesses plasmin-like activity which can activate 
additional fluid-phase plasminogen molecules, and lyse fibrin clots in the presence of 
circulating host plasmin inhibitors (Figure 1.8) (Takada and Takada 1989; Wang et 











Figure 1.8 Potential mechanisms of cell surface plasmin acquisition by GAS. Specialised 
plasminogen binding M proteins (PAM, Prp) can (A) capture plasminogen directly to the cell surface, 
which can then be activated by host (uPA/tPA) or bacterial (streptokinase, SK) plasminogen 
activators; or a pre-formed trimolecular complex consisting of type 2b streptokinase, plasminogen and 
fibrinogen. (B) Fibrinogen receptors, such as the M1 protein, require the pre-assembled trimolecular 
complex composed of type 2a streptokinase, plasminogen and fibrinogen to facilitate cell surface 
plasmin acquisition. (C) Type 1 streptokinase will combine with plasminogen to exhibit a complex 
with plasmin activity, which can then bind to plasminogen receptors, or combine with fibrinogen to 
interact with fibrinogen receptors. Adapted from McArthur et al. (2008). 
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This indirect method of plasminogen acquisition is important for GAS strains that do 
not possess high affinity plasminogen-binding receptors, and has been more 
frequently associated with invasive than non-invasive GAS infections (McKay et al. 
2004; Walker et al. 2014). 
1.7 Plasminogen and invasive GAS disease 
The broad substrate repertoire of plasmin and the high abundance of plasminogen 
circulating in plasma renders the human plasminogen activation system an attractive 
and vulnerable target for exploitation by pathogenic bacteria. Host plasminogen is 
exploited by a number of bacterial species including, Borrlelia burgdorferi, Yersinia 
pestis, and S. aureus  (Kuusela et al. 1990; Sodeinde et al. 1992; Coleman et al. 
1995; Sanderson-Smith et al. 2012). The role of the plasminogen activation system 
and its involvement in bacterial virulence has largely focused on the ability of GAS 
to degrade and facilitate the breakdown of ECM components, and fibrin clots via the 
activation of plasminogen and accumulation of plasmin (Figure 1.9). The fibrin 
network is essential in host defence against bacteria, and many pathogens including 
GAS, have evolved to escape from fibrin encapsulation, aiding in bacterial 
dissemination into sterile tissue sites (Lahteenmaki et al. 2005). 
The critical role of plasminogen binding by GAS, and the potential to cause highly 
invasive infection has been supported by several epidemiological studies and 
utilisation of animal models (Sun et al. 2004; Sanderson-Smith et al. 2012). For a 
subset of GAS isolates, the ability to accumulate cell surface plasmin is a pre-
requisite for systemic bacterial spread. The M1T1 GAS clone has been paralleled 
with the outbreak of invasive GAS disease in recent decades, and is also the most 
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frequently isolated serotype in invasive streptococcal infections globally (Aziz and 
Kotb 2008). The ability of GAS to sequester and activate cell-bound plasminogen 
was essential for invasive disease initiation of M1T1 GAS (Cole et al. 2006). In 
contrast, GAS skin infections that are endemic in the Northern Territory’s Aboriginal 
populations result from multiple M serotypes that are uncommon in the Western 
world (Hassell et al. 2004). These non-M1T1 GAS serotypes have also shown 
dependence on cell-bound plasmin activity for establishing bacterial virulence 
(Sanderson-Smith et al. 2008; Tsatsaronis et al. 2015). 
The importance of the interaction between human plasminogen and streptokinase 
was first highlighted by Khil et al. (2003). In this study, subcutaneous co-infection 
of plasminogen and GAS significantly decreased mice survival (Khil et al. 2003). 
The development of a humanised plasminogen transgenic mouse model by Sun et al. 
(2004) thereafter significantly enhanced the understanding of GAS-host interactions. 
In this model, mice expressed approximately 17% of the human plasminogen of that 
observed in normal human plasma (Sun et al. 2004). Infection of transgenic 
humanised mice with ska-expressing GAS strain resulted in 75% mice mortality, in 
distinct contrast to 27% mice mortality when infected with an isogenic ska-deleted 
derivative (Sun et al. 2004). This model emphasised the importance of the species 
specificity of streptokinase for human plasminogen, with little or no reactivity with 
plasminogen derived from other species including mouse. Using this same murine 
infection model, inoculation with a PAM-positive GAS strain resulted in increased 
mice mortality compared to infection with PAM-negative GAS (Sun et al. 2004). 
Similarly, abrogation of plasminogen binding by Prp resulted in a reduced capacity 
of the highly invasive GAS strain NS88.2 to accumulate plasmin at the bacterial cell 
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surface, and was subsequently avirulent in a mouse model of infection (Sanderson-
Smith et al. 2008). Similar results were found in a mouse skin infection model that 
showed the ability of GAS to initiate invasive disease was strongly correlated with 
the presence of surface-associated plasmin activity (Li et al. 1999). The virulence of 
M1T1 GAS was also found to be dependent on the presence of human plasminogen 











Figure 1.9 Current proposed model of streptokinase-generated plasmin facilitating GAS host 
invasion. The highly virulent GAS-secreted streptokinase facilitates bacterial invasion via hijacking 
the host plasminogen (Plg) activation system. Streptokinase (SK) activates plasminogen attached to 
the GAS cell surface, resulting in bacterium-bound plasmin that is protected from plasmin inhibitors. 
Alternatively, streptokinase can complex with plasminogen that activates other free plasminogen 
molecules to plasmin. After passing through the host cellular layer, plasmin at the GAS cell surface 
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Clearly, the ability of GAS to recruit plasminogen and accumulate plasmin at the 
bacterial cell surface is important for the progression of GAS disease, and provides 
another mechanism to exploit host fibrinolysis for bacterial invasion (Figure 1.9). 
Other studies support a protective role for plasminogen in host immune evasion, and 
colonization during streptococcal infection. Such studies describe a role for 
plasminogen bound at the GAS surface to evade macrophage killing, and facilitate 
adherence to laryngeal epithelial cells (Pancholi et al. 2003; Siemens et al. 2011). 
1.8 Role of plasmin(ogen) in host defence 
The plasminogen activation system and the innate immune system share a series of 
serine activators that interact during the inflammatory response (Amara et al. 2008). 
The exact molecular mechanisms involved in this interplay still remains elusive. 
Plasmin has multiple substrates in the host, and thus affects a wide spectrum of 
biological activities. It can readily degrade components of the ECM and activate 
matrix metalloproteases, and more recent studies have established a role for plasmin 
in complement activation, the bradykinin system and migration of leukocytes to 
wound sites during infection (Bugge et al. 1996a; Del Rosso et al. 2008; Peetermans 
et al. 2015). Plasmin(ogen) has a high affinity for endothelial cells and platelets, and 
can induce neutrophil aggregation and adherence to the endothelium (Hajjar et al. 
1986; Miles et al. 1986; Ryan et al. 1992). In vivo studies have highlighted the 
importance of plasmin(ogen) in immune cell recruitment during inflammation. In 
these studies, mice deficient in plasminogen are more resistant to inflammatory 
stimuli, have diminished macrophage infiltration across the ECM, and have defective 
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wound healing and tissue repair mechanisms (Schuster et al. 2007; Gong et al. 
2008). This supports findings from earlier studies in an acute peritoneal murine 
inflammation model, where recruitment of lymphocytes and monocytes was 
markedly blunt in plasminogen-deficient mice compared to wild-types (Ploplis et al. 
1998; Busuttil et al. 2004). Clearly, these studies established that plasmin(ogen) 
strongly influences immune cell recruitment during an inflammatory response.  
Fibrin is one of the most physiologically important targets of plasmin in vivo (Bugge 
et al. 1996b). The presence of fibrin is an absolute critical host defence mechanism 
for the containment of invading bacteria and promoting inflammation (Sun et al. 
2004; Sun et al. 2009). Fibrin(ogen) can directly interact with integrins on a number 
of innate immune cells including monocytes, macrophages, neutrophils and dendritic 
cells, and also plays a significant role in their recruitment and activation (Delvaeye 
and Conway 2009). Fibrinogen depleted mice display a dampened inflammatory 
response when infected with plague agent Yersinia pestis, and reduced thrombin 
generation has been linked with increased mice susceptibility to GAS infection 
(Degen et al. 2007; Sun et al. 2009). Furthermore, cleavage of fibrinogen leads to 
degradation products that can affect blood vessel permeability, promote adhesion, 
and accumulation of immune cells (Leavell et al. 1996; Flick et al. 2004). Thus, 
plasmin-mediated escape from fibrin clots can result in an overwhelming immune 
response and can be detrimental for the host. More recently, studies have focused on 
the interaction between plasmin and host proteins. In vitro studies have demonstrated 
that plasmin is capable of degrading essential components of the complement 
system, as well as immunoglobulins, resulting in the release of chemotactic 
fragments (Lachmann et al. 1982; Schaiff and Eisenberg 1997). A recent study found 
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that plasmin and coagulation factors Xa, XIa can cleave complement factors C5 and 
C3 to generate the potent chemoattractants C5a and C3a (Amara et al. 2010). 
Similarly, Barthel et al. (2012a) recently showed that plasminogen binds to 
complement factors C3, C3b and C5, and when activated by uPA, plasmin cleaves 
these proteins into inactivate fragments and inhibits complement activation in rabbit 
and sheep erythrocytes. Thus, the inhibitory effects of plasmin on complement 
activation further provides an explanation for the acquisition of plasmin(ogen) by 
microorganisms to evade recognition by the host innate immune response.  
1.9 Plasmin-mediated evasion of complement 
The multifaceted nature of the complement cascade is difficult to overcome by 
pathogenic bacteria. C3b is a key component of the complement system, and serves 
to opsonise and prime bacteria for eradication by phagocytes via the recognition of 
receptors on phagocytic cells (Lambris et al. 2008). In this way, C3b plays a critical 
role in the initial stages of host immunity. Several pathogens have developed the 
ability to manipulate the host plasminogen activation system to evade the 
bactericidal activity of C3b. Plasmin has been shown to degrade important 
complement factors (Seya and Nagasawa 1985; Ramu et al. 2007). More 
importantly, recent studies have revealed a role for bacterial activation of 
plasminogen and plasmin acquisition in complement evasion. PgtE-mediated 
plasminogen activation at the surface of Salmonella enterica, a common food-borne 
pathogen, leads to the degradation of C3b, as well as complement factors C4b and 
C5 (Ramu et al. 2007). Whilst plasmin at the surface of S. aureus can cleave C3b, 
and plasmin formed by the conversion of plasminogen by staphylokinase 
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(plasminogen activator of S. aureus), leads to decreased opsonisation and enhanced 
bacterial survival from neutrophil killing (Rooijakkers et al. 2005). More recently, a 
novel plasminogen binding protein of Streptococcus pneumoniae (PepO) was 
identified, which upon subsequent plasminogen binding and activation by uPA, led 
to plasmin-mediated degradation of C3b (Agarwal et al. 2013). A large number of 
other human pathogens share similar strategies of plasmin-mediated immune evasion 
including Bacillus anthracis (Chung et al. 2011), Borrelia burgdorferi (Grosskinsky 
et al. 2009), Pseudomonas aeruginosa (Kunert et al. 2007), Salmonella typhimurium 
(Ramu et al. 2007) and Haemophilus influenzae (Barthel et al. 2012b; Koenigs et al. 
2013). Furthermore, plasmin-bound to spores of Borrelia burgdorferi cleave C3b 
molecules in rabbit bronchoalveolar fluid which led to a decrease in complement-
mediated macrophage phagocytosis (Grosskinsky et al. 2009). Over 50 years ago, 
the addition of streptokinase to human serum was shown to digest complement 
proteins C1, C2, C3 and C4, and inhibit complement activation (Pillemer et al. 
1953). Potentially, there is a role for bacterial-associated plasmin in the evasion of 
host complement attack. Whilst this has been demonstrated for some common 
human pathogens, the contribution of plasminogen and plasmin acquisition in 
complement evasion by GAS however, has received little attention. This thesis will 
in part, explore whether similar complement evasion strategies are employed by 
GAS. 
1.10 Host activators in bacterial disease 
The phenomenon of subverting host plasminogen has been well-described for several 
invasive bacteria (Li et al. 1999; Magalhaes et al. 2007; Guo et al. 2008), viruses 
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(Goto and Kawaoka 1998) and parasites (Rojas et al. 2008) via expression of surface 
plasminogen receptors or acquisition of host activators. However, few bacterial 
species produce their own activators, of which streptokinase of GAS and 
staphylokinase of S. aureus are the most well-characterised. Human activators uPA 
and tPA are therefore necessary to promote plasmin-mediated host invasion for 
many other major pathogens that interact with the plasminogen activation system. 
Enhanced tPA-mediated plasminogen activation occurs at the surface of E. coli, 
Helicobactor pylori and Neisseria meningitides, while plasminogen at the surface of 
Salmonella typhyrium, Salmonella enteritidis, Borrelia burgdorferi and 
Streptococcus pneumoniae can be converted to plasmin by either uPA or tPA 
(Sjobring et al. 1994; Klempner et al. 1995; Yavlovich et al. 2004; Lähteenmäki et 
al. 2005; Magalhaes et al. 2007). The GAS M protein also binds plasminogen that 
can be activated by host activators in vitro (Berge and Sjobring 1993). Even without 
activation, recruitment of plasminogen to the bacterial cell surface has been linked to 
pathogenicity (Lottenberg et al. 1994). These findings strongly suggest that host 
activators are important in plasminogen activation and plasmin acquisition at the 
bacterial surface, and therefore, play a significant role in bacterial pathogenesis. How 
uPA and tPA are involved in GAS virulence in vivo remains to be determined. The 
role of streptokinase has been well-studied however, whilst streptokinase is secreted 
by all GAS isolates, this potent plasminogen activator is not present throughout the 
entire course of streptococcal infection. Streptokinase was found absent from 
supernatants harvested during the early phase of the GAS growth cycle (McArthur et 
al. 2008). Additionally, the cysteine protease SpeB that is secreted during the later 
stages of growth by GAS, has the ability to degrade streptokinase (Rezcallah et al. 
   
Chapter 1 Review of the Literature 
 
Page | 44 
 
2004; McArthur et al. 2008). These observations further underscore the importance 
that host activators may play in GAS virulence, and forms a major focus of this 
thesis. 
1.11 Conclusions 
GAS is a versatile human-specific pathogen that has evolved numerous strategies to 
infect the host, overcoming tissue and immune barriers to infection. Multiple 
virulence factors expressed by GAS enable the organism to hijack the plasminogen 
activation system by sequestering host plasminogen and acquiring localised 
proteolytic plasmin activity. The presence of plasmin at the bacterial cell surface 
leads to the degradation of fibrin clots and tissue barriers, and facilitates GAS 
migration from primary sites of infection into more distant and sterile host tissue. 
The ability to sequester cell surface plasmin is a pre-requisite for systemic invasive 
disease for a subset of GAS isolates. Recently, cell surface plasmin acquisition by 
other important human pathogens has been implicated in the degradation of major 
opsonins, including immunoglobulins and complement. This supports the idea that 
subversion of the plasminogen activation system by bacteria may not only facilitate 
their ability to breakdown natural defence barriers, but also to avoid elimination by 
innate immune phagocytic cells. GAS possesses many virulence factors that inhibit 
multiple levels of complement activation, suggesting that avoidance of innate 
immune surveillance is critical for GAS pathogenesis. Furthermore, the ability of 
endogenous uPA or tPA to mediate bacterial cell surface plasmin acquisition impacts 
on host survival for a number of pathogenic bacteria. There is little known about the 
roles of these activators in the progression of GAS disease. Thus, investigating the 
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interaction between GAS, the host fibrinolytic system and its impact on innate 
immune effectors, is essential for the enhanced understanding of the pathogenesis of 
GAS during the early stages of infection, and will be the foundation of this thesis.  
1.12 Project aims 
The present study aimed to explore the impact of plasmin acquisition by GAS on 
evasion of host innate immunity, and the contribution of host plasminogen activators 
in GAS virulence in vivo. Two clinically relevant GAS isolates were selected for 
study; the highly invasive, globally disseminated M1T1 GAS isolate 5448 which has 
been associated with the increased frequency of severe cases of invasive GAS 
disease (Aziz and Kotb 2008), and NS88.2 which was isolated from an invasive 
infection in the Northern Territory of Australia (McKay et al. 2004). 
The specific objectives of this study were five-fold: 
i. Assess the impact of plasmin at the GAS cell surface on C3b 
deposition in vitro and in vivo. 
ii. Establish a mouse model to examine how plasminogen acquisition 
and activation at the GAS cell surface impacts on complement-
mediated neutrophil phagocytosis. 
iii. Elucidate the role of host activator uPA in a mouse model of invasive 
GAS infection.  
iv. Assess the potential of commercial and novel drug inhibitors that 
target uPA-mediated plasminogen activation as therapeutics against 
GAS infection in a humanised plasminogen mouse infection model.  
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v. Elucidate the role of host activator tPA in a mouse model of invasive 
GAS infection.  
This thesis extends our understanding of the role of the human fibrinolytic system in 
invasive GAS disease. 
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This chapter contains general methods and resources that were used throughout this 
study and is referenced accordingly. Methods that were used in specific studies are 
described in the corresponding chapters. The components for all solutions and 
buffers are listed in detail in Appendix A. 
2.1 Bacterial strains and culture conditions  
2.1.1 GAS 
Unless otherwise noted, GAS strains used in this study were supplied by Dr. Martina 
Sanderson-Smith (University of Wollongong, Australia), or constructed as discussed 
in section 2.2. This study employed two clinically important sets of GAS strains 
including NS88.2, derived from the Northern Territory of Australia, and the globally 
disseminated M1T1 GAS clone, 5448. GAS strain NS88.2 was isolated from a case 
of invasive blood infection and has been described previously (McKay et al. 2004). 
The isogenic derivative NS88.2prp consists of mutated residues within the 
plasminogen binding region of Prp, and is attenuated for plasminogen binding and 
virulence in a mouse model of invasive infection (Sanderson-Smith et al. 2008). 
Isogenic GAS mutant NS88.2∆ska was provided by Dr. Jason McArthur (University 
of Wollongong, Australia). A precise, in-frame allelic replacement of the gene 
encoding streptokinase (ska) with cat encoding chloramphenicol transferase was 
created in wild-type GAS strain NS88.2 using established methods (Cook et al. 
2012). Phenotypic characterisation of this isogenic mutant strain was performed 
including analysis of growth rate, capsule production and streptokinase secretion as 
described by Cook et al. (2012) (data not shown). GAS strain 5448 expresses the M1 
protein, and is representative of the globally disseminated M1T1 clone that is 
responsible for high rates of invasive disease (Aziz and Kotb 2008). The 
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streptokinase-deficient GAS strain 5448Δska was created as detailed above by Dr. 
Martina Sanderson-Smith, and has been previously described (Hollands et al. 2012). 
The mutation was reversed by replacement of the cat gene with the wild-type ska 
gene to create the reverse-complemented GAS strain 5448ΔskaRC, which displays 
phenotypic characteristics akin to the parent strain 5448.  
Streptococci were routinely cultured at 37 °C in static liquid cultures of Todd Hewitt 
Broth (Difco, Liverpool, Australia) supplemented with 1% yeast extract (THBY) and 
inoculated with single, hemolytic GAS colonies grown on horse blood agar (HBA), 
(Oxoid, Hampshire, UK) or on Todd Hewitt agar (THA). In all experiments, 
overnight starter cultures were used to inoculate pre-warmed THBY at a ratio of 
1:10. Prior to the addition of GAS to various assays described in this project, 
bacterial cultures were grown at 37 °C until an optical density of 600 nm at 0.5 
(OD600 0.5) was reached.  
2.1.2 E. coli 
E. coli was propagated in Lysogeny broth (LB), or on LB agar at 37 C overnight. 
For antibiotic selection, erythromycin was supplemented at 2 µg/mL for GAS and 
500 µg/mL for E. coli. 
2.2 Growth curves 
GAS strains were initially characterised by measuring rates of bacterial growth in 
THBY. GAS starter cultures were inoculated 1 mL into 40 mL of pre-warmed 
THBY and grown at 37 ºC as described in section 2.1.1. Over an 8 h growth period, 
the OD600nm of 1 mL samples of growth culture were recorded every 30 min. To 
ensure that GAS numbers were uniform in all experiments, colony forming units per 
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mL (CFU/mL) were calculated by harvesting exponential cultures of streptococci at 
OD600 0.5. To a 96-well microtiter plate (Grenier Bio-one, Frickenhausen, Germany) 
containing 180 µL of 0.75% (w/v) sterile saline, 20 µL of each bacterial suspension 
was added and diluted in a 10-fold titration down the plate in triplicate. Ten 
microliter volumes of each dilution (at 10-4, 10-5 and 10-6) were plated onto THA 
with subsequent overnight incubation at 37 ºC. Colonies were enumerated and CFU 
calculated as an average of triplicates.  
2.3 DNA manipulation 
2.3.1 Plasmid extraction 
To facilitate flow cytometry studies, GAS strains NS88.2, NS88.2prp and 
NS88.2∆ska expressing the Green Fluorescent Protein (GFP) were constructed using 
the expression vector pDCermGFP, kindly provided by Professor Victor Nizet 
(University of California, San Diego). This vector contains a gfp gene placed behind 
the constitutive tet, cat and erm promoters (Jeng et al. 2003). pDCermGFP was 
initially extracted from E. coli cells in a liquid culture using the Wizard® Plus SV 
Minipreps DNA Purification System (Promega, Madison, WI). A volume of 20 mL 
of LB supplemented with 500 ug/mL of erythromycin was inoculated with a single 
bacterial colony and left growing at 37 ºC overnight at 190 rpm on an orbital shaker 
(Bioline, Alexandria, Australia). Cells were harvested by centrifugation at 5,000 xg 
for 10 min using a Heraeus Biofuge Primo centrifuge (Thermo Scientific, Waltham, 
MA), prior to performing a plasmid extraction according to the manufacturers’ 
specifications. The extracted plasmid concentration was determined using agarose 
gel electrophoresis as described in section 2.3.2.   
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2.3.2 Agarose gel electrophoresis 
Agarose gel electrophoresis was routinely used to visualise and confirm the 
extraction of pDCermGFP. Samples were prepared by mixing 5 µL of DNA with 1 
µL of loading dye prior to loading onto a 1% agarose egel. Electrophoresis was 
performed at 100 V for 1 h in 1xTAE buffer using a MiniSub™ Cell GT 
electrophoresis tank (Bio-Rad, Hercules, CA). Once electrophoresed, agarose gels 
were stained in ethidium bromide solution (1 µg/mL) for 20 min with gentle 
agitation followed by destaining in dH2O for 10 min. To visualise DNA bands, the 
gel was placed under ultraviolet light in a Novaline Gel Documentation System 
(Novex, Paddington, Australia). HyperLadder-1 DNA molecular weight marker 
(Bioline) was used as a comparison to determine the approximate size, and 
concentration of DNA samples via extrapolation from a standard curve. 
2.4 Bacterial transformation 
2.4.1 Preparation of electrocompetent GAS 
Electrocompetent cells of GAS strains NS88.2 and NS88.2prp were prepared for 
transformation by inoculating 120 mL of pre-warmed THBY with 4 mL of overnight 
starter cultures of either GAS strain. Cultures were shaken at 190 rpm and grown 
until an OD600nm 0.5 was reached. Cells were then harvested by centrifugation at 
7,000 xg for 10 min and washed twice by subsequent resuspension in 5 mL and 2mL 
of chilled 0.625 M sterile filtered sucrose. Following the final wash, cells were 
resuspended in a volume of 500 µL of sucrose and were then used immediately or 
stored in 50 µL aliquots at -80 ºC.  
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2.4.2 Transformation of electrocompetent GAS 
Transformation of GAS strains with pDCermGFP was initiated by adding 
approximately 180 ng of plasmid DNA to 50 µL of fresh or thawed electrocompetent 
NS88.2 or NS88.2prp GAS cells in a microfuge tube. The transformation mixture 
was transferred to a pre-chilled electroporation cuvette. Immediately thereafter, 
electroporation was conducted using the Gene Pulser™ electroporation apparatus 
(Bio-Rad) with the following settings: 1.25 kV, 600 Ω and 25 µFD. Following 
electroporation, the transformation mixture was diluted in 500 µL of 0.25 M sucrose/ 
THBY and grown for 1 h at 37 ºC. For each transformation culture, aliquots of 100 
µL and 400 µL were plated onto THA plates containing 2 µg/mL of erythromycin 
and grown overnight at 37 ºC. Positive transformants were screened by plating onto 
HBA plates and incubating overnight at 37 ºC, and the presence of streptococci was 
confirmed by haemolysis on HBA plates, while the insertion of pDCermGFP was 
evaluated using flow cytometry.  
2.5 Flow cytometry 
Flow cytometry analysis was employed to confirm the insertion of pDCermGFP into 
streptococci. A 1 mL aliquot of bacterial culture was harvested and pelleted at mid-
logarithmic phase (OD600 0.5) for 10 min at 5,000 xg. Following two wash steps in 
PBS, cells were resuspended in 500 µL of PBS and fixed with an equal volume of 
4% paraformaldehyde (PFA). To this mixture, a further 500 µL of PBS was added 
and samples were analysed using a BD LSRII flow cytometer (Franklin Lakes, NJ). 
A total of 10,000 cells were collected and gated for fluorescent streptococci at 
excitation and emission wavelengths of 488 nm and 515/20 nm respectively. Gating 
parameters used to detect fluorescent GAS remained consistent throughout this 
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study. Data were collected using a BD FACSDiva Software version 6.1.3 and 
analysed with FlowJo7 8.4.6 (TreeStar Inc., Ashland, OR).  
2.6 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) 
Throughout this project, proteins were routinely separated using SDS-PAGE 
performed in a PROTEAN™ Cell System (Bio-Rad). In order to denature proteins 
and reduce disulphide linkages, protein samples, unless otherwise stated, were boiled 
for 10 min in 1X reducing sample buffer and loaded onto 10% (w/v) acrylamide 
resolving gels [with a 4% (w/v) stacking gel] in aliquots of 10 µL. Electrophoresis 
was conducted at 200 V for 50 min in 1X SDS-PAGE running buffer using a 
PowerPac300 supply unit (Bio-Rad). Protein bands were visualised via staining the 
gel in excess amounts of Coomassie Brilliant Blue Rapid Stain overnight with 
constant agitation on an orbital shaker (Edwards Instrument Co., Narellan, 
Australia). Removal of excess dye from the background gel matrix was achieved by 
destaining the gel with a methanol and glacial acetic acid solution with gentle 
agitation. Frequent replacement of this solution was performed as required. 
Molecular weights of proteins were estimated using a standard curve generated via 
the Unstained PageRuler Protein Ladder (Fermentas, Lithuania), loaded into wells in 
5 µL aliquots. Gels were scanned using a GS-800 calibrated densitometer (Bio-Rad). 
2.7 Western blot analysis 
Following SDS-PAGE sample separation, specific detection of C3b, plasminogen, 
and streptokinase was performed via Western blotting. Proteins were 
electrophoretically transferred onto Nitrocellulose BioTrace ™ membrane (Pall 
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Corporation, Port Washington, NY) at 100 V for 1 h at 4 ºC in western transfer 
buffer with constant stirring using a Mini Trans-Blot® apparatus (Bio-Rad). Post-
transfer, blots were blocked overnight with 10% skim milk (Difco, Liverpool, 
Australia) in PBS at 4 ºC to prevent nonspecific protein detection by primary and 
secondary antibodies. To detect the presence of complement, plasminogen, or GAS-
secreted streptokinase, membranes were incubated with constant agitation for 1 h at 
room temperature in a heat-sealed plastic lock bag containing polyclonal goat 
antisera raised against human C3 (Calbiochem, San Diego, CA) diluted 1:6000, 
rabbit anti-human plasminogen (Calbiochem) diluted 1:5000, or rabbit polyclonal 
anti-streptokinase serum diluted 1:3000 in 1% (w/v) skim milk. Bound primary 
antibodies were probed using horseradish peroxidase (HRP)-conjugated rabbit anti-
goat IgG (Invitrogen, Carlsbad, CA) diluted 1:6000 (for complement detection), goat 
anti-rabbit IgG (Invitrogen) diluted in either 1:8000 (for plasminogen detection), or 
1:4000 (for streptokinase detection) in 1% skim milk. Membranes were incubated for 
1.5 h under the same conditions as above. Between all incubations, excess antibody 
was removed by rinsing the membrane three times with PBS for 5 min with mild 
agitation. After the final wash, the membrane was equilibrated with 100 mM Tris 
(pH 7.6) for 2 min. Protein bands were visualised via the chromogenic, or enhanced 
chemiluminescence detection methods. Visualisation was achieved using 3,3’-
diaminobenzadine tetrahydrochloride hydrate solution, and the reaction ceased by 
several rinses with dH2O, the membrane light-protected and air-dried overnight. For 
the enhanced chemiluminescence method, a Pierce Biotechnology kit (Rockford, Ill., 
USA) was used to visualise bands on Amersham Hyperfilm (GE Healthcare, 
Sweden) following the manufacturers’ instructions. Membranes and exposed X-ray 
films were analysed and scanned using the densitometer as per section 2.6.  
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2.8 GAS cell surface plasmin acquisition 
2.8.1 Streptokinase-mediated cell surface plasmin acquisition 
Relative levels of plasmin accumulated at the cell surface of GAS were measured as 
described (Cole et al. 2006). To facilitate cell surface plasmin acquisition, GAS were 
harvested at mid-log phase (approximately 1 x 108 CFU/mL) and cultured in the 
presence of 100 nM Glu-plasminogen (Haemotologic Technologies Inc., Essex 
Junction, VT) for 2 h at 37 °C. Under these conditions, GAS virulence factors that 
interact with plasminogen are secreted including streptokinase, which meditates the 
activation of plasminogen to plasmin (Christner et al. 1997). Glu-plasminogen was 
omitted from negative controls. Bacterial cultures were pelleted by centrifugation at 
14,000 xg for 10 min and washed twice in PBS to remove any unbound 
plasminogen. After the final wash, cells were resuspended in 45 µL of PBS followed 
by the addition of the plasmin- and streptokinase-activated plasminogen-specific 
chromogenic substrate S-2251 (Chromogenix, Bedford, MA), or Spectrozyme PL 
(American Diagnostica, Stamford, CT) at a final working concentration of 0.5 mM 
and incubated overnight at 37 °C. Bacteria were then centrifuged at 14,000 xg for 10 
min, and the supernatant moved to a 96-well microtiter plate. Plasmin activity 
produced by each GAS strain was measured spectrophotometrically at 405 nm (A405) 
using a SpectraMax® plate reader (Molecular Devices, Sunnyvale, CA). 
2.8.2 Host plasminogen activator-mediated cell surface plasmin acquisition 
The ability of host-derived uPA and tPA to facilitate plasminogen activation at the 
GAS cell surface was assessed. GAS was incubated for 3 h at 37 °C with 0.5 mg/mL 
human Glu-plasminogen and a combination of either 3 IU human or mouse tPA 
(Abcam, Melbourne, Australia) or human or mouse uPA (Calbiochem). Controls 
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included the sole incubation of Glu-plasminogen, plasminogen activator and PBS 
only. GAS were washed and subsequent levels of cell surface plasmin activity 
measured as described in section 2.8.1.  
2.8.3 Cell surface plasmin acquisition in plasma 
GAS cell surface plasmin acquisition in human or mouse plasma ex vivo was 
conducted as described elsewhere (Cole et al. 2006; Sanderson-Smith et al. 2008). 
GAS were incubated in 10 mM sodium-citrated plasma obtained from human 
(volunteer donors), or mouse (AlbPLG1, AlbPLG1/uPA-/- or AlbPLG1/tPA-/-) for 3 h 
at 37 °C. Plasmin bound to the GAS cell surface was measured as described in 
section 2.8.1.  
2.9 Plasminogen acquisition in plasma 
Plasminogen binding to the GAS cell surface was detected using Western blot 
analysis following incubation of GAS in either human or mouse plasma (Sanderson-
Smith et al. 2008). Plasminogen bound to the bacterial cell surface was eluted with 
100 nM glycine-HCl (pH 2.0), and the eluent was screened for the presence of 
plasminogen using rabbit anti-human plasminogen (Calbiochem) as described in 
section 2.7. 
2.10 Animal infection studies 
2.10.1 Ethics statement 
All animal experiments complied with the NHMRC Australian code for the care and 
use of animals for scientific purposes, the NIH Guide for the care and use of 
laboratory animals, and the University of Note Dame Institutional Animal Care and 
Use Committee (IACUC). Permission to perform animal experiments was granted by 
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the University of Notre Dame (Notre Dame, Indiana), and University of Wollongong 
ethics committees. Animals were continuously monitored throughout experiments by 
trained caretakers.  
2.10.2 Animals 
Male and female mice heterozygous (AlbPLG1+/-) for the human plasminogen 
transgene were established and genotyped via standard PCR analysis as described in 
section 2.10.3 (Sun et al. 2004; Cole et al. 2006). Mice homozygous (AlbPLG1+/+) 
for the human plasminogen transgene were generated and characterised as described 
in section 2.10.4). Characterisation of uPA and tPA in GAS virulence was assessed 
using mice deficient in expression of uPA (AlbPLG1/uPA-/-), or tPA (AlbPLG1/tPA-/-
) in a humanised plasminogen heterozygous background. For studies assessing the 
effect of uPA drug inhibitors in GAS pathogenesis, homozygous AlbPLG1 mice 
were employed further as described in section 4.3. Mouse colonies were bred and 
maintained at the University of Wollongong and Australian BioResources 
(AlbPLG1+/+ and AlbPLG1+/-), or University of Notre Dame (AlbPLG1/uPA-/- and 
AlbPLG1/tPA-/-). 
2.10.3 Genotyping of heterozygous human plasminogen mice 
Following overnight storage at -20 °C, DNA from ear cuttings of offspring was 
extracted using REDextract-N-AMP Tissue PCR kit according to the manufacturer’s 
instructions (Sigma-Aldrich, St. Louis, MO). Standard PCR was performed using the 
following parameters: initial denaturation (94 °C for 2 min), [denaturation (94 °C for 
40 s), annealing (55 °C for 40 s), extension (72°C for 2 min) x35 cycles], final 
extension (72 °C for 4 min), and cooling (25 °C for 3 min). To distinguish between 
transgenic human plasminogen mice and wild-type mice, PCR products underwent 
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agarose electrophoresis on a 1.5% agarose gel (section 2.3.2). Transgenic humanised 
plasminogen mice displayed two bands at approximately 160 bp and 340 bp, 
indicative of human and mouse plasminogen respectively, while wild-type mice 
display only a single band at 340 bp. 
2.10.4 Generation and characterisation of homozygous humanised plasminogen 
mice 
A homozygous mouse line transgenic for human plasminogen was established and 
kindly gifted by Dr. Nicholas West and Mercedes Monteleone (University of 
Sydney, Australia). Male and female, heterozygous humanised plasminogen mice 
were backcrossed, and the resultant litters were genotyped following DNA extraction 
from ear cuttings. The tissue samples were incubated in 100 µL of lysis buffer [(100 
mM Tris, pH 7.5, 5 mM EDTA, 200 mM NaCl, 0.5% (v/v) Tween-20, 15 µL 
proteinase K (1 mg/mL)] at 56 ºC for 4 h. The DNA samples were then used directly 
as templates for the detection of the transgene by PCR. Quantitative RT-PCR to 
identify progeny from the cross with higher levels of the human plasminogen 
transgene was performed as heterozygous and homozygous mice are 
indistinguishable via standard PCR analysis. The primers plasminogen A (5’-
CAGCTCCCTGTGATTGAGAA-3’) and plasminogen B (5’-
GAAGTGACTCCTTGTAAAATG-3’) were designed and used for quantitative RT-
PCR. Two male and two female individual mice displayed elevated transgene levels 
for human plasminogen, and were subsequently backcrossed to wild-type C57Bl/6J 
mice for confirmation of the homozygous genotype. Transgenic parents that gave 
rise to 100% heterozygous offspring (n ≥ 6 per litter), determined by standard PCR, 
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were confirmed to be homozygous for the human plasminogen transgene 
(AlbPLG1+/+) and retained to establish the breeding colony.  
The level of mouse plasminogen in mouse plasma was assessed by Dr. Martina 
Sanderson-Smith using a mouse plasminogen-specific ELISA kit (CSB-
EL018188MO) according to the manufacturers’ instructions (Cusabio, Wuhan, 
China). The level of activatable human plasminogen in both mouse lines were 
assessed via diluting human and mouse plasma samples 1:10 in assay buffer (10 mM 
HEPES, 150 mM NaCl, 0.01% Tween-20, pH 7.4). Activation of human 
plasminogen present in the mouse plasma samples was assessed by Dr. Jason 
McArthur. Briefly, human plasminogen was converted to plasmin by the addition of 
5 nM group C streptokinase (Cook et al. 2012), and incubated for 15 min at room 
temperature. Plasmin generation was then measured and monitored overtime as 
described in section 2.8.1. Plasmin activity, expressed as a percentage of human 
plasma, was calculated by [(A405 mouse plasma ÷ A405 human plasma) × 100]. All 
reactions were linear over the initial 20 min of the reaction. Cell surface plasmin 
acquisition by GAS strain NS88.2 in plasma derived from either mouse line was 
determined as detailed in section 2.8.3.  
2.10.5 GAS inoculum preparation 
Prior to each GAS infection study, multiple practice inoculums were performed to 
ensure that bacterial colony numbers were uniform across each study. Bacterial 
inoculums were prepared via harvesting cultures at mid-log phase (OD600 0.5), and 
washing twice with 0.7% (w/v) sterile saline. Pellets were then resuspended in saline 
to a final volume appropriate for the desired inoculum concentration, and kept on ice 
prior to mice administration.  
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2.10.6 Mouse preparation 
To facilitate the ease of injections, mice underwent hair removal on their right/left 
flanks via shaving and application of depilatory cream. Immediately prior to 
subcutaneous or intradermal GAS infections, mice were anaesthetised via isoflurane 
(Lyppard, Castle Hill, Australia) inhalation. 
2.10.7 Assessment of GAS virulence using a mouse model of infection 
In order to investigate the role of host activators uPA and tPA in GAS pathogenesis, 
GAS virulence was assessed using transgenic AlbPLG1 mice expressing human 
plasminogen, and mice deficient in either uPA (AlbPLG1/uPA-/-) or tPA 
(AlbPLG1/tPA-/-). Individual cohorts of mice were age and gender-matched between 
6-12 weeks old, and were selected in cohorts of eight or ten mice for tPA and uPA 
studies respectively. For tPA studies, AlbPLG1+/- and AlbPLG1/tPA-/- mice were 
subcutaneously inoculated in the right flank with 1 x 109 CFU/mL of parent GAS 
strain 5448, while a higher dose of 1 x 1010 CFU/mL of GAS strains 5448 and 
5448∆ska were inoculated in AlbPLG1+/- and AlbPLG1/uPA-/- mice for uPA studies 
in 100 µL injection volumes. To confirm GAS virulence in mice homozygous for the 
human plasminogen transgene, cohorts of ten age and sex-matched AlbPLG1+/-, or 
AlbPLG1+/+ mice were subcutaneously infected with GAS as described previously 
(Sanderson-Smith et al. 2008). In all studies, mice were closely monitored over a 
ten-day period, and moribund mice were sacrificed via CO2 asphyxiation.  
2.10.8 Bacterial dissemination 
In order to determine the progression of invasive GAS disease, bacterial load at the 
initial site of infection, in internal organs and in the bloodstream were assessed. 
Cohorts of three mice (AlbPLG1 and AlbPLG1/tPA-/- or AlbPLG1/uPA-/-) were 
Chapter 2 General Materials and Methods 
 
Page | 61 
 
subcutaneously infected with a high bacterial load of 4 x 109 CFU/mL or 4 x 1010 
CFU/mL GAS for tPA or uPA studies, respectively. Approximately 48-72 h post-
infection, the liver, spleen and skin at the site of infection were harvested and kept 
ice-cold in 0.7% (w/v) sterile saline at all times, whilst blood was collected and 
diluted 1:10 in sterile saline at room temperature. Immediately after, homogenates of 
these organs were prepared using the Bio-Gen PRO200 (PRO Scientific, Oxford, 
CT). For each sample, organs were homogenised for approximately 2 x 30 s or until 
completely uniform. In between each sample, the homogeniser was cleaned three 
times with 70% (v/v) ethanol and PBS. Tweezing to completely remove any tissue 
remnants was performed before proceeding with the next sample. Bacterial load was 
determined by plating serial 10-fold dilutions overnight on HBA, and the CFU 
enumerated the following day. Lesion sizes at the site of infection were also 
recorded, and the mean skin lesion calculated as Area = [π (Length x Width)/4] 
according to the method of Khil et al. (2003). 
2.11 Statistical analysis 
All statistical analysis was performed using GraphPad Prism version 5.0 (GraphPad 
Software Inc., San Diego, CA).  Differences in the level of plasmin acquisition at the 
GAS cell surface were determined using Student’s t-test. Animal survival studies 
were determined by log-rank test. All other data were analysed using one-way 
analysis of variance with Tukey’s multiple comparison test. Data sets were 
considered statistically significant at P < 0.05. 
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This chapter has been published in the Journal of Innate Immunity and presents data 
generated by co-authors, as outlined on page x, and will be acknowledged 
accordingly. 
Reference: 
Diane Ly, Jude M. Taylor, James A. Tsatsaronis, Mercedes M. Monteleone, Amanda 
S. Skora, Cortny A. Donald, Tracy Maddocks, Victor Nizet, Nicholas P. West, Marie 
Ranson, Mark J. Walker, Jason D. McArthur, Martina L. Sanderson-Smith (2014). 
Plasmin(ogen) acquisition by Group A Streptococcus protects against C3b-mediated 
neutrophil killing. Journal of Innate Immunity. 6: 240-250.  
3.1 Abstract 
The acquisition of host protease plasmin to the bacterial cell surface is critical during 
invasive disease initiation by GAS. Recent evidence has shown that localised 
plasmin activity prevents opsonisation of several bacterial species by key 
components of the innate immune system in vitro. Here, we demonstrate that 
plasmin at the GAS cell surface is able to degrade complement factor C3b, and that 
plasminogen acquisition is associated with a decrease in C3b opsonisation and 
neutrophil-mediated killing in vitro. Furthermore, the ability of GAS to acquire cell 
surface plasmin(ogen) correlates directly with a decrease in C3b opsonisation, 
neutrophil phagocytosis, and increased bacterial survival in a humanised 
plasminogen mouse model of infection. These findings demonstrate that localised 
plasmin(ogen) plays an important role in facilitating GAS escape from the host 
innate immune response and increases bacterial virulence in the early stages of 
infection.  
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3.2 Introduction 
Superficial infections including pharyngitis and impetigo follow from GAS 
colonising epithelial surfaces of the upper respiratory tract and skin, while further 
dissemination into sterile tissue sites can lead to life-threatening conditions such as 
necrotising fasciitis and STSS (Walker et al. 2014). The high global disease burden 
of invasive GAS infections necessitates identification of key mechanisms of 
pathogenesis, particularly in the early stages of infection.  
Subversion of the host plasminogen activation system is critical to the initiation of 
invasive infection by GAS (Sun et al. 2004; Cole et al. 2006; Sanderson-Smith et al. 
2008). Plasminogen circulates as a 92 kDa zymogen in blood and extracellular fluids 
at an approximate concentration of 2 µM (Ogston 1980). Activation of plasminogen 
to the broad spectrum protease plasmin can be mediated by mammalian activators 
uPA and tPA, or bacterial activators including the GAS secreted protein 
streptokinase. GAS expresses multiple cell surface receptors for plasmin(ogen), 
including GAPDH, SEN and PAM/Prp (Sanderson-Smith et al. 2012). Once 
localised to the bacterial cell surface, plasmin is able to facilitate degradation of 
ECM components, fibrin clot and host tissue barriers, leading to widespread bacterial 
dissemination. More recently, plasmin-mediated evasion of host immunity has 
emerged as a key mechanism in bacterial pathogenesis (Hollands et al. 2012; 
Sanderson-Smith et al. 2012). 
The complement system is a critical component of the innate immune response 
against pathogenic organisms and involves the coordinated action of over 30 
proteolytic plasma enzymes (Beutler 2004). Activation of the complement cascade 
occurs via three distinct routes, comprising the classical, alternate and lectin 
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pathways. Each of these pathways however, converge at a central step involving the 
cleavage product of C3 convertase, C3b, a key opsonin that binds to microbial 
surfaces. Phagocytes such as macrophages and neutrophils recognise opsonised 
bacteria via specific complement receptors, leading to phagocytosis and microbial 
killing.  
Plasmin has been shown to degrade C3b, and streptokinase-generated plasmin 
inactivates complement components C1, C2, C3 and C4 (Pillemer et al. 1953; Seya 
and Nagasawa 1985). Additionally, plasmin-mediated C3b degradation by human 
bacterial pathogens has been observed in vitro (Rooijakkers et al. 2005). In this 
study, we demonstrate for the first time that plasmin localised at the GAS surface 
degrades human C3b, and that cell surface plasminogen acquisition correlates with 
decreased C3b deposition and resistance to complement-mediated neutrophil killing 
in vitro. Furthermore, we show that surface-associated plasmin(ogen) correlates with 
reduced C3b deposition, C3b-mediated neutrophil killing, and increased bacterial 
survival in vivo.  
3.3 Methods and materials 
3.3.1 Characterisation of GAS strains 
In vitro characterisation was performed to confirm the phenotypic properties of wild-
type GAS strain NS88.2 and its isogenic mutants, NS88.2prp and NS88.2∆ska. 
These GAS strains are described in detail previously (section 2.1.1). Growth kinetics 
and streptokinase-mediated cell surface plasmin acquisition by GAS were assessed 
as described in sections 2.2 and 2.8.1 respectively. The level of hyaluronic acid 
capsule produced by GAS was confirmed previously by Dr. Martina Sanderson-
Smith (Sanderson-Smith et al. 2008; Cook et al. 2012). 
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3.3.1.1 Screening for streptokinase expression 
Detection of streptokinase was performed according to the method of Cook et al. 
(2012). Briefly, GAS were grown to mid-logarithmic phase, and cultures were 
subjected to centrifugation to sediment bacterial cells. Five millilitres of GAS 
supernatant was collected and sterile filtered using a 0.22 µm filter (Millipore). 
Proteins underwent trichloroacetic acid (TCA) precipitation, whereby supernatant 
was incubated with 10 % (v/v) TCA in a 1:1 ratio on ice for 20 min, followed by 
centrifugation for 15 min at 14,000 xg and resuspended in ice-cold 100 % (v/v) 
ethanol. After 5 min centrifugation, supernatant was removed by aspiration and the 
remaining protein pellet dried in the fume-hood. Finally, the pellet was resuspended 
in 100 mM Tris-HCl (pH 7.6) and the sample subjected to Western blotting (section 
2.7).  
3.3.2 Human C3b degradation 
The ability of exogenous plasmin to degrade C3b was assessed according to the 
methods described by Rooijakkers et al. (2005). In 50 µL reaction volumes, 1 µg 
human C3b (Calbiochem) was incubated alone in PBS (positive control), or in PBS 
containing either 100 nM Glu-plasminogen, 100 nM group C streptokinase (SKc; 
Sigma Aldrich), 100 nM human plasmin (Haemotologic Technologies Inc.), or a 
combination of 100 nM Glu-plasminogen and 100 nM SKc. Following overnight 
incubation at 37 ºC, samples were centrifuged and the supernatants collected and 
separated on a 10% SDS-PAGE gel under reducing conditions. Protein bands were 
visualised using enhanced chemiluminescence reagents as described in section 2.7. 
Similarly, the impact of GAS cell surface plasmin activity on C3b was assessed 
following an overnight incubation of GAS with or without cell surface plasmin in the 
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presence of 0.5 µg C3b in a total volume of 10 µL. C3b, and its degraded fragments 
were analysed as above.   
3.3.3 Characterisation of C3b deposition in vitro 
Whole-cell ELISA was used to analyse the influence of fluid-phase plasmin on C3b 
deposition according to the methods of Rooijakkers et al. (2005). Washed bacteria 
were resuspended in ELISA coating buffer, and 100 µL of this suspension was used 
to coat wells of a microtiter plate for 2 h at 37 ºC followed by an overnight 
incubation at 4 ºC. Between all incubations, wells were washed thrice with PBS 
containing 0.05% (v/v) Tween-20 (PBST). Unsaturated binding sites were then 
blocked with 100 µL of 1% (w/v) bovine serum albumin (BSA) in PBS for 1 h at 37 
ºC. To facilitate C3b deposition on bacterial surfaces, citrated human plasma was 
serially diluted 1:3 across the plate in 1% (w/v) BSA and incubated for 20 min at 37 
ºC. Negative controls did not receive aliquots of human plasma. Following washing, 
50 µL of 100 nM human plasmin or 1% (w/v) BSA were added to each well, and the 
plate incubated for 1 h at 37 ºC. An overnight incubation at 37 ºC was conducted 
after the addition of 50 µL of goat anti-C3 polyclonal primary antibody diluted 
1:1000 in 1% (w/v) BSA to allow detection of bound C3b. Anti-C3 antibodies were 
probed using 50 µL HRP-conjugated rabbit anti-goat IgG diluted 1:2000 for 1 h at 
37 ºC. Thereafter, the assay was visualised by the addition of 50 µL of substrate 
solution containing o-phenylenediamine, the reaction stopped with 1 M HCl, and the 
absorbance measured spectrophotometrically at 490 nm. GAS-coated wells were 
confirmed with polyclonal rabbit anti-M antisera diluted 1:1000 in 1% (w/v) BSA, 
which has previously been shown to specifically detect GAS M proteins in microtiter 
assays (Sanderson-Smith et al. 2006). HRP-conjugated goat anti-rabbit IgG 
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(Millipore, Billerica, MA) diluted 1:2000 in 1% (w/v) BSA was used to detect any 
bound antibodies. 
The impact of GAS localised plasmin activity on C3b deposition was analysed by 
incubating fluorescent GAS in 100 µL of 50% human or mouse plasma diluted in 
PBS for 10 min at 37 ºC. Following two washes with PBST, non-specific binding 
sites were blocked by incubating bacteria with human IgG (Invitrogen, Carlsbad, 
CA) diluted 1:500 in PBS for 30 min on ice without light. Washed bacteria were 
resuspended in 200 µL of PBS, which was subsequently divided into two 100 µL 
samples. Under light protection, surface bound C3b was detected by incubation of 
samples for 1 h on ice with 0.2 µg of phycoerythrin (PE)-conjugated anti-human C3 
monoclonal antibody (Cederlane Laboratories Ltd., Burlington, Canada), or 0.2 µg 
of PE-labelled mouse IgG1 isotype control (Cederlane Laboratories Ltd.) to identify 
background fluorescence. Prior to flow cytometry analysis, bacterial cells were 
resuspended in 100 µL PBS, fixed in 100 µL 4% (w/v) paraformaldehyde (PFA) and 
made up to a final volume of 400 µL with PBS. Alternatively, to confirm the 
presence or absence of bacterial cell surface plasmin activity, opsonised bacteria 
were incubated with the plasmin-specific substrate S-2251 for 1 h at 37 ºC and 
absorbance read at 405 nm. Gating for fluorescent GAS and attached C3b molecules 
was performed using an argon laser with an excitation wavelength of 488 nm 
(excitation wavelength of GFP and PE). GFP-expressing GAS were detected at an 
emission wavelength of 515/20 nm, while PE-labelled monoclonal antibodies 
generated against human C3 and mouse IgG1 isotype control were gauged with an 
emission intensity at 575/26 nm. The amount of C3b deposited on bacterial surfaces 
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was expressed as a percentage of fluorescent GAS. A total of 10, 000 cells were 
collected for each sample. 
3.3.4 C3b deposition and neutrophil phagocytosis in vivo 
Transgenic humanised plasminogen mice (AlbPLG1+/+) aged 6-8 weeks were 
intradermally injected into right and left shaved flanks with eGFP-expressing GAS 
strains NS88.2 (n = 8), NS88.2prp (n = 4) or NS88.2∆ska (n = 4) at approximately 1 
x 108 CFU. Mice were sacrificed by CO2 asphyxiation 4 h thereafter, and the 
intradermal layer at the site of infection was lavaged twice with 500 µL of 0.7% 
(w/v) saline. C3b deposition on recovered GAS was assessed by flow cytometry as 
described in section 3.3.3. Supernatants collected from mice injected with saline only 
served as controls for background fluorescence. Lavage fluid recovered from the 
right and left flanks of each mouse were pooled to increase the yield of bacterial 
cells.  
The uptake of GAS by mouse neutrophils ex vivo was assessed by Dr. Jude Taylor 
(University of Wollongong, Australia). Briefly, recovered cells from each flank were 
blocked with Fc Block (anti-mouse CD16/32; Biolegend, San Diego, California). 
Cells were then added to a cocktail of Ly6C, Ly6G, and CD45 (Biolegend) diluted in 
FACS buffer according to the manufacturers’ instructions (Dulbecco’s PBS, 0.2% 
(w/v) BSA, 1 mM NaN3). After incubation for 20 min on ice, cells were washed and 
resuspended in a final volume of 0.5 mL of FACS buffer prior to analysis via flow 
cytometry. Phagocytosis was determined by fluorescent GAS uptake by mouse 
neutrophils.  
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3.3.5 GAS survival in vivo 
The ability of NS88.2 (n = 6), NS88.2prp (n = 5) and NS88.2∆ska (n = 5) to survive 
in vivo was determined via pelleting collected bacteria following infection at 14,000 
xg for 10 min as described in section 3.3.4. In a microtiter plate, resuspended 
bacteria were serially diluted in sterile Milli-Q water and plated onto HBA overnight 
at 37 °C and the number of bacterial colonies enumerated.  
3.3.6 Complement-mediated neutrophil killing 
3.3.6.1 Ethics statement 
All volunteers provided informed consent prior to donating blood samples according 
to the conditions outlined in HE08/250 approved by the University of Wollongong 
Human Ethics Committee, Wollongong, Australia.  
3.3.6.2 Preparation of GAS 
The ability of plasmin-coated GAS to resist the phagocytic killing by human 
neutrophils was assessed in vitro according to Hollands et al. (2012). GAS with or 
without cell surface plasmin activity were opsonised with autologous human plasma 
for 10 min at 37 °C.  Following two washes with PBS, bacteria (2 x 104 CFU) were 
serially diluted in RPMI 1640 media (Invitrogen) containing 2% heat inactivated 
plasma and placed on ice until required. Alternatively, bacteria were also screened 
for the presence or absence of cell surface plasmin activity as described in section 
2.8.1.  
3.3.6.3 Isolation of neutrophils 
Human neutrophils were freshly isolated from 20 mL of citrated (0.5 M sodium 
citrate) venous blood of healthy volunteers. To separate blood into distinct cellular 
fractions, 5 mL of anticoagulated whole blood was carefully layered over an 
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equivalent volume of Polmorphprep™ (Axis-Shield, Oslo, Norway) in four separate 
falcon tubes to create a density gradient of sodium diatrizoate containing neutrophils. 
The tubes were centrifuged for 25 min at 500 xg using a swing-out rotor bucket of 
the Heraeus Multifuge X3R Centrifuge (Thermo Scientific, Waltham, MA) with 
acceleration and deceleration set at 9 and 0 respectively. Following this, the upper 
plasma layer was collected and stored at -20 ºC, while neutrophils were harvested 
from the leukocyte-rich fraction using a 1 mL pipette tip. The cell suspension was 
then diluted in 50 mL of PBS, followed by centrifugation for 10 min at 180 xg with 
full deceleration. Cells were washed twice by resuspending in 200 µL of PBS, 
followed by gentle inversion in a hyptonic solution of 5 mL sterile water for 10 sec 
to lyse residual contaminating erythrocytes. Lysis was stopped by the addition of 45 
mL of PBS and cells pelleted as above. To determine the number of isolated 
neutrophils, standard haemocytometer techniques was employed. Briefly, neutrophils 
were diluted 1:10 in PBS, and 10 µL of this suspension was allowed to stain for 3 
min with an equal volume of 0.4% (w/v) trypan blue dye (Sigma-Aldrich, St. Louis, 
MO). The trypan blue cell suspension was then transferred to the haemocytometer 
chamber and the number of viable cells (opaque coloured) was analysed by 
exclusion of trypan blue dye under a light microscope (Leica, Wetzlar, Germany). 
Cell concentration was then adjusted to 2 x 105 neutrophils by dilution in RPMI 
1640 media supplemented with 2% heat inactivated plasma.  
3.3.6.4 Neutrophil killing of GAS 
To a 96-well flat-bottomed cell culture plate (Greiner Bio-one, Frickenhausen, 
Germany), 100 µL of 2 x 104 CFU of GAS was mixed with 100 µL of 2 x 105 
neutrophils suspended in RPMI 1640 containing 2% heat inactivated plasma 
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(multiplicity of infection = 1:10). To synchronise bacterial contact with neutrophils, 
the plate was centrifuged at 180 xg for 10 min. Phagocytosis was facilitated at 37 ºC 
for 30 min. Hypertonic lysis of neutrophils was performed by immediately 
transferring the reaction mixture in sterile water and serially diluted 1:10. The 
appropriate dilutions (10-1-10-3) were plated on THA overnight and CFU/mL 
enumerated the following day. Growth controls consisted of bacteria incubated under 
the same conditions in the absence of neutrophils. The percent of surviving GAS was 
calculated by: [(experimental well) ÷ (control well)] x 100. 
3.4 Results 
3.4.1 Phenotypic characterisation of GAS strain NS88.2 and its isogenic mutants 
The phenotypic properties of GAS strain NS88.2 and the isogenic mutants, 
NS88.2prp and NS88.2Δska, were confirmed via examining the growth kinetics, 
capsule expression and the ability to acquire cell surface plasmin in vitro of each 
strain. Mutation of Prp, or deletion of streptokinase did not alter the growth in 
THBY of NS88.2prp or NS88.2Δska compared to the parent strain NS88.2 (Figure 
3.1A). Western blot analysis confirmed the lack of streptokinase secretion by 
NS88.2Δska, whilst strains NS88.2 and NS88.2prp expressed equivalent amounts of 
streptokinase (Figure 3.1B). All strains produced similar levels of hyaluronic acid 
capsule at the cell surface, and plasmin acquisition assays showed that as expected, 
NS88.2prp and NS88.2Δska accrued significantly less plasmin at the bacterial 
surface compared to NS88.2 (Figure 3.1D). These strains were therefore deemed 
appropriate for this study.  
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Figure 3.1 In vitro characterisation of NS88.2, and the isogenic prp and ska deletion mutants. (A) 
Growth of NS88.2, NS88.2prp and NS88.2∆ska. (B) Western blot analysis of streptokinase secreted 
into culture supernatants. An arrow indicates the major immunoreactive band. (C) NS88.2, 
NS88.2prp and NS88.2∆ska produce equivalent levels of hyaluronic acid capsule. (D) GAS cell 
surface plasmin acquisition in culture supernatants with the addition of Glu-plasminogen. Data 
represents the mean ± SEM of two independent experiments performed in triplicate. Asterisks 
indicate statistical significance, ***P < 0.001. 
 
3.4.2 Plasmin at the GAS cell surface degrades human C3b 
GAS-secreted streptokinase mediates plasminogen activation by the formation of a 
1:1 stoichiometric complex with plasminogen, resulting in a complex equipped with 
plasmin and plasminogen activator activity (Reddy and Markus 1972). To confirm 
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for plasmin generated using host activators, we employed a solution phase 
degradation assay followed by Western blot analysis. Streptokinase-generated 
plasmin degraded C3b, whereas no degradation was seen in the presence of either 
streptokinase or plasminogen alone (Figure 3.2A). To further assess the ability of 
plasmin sequestered to the GAS cell surface to degrade C3b, we employed a wild-
type parent GAS strain (NS88.2), and its isogenic mutants abrogated for either cell 
surface plasmin acquisition (NS88.2prp), or streptokinase expression (NS88.2∆ska). 
C3b degradation by GAS was dependent on the presence of cell surface plasmin. 
Following pre-incubation with plasminogen, wild-type GAS strain NS88.2 degraded 
C3b, however, incubation of C3b with NS88.2prp or NS88.2∆ska, which do not 
accumulate plasmin under these conditions, did not result in detectable C3b 
degradation (Figure 3.2B). Likewise, all GAS strains were not able to degrade C3b 
without a source of cell surface plasmin activity (Figure 3.2B). These data clearly 
demonstrate that streptokinase-generated plasmin, and plasmin localised to the GAS 
cell surface is sufficient for complement C3b degradation. 
3.4.3 Plasmin(ogen) reduces C3b deposition on GAS in vitro 
Analysis of GAS cell surface plasmin acquisition assays confirmed that as expected, 
neither NS88.2prp nor NS88.2Δska bound significant levels of plasmin at the 
bacterial surface (Figure 3.3A). Western blot analysis of proteins eluted from the 
GAS cell surface confirmed that both NS88.2 and NS88.2Δska bound plasminogen 
in human plasma, whilst NS88.2prp did not (Figure 3.3B). To determine if fluid-
phase plasmin was able to deplete C3b from the bacterial surface, C3b deposition on 
the GAS cell surface in the presence or absence of plasmin was measured using 
whole-cell ELISA. C3b deposition was found to be dose-dependent, with saturation  
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Figure 3.2 Streptokinase-generated plasmin and GAS cell surface plasmin degrade C3b. In both 
panels, protein samples were resolved by SDS-PAGE under reducing conditions and transferred onto 
a nitrocellulose membrane. Cleavage of C3b was analysed via Western blotting using goat anti-C3 
IgG and HRP-conjugated rabbit anti-goat secondary antibody. (A) Human C3b was incubated 
overnight singly (lane 1), or together with plasminogen (Plg; lane 2); streptokinase (SK; lane 3); 
human plasmin (lane 4), or a combination of plasminogen and streptokinase (lane 5). (B) GAS were 
pre-incubated with (+) or (-) without 100 nM Glu-plasminogen for 2 h at 37 °C, followed by an 
overnight incubation with 1 µg C3b. Intact C3b is visible as the α- and  β-chain (lane 1). Plasmin at 
the cell surface of NS88.2 partially cleaved C3b into smaller degradation products (lane 2). C3b 
remained intact and was not cleaved in the absence of plasmin at the cell surface of NS88.2 (lane 3), 
or when NS88.2prp or NS88.2Δska was incubated with C3b (lanes 4-7). 
 
occurring in 33% human plasma. The addition of exogenous plasmin after 
opsonisation resulted in a significant decrease in the amount of C3b detected at the 
GAS cell surface (P < 0.001; Figure 3.3C). No signal was detected when GAS was 
incubated with 1% BSA alone (data not shown). We next assessed the impact of 
bacterial cell surface plasmin activity on C3b deposition. Each isogenic GAS strain 
set was transformed with an eGFP-expressing plasmid, opsonised with human 
plasma, and C3b deposition measured via flow cytometry. Significantly less C3b 
was detected at the surface of wild-type strain NS88.2, which accumulates 
A B 
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plasmin(ogen) on its cell surface, than NS88.2prp (P < 0.01), which does not 
accumulate plasmin(ogen) at the cell surface. However, no significant difference was 
seen in C3b deposition between NS88.2 and NS88.2Δska (Figure 3.3D). No 
significant fluorescence was detected using an isotype-matched control antibody 
(data not shown). These data suggest that plasminogen binding by NS88.2 and 
NS88.2Δska, which showed decreased levels of C3b at the cell surface, while 
NS88.2prp was readily opsonised by C3b, rather than plasmin activation or 
acquisition is responsible for the decrease in C3b deposition. 
3.4.4 Plasminogen at the GAS cell surface impairs complement-mediated 
neutrophil killing 
One consequence of C3b deposition on microbial surfaces is phagocytosis and 
killing by neutrophils. Therefore, to further examine the functional significance of 
observed decreases in C3b deposition, bacteria were opsonised with human plasma 
and survival in the presence of human neutrophils was measured. Wild-type strain 
NS88.2 was significantly more resistant to neutrophil killing compared to NS88.2prp 
(P < 0.05). There was no significant difference between the survival of NS88.2 and 
NS88.2Δska in the presence of human neutrophils (Figure 3.4A). To confirm that 
this observation was complement dependent, the assay was repeated using comple-
ment-depleted plasma. No significant differences in survival of wild-type and mutant 
GAS strains were observed in the absence of complement (Figure 3.4B). Incubation 
of bacteria with Spectrozyme PL after opsonisation confirmed that wild-type GAS 
strain NS88.2 sequestered significantly higher levels of cell surface plasmin than 
either the NS88.2prp (P < 0.001) or NS88.2Δska (P < 0.01) mutants (Figure 3.4C),
Chapter 3 Plasmin(ogen) Acquisition Protects GAS from Complement-mediated Neutrophil Killing 









Figure 3.3 Plasmin(ogen) decreases C3b deposition on GAS in vitro. The acquisition of plasmin or plasminogen at the GAS cell surface was confirmed via (A) 
incubating bacteria with the plasmin-specific substrate Spectrozyme PL overnight, or (B) Western blot analysis of proteins eluted from the bacterial cell surface following 
incubation in human plasma. (C) The impact of fluid-phase plasmin on C3b deposition on the GAS cell surface was assessed using whole-cell ELISA. The addition of 
exogenous plasmin after bacterial opsonisation led to a significant decrease in C3b attachment to the bacterial surface (P < 0.001). (D) In order to assess the impact of cell 
surface plasmin on C3b deposition, bacteria were opsonised at 37 °C for 10 min in 50% human plasma as a source of complement and plasmin(ogen). Nonspecific binding 
sites were blocked by incubating bacteria with human IgG and surface-bound C3b was probed using PE-conjugated monoclonal antibody raised against human C3. Alter-
natively, cells were stained with PE-labelled mouse IgG isotype control. C3b deposition on the bacterial surface was analysed using flow cytometry. C3b deposition was 
significantly reduced on the surface of NS88.2 compared to NS88.2prp (P < 0.001), but not NS88.2Δska. Histograms show the shift in mean fluorescence intensity (MFI) 
between GAS stained with the isotype control (grey) and an anti-C3 antibody (white). Bars indicate means ± SEM of triplicates expressed in MFI. Data are representative 
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Figure 3.4 Plasminogen at the GAS cell surface confers protection to C3b-mediated killing. 
Bacteria were opsonised with 50% human plasma for 10 min at 37 °C as a source of plasminogen and 
complement. Washed bacteria were co-cultured with purified human neutrophils for 30 min at 37 °C 
to allow for phagocytic uptake, with phagocytosis disrupted by hypotonic lysis of neutrophils. The 
numbers of viable bacterial colonies were enumerated after overnight incubation at 37 °C. Negative 
controls consisted of bacteria incubated under the same conditions without neutrophils. (A) NS88.2 
was significantly more resistant to complement-mediated neutrophil killing than NS88.2prp (P < 
0.01), but not NS88.2Δska. (B) Bacteria were alternatively incubated with C3-depleted plasma. GAS 
strains showed no differences in neutrophil killing. (C) Opsonised bacteria were also incubated with 
the plasmin-specific substrate Spectrozyme PL overnight to confirm levels of cell surface plasmin 
activity. Bars indicate means ± SEM of triplicate determinations from three independent experiments 
with different plasma donors. Asterisks indicate statistical significance, **P < 0.01; ns, non-
significant. 
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3.4.5 Plasmin(ogen) acquisition is associated with immune evasion in vivo 
To extend the investigation of the effect of GAS cell surface plasminogen acquisition 
on C3b deposition in vivo, an animal model of infection was established in mice 
expressing the human plasminogen transgene. Previously published work has 
indicated that mice heterozygous for the AlbPLG1 transgene are more susceptible to 
infection with GAS strain NS88.2 (Sanderson-Smith et al. 2008). Here, a 
homozygous mouse line was employed, which expresses two copies of the AlbPLG1 
gene. Both mouse lines expressed equivalent levels of mouse plasminogen (197.46 ± 
19.37 and 169.55 ± 28.22 μg/ml for heterozygous and homozygous mice, 
respectively). Mice heterozygous for the AlbPLG1 transgene express approximately 
17% the level of human plasminogen found in human plasma (Sun et al. 2004). The 
level of activatable human plasminogen in the homozygous mouse line was found to 
be 34% (±2.3%) that of the level in human plasma. Plasma from the homozygous 
mouse line displayed higher levels of streptokinase-mediated plasminogen activation 
and resulted in increased cell surface plasmin acquisition by GAS compared with 
plasma from heterozygous mice (Appendix B). Overall virulence of GAS strain 
NS88.2 was equivalent in the two mouse lines (Appendix B). Cohorts of 4 sex-
matched mice aged between 8 and 10 weeks were intradermally inoculated with 1 × 
10
8 
CFU of eGFP-expressing NS88.2, NS88.2prp or NS88.2Δska GAS strains. The 
site of infection was lavaged 4 h after inoculation, and C3b deposition analysed by 
flow cytometry. Significantly lower levels of C3b were detected at the surface of 
wild-type strain NS88.2 compared to mutant NS88.2prp (P < 0.001; Figure 3.5A). 
The significance of decreased C3b deposition was further assessed by comparing the 
number of eGFP-positive neutrophils isolated from the flank 4 h after infection with 
eGFP-expressing NS88.2, NS88.2prp or NS88.2Δska. NS88.2prp showed 
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significantly higher levels of association with neutrophils than NS88.2 or 
NS88.2Δska (P < 0.001; Figure 3.5B), suggesting that increased C3b deposition at 
the surface of this strain results in an increase in uptake by neutrophils. Finally, the 
bacterial load following infection with wild-type and mutant GAS strains was 
compared. A significantly higher bacterial load at the site of infection was seen for 
NS88.2 compared with NS88.2prp (P < 0.01), however there was no significant 
difference between the number of bacteria recovered for NS88.2 and NS88.2Δska 
after infection, as expected (P > 0.05; Figure 3.5C). The propensity to acquire cell 
surface plasmin(ogen) therefore correlates with reduced complement deposition and 
increased bacterial survival in vivo. Thus, we were able to establish a mouse model 
to examine the impact of plasmin(ogen) acquisition by GAS on complement-
mediated neutrophil phagocytosis. To further investigate the mechanism behind the 
findings in vivo, C3b deposition, cell surface plasmin acquisition, and cell surface 
plasminogen acquisition in vitro using humanised mouse plasma was compared. 
Consistent with the findings of both the in vitro studies using human plasma and the 
in vivo findings, C3b deposition in mouse plasma was significantly lower for NS88.2 
compared with NS88.2prp, but not NS88.2Δska (Figure 3.6A). However, subsequent 
analysis of cell surface plasmin acquisition by GAS in mouse plasma revealed that 
NS88.2Δska accumulated significantly higher levels of plasmin compared to 
NS88.2prp (P < 0.05; Figure 3.6B). Western blot analysis of proteins eluted from the 
GAS cell surface confirmed that both NS88.2 and NS88.2Δska, which showed 
decreased levels of C3b at the cell surface, bound plasminogen in mouse plasma, 
whilst NS88.2prp, which was readily opsonised by C3b, did not (Figure 3.6C). The 
observed similarity in C3b deposition in vivo between NS88.2Δska and the wild-type 
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Figure 3.5 Plasmin(ogen) at the GAS cell surface is associated with immune evasion in an 
intradermal infection model. Transgenic humanised plasminogen mice were inoculated with 1 × 108 
CFU of eGFP-expressing GAS strains NS88.2, NS88.2prp or NS88.2Δska via intradermal injection 
into the right and left flanks. Four hours after infection, wound sites were lavaged with saline and the 
recovered supernatants collected. (A) C3b deposition on the surface of NS88.2 was significantly 
reduced compared to NS88.2prp (P < 0.001), while C3b deposition levels were comparable between 
NS88.2 and NS88.2Δska. Bars indicate means ± SEM of duplicates in three independent experiments 
(n = 6) expressed as MFI for C3b deposition. (B) GAS strain NS88.2prp was phagocytosed by mouse 
neutrophils 4 h after infection when compared to NS88.2 or NS88.2Δska (P < 0.0001). (C) A 
significantly lower bacterial load was obtained for NS88.2prp compared to NS88.2 and NS88.2Δska 
(P < 0.01). Data are combined from four (NS88.2prp and NS88.2Δska) and five (NS88.2) 
independent experiments performed in duplicate. Asterisks indicate statistical significance, ***P < 
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Figure 3.6 Plasmin(ogen) decreases C3b deposition on GAS in mouse plasma. (A) In order to assess the impact of cell-surface plasmin (ogen) on C3b deposition, 
bacteria were opsonised at 37 °C for 10 min in 50% mouse plasma as a source of complement and plasmin(ogen). Non-specific binding sites were blocked by incubating 
bacteria with human IgG and surface-bound C3b was probed using phycoerythrin (PE)-conjugated monoclonal antibody raised against human C3. Alternatively, cells 
were stained with PE-labelled mouse IgG isotype control. C3b deposition on the bacterial surface was analysed using flow cytometry. C3b deposition was significantly 
reduced on the surface of NS88.2 compared to NS88.2prp (P < 0.01), but not NS88.2Δska. Histograms show the shift in mean fluorescence intensity (MFI) between GAS 
stained with the isotype control (grey) and an anti-C3 antibody (white). Bars indicate mean ± SEM of triplicates expressed in MFI, representative of two independent 
experiments. (B) GAS cell surface plasmin activity was confirmed by incubating bacteria with the plasmin-specific substrate Spectrozyme-PL overnight. (C) GAS cell 
surface plasminogen acquisition was confirmed by Western blot analysis of proteins eluted from the GAS cell surface following incubation in mouse plasma. Data is 






































































 NS88.2   
C B 




















































Chapter 3 Plasmin(ogen) Acquisition Protects GAS from Complement-mediated 
Neutrophil Killing 
 
Page | 83 
 
3.5 Discussion 
The ability of GAS to activate and sequester the host protease plasmin to the cell 
surface has been linked to bacterial dissemination and degradation of host tissue 
barriers during invasive disease initiation (Sun et al. 2004; Sanderson-Smith et al. 
2012). Here, we establish a mouse model to demonstrate for the first time that 
plasmin(ogen) acquisition protects GAS from complement-mediated neutrophil 
phagocytosis and results in increased bacterial load during the early stages of 
infection.  
During the initial stages of infection, invading pathogens must overcome innate 
immune barriers, including the bactericidal effects of complement. C3b plays a 
pivotal role in the innate immune response to bacterial infection, and opsonisation of 
bacteria with C3b facilitates neutrophil phagocytosis. GAS has evolved a wealth of 
strategies to reduce complement deposition at the bacterial cell surface, including 
expression of M protein (Kwinn and Nizet 2007). The presence of M6 and M49 at 
the GAS cell surface has been linked to protection from C3b-mediated phagocytosis 
(Jacks-Weis et al. 1982), while fibrinogen and factor H binding by certain M 
serotypes has been shown to block C3b deposition at the bacterial cell surface 
(Kwinn and Nizet 2007). To date, over 234 different M protein types have been 
identified, and M protein function is highly diverse (McMillan et al. 2013; 
Sanderson-Smith et al. 2014). This study defines a new role for plasminogen-binding 
M proteins in GAS resistance to phagocytosis.  
Plasmin exhibits broad-spectrum protease activity, which is central to its 
involvement in inflammation, fibrinolysis, and tissue remodeling (Saksela and Rifkin 
1988). However, these properties necessitate strict regulation of proteolysis under 
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normal conditions. Secretion of streptokinase by GAS facilitates plasmin generation 
independent of host activators, while attachment of plasmin to the bacterial cell 
surface protects plasmin from circulating inhibitors such as α2-antiplasmin. In this 
way, GAS are able to acquire a source of unregulated surface proteolytic activity 
(Sanderson-Smith et al. 2012). This study shows that the ability of GAS strain 
NS88.2 to degrade C3b is dependent on the presence of cell su.rface plasmin 
activity. However, our data suggest it is the ability of NS88.2 to accumulate 
plasminogen at the cell surface, rather than plasmin, that is protective against C3b-
mediated phagocytosis. Minimal C3b degradation was seen following overnight 
incubation of GAS with C3b. This suggests that the activity of surface-localised 
plasmin for soluble C3b is low. Interestingly, a number of studies assessing C3b 
degradation by surface-localised plasmin show similar results, with intact C3b still 
visible after 24 h (Barthel et al. 2012a; Barthel et al. 2012b). This may explain the 
findings in this study that there is limited correlation between cell surface plasmin 
acquisition and C3b deposition. Subsequent in vitro analyses using human plasma 
indicated no correlation between cell surface plasmin accumulation and C3b 
deposition at the GAS cell surface. Rather, decreased C3b deposition correlated with 
the ability of GAS to sequester plasminogen to the cell surface. However, assays 
performed using plasma from humanised plasminogen mice revealed that reduced 
C3b deposition correlates with both cell surface plasmin and cell surface 
plasminogen acquisition. This may be indicative of differences between mouse 
plasma and human plasma, even in this humanised mouse model. It is therefore 
difficult to rule out a role for plasmin acquisition in the in vivo model, and it may be 
that in this context, both plasminogen and plasmin at the GAS cell surface provide 
protection against C3b deposition. Given the low level of soluble C3b degradation 
Chapter 3 Plasmin(ogen) Acquisition Protects GAS from Complement-mediated 
Neutrophil Killing 
 
Page | 85 
 
detected by surface-localised plasmin, it may be that localised plasmin is more 
efficient at cleaving surface-deposited C3b, and our data clearly show that soluble 
plasmin can facilitate the removal of C3b from the GAS cell surface. Alternatively, it 
has been shown that degradation of C3b by plasmin inhibits complement activation 
by preventing the formation of the C3 convertase C3bBb (Barthel et al. 2012a). It is 
therefore possible that plasmin-mediated removal of C3b from the GAS cell surface 
blocks this pathway and is responsible for the reduced levels of C3b deposition seen 
in vivo.  
Recently, it has been demonstrated that plasminogen binds to complement 
components C3, C3b and C3d, and when activated to plasmin by host uPA, plasmin 
cleaves C3b, inhibits complement activation, and prevents complement-mediated 
hemolysis of rabbit erythrocytes (Barthel et al. 2012a). The cleavage fragments of 
C3b generated in this study using streptokinase-activated plasminogen or 
commercially obtained exogenous plasmin were found to be of similar but not 
identical in size to those reported by Barthel et al. (2012a). Differences in 
electrophoretic mobility may reflect different commercial sources of C3b, or 
differences in the length of time C3b was incubated with a plasmin source between 
the two studies. However, both the previous study and the current study indicate that 
surface-localised plasmin degrades C3b.  
GAS is equipped with an arsenal of virulence factors that together exert anti-
phagocytic properties. Both M and M-like proteins have been linked to the survival 
of certain GAS strains inside human neutrophils and blood (Kihlberg et al. 1995; 
Staali et al. 2003), while pore-forming streptolysin S and O exert cytotoxic activity 
on host neutrophils and impair their recruitment to the site of bacterial infection 
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(Andersen and Duncan 1980; Lin et al. 2009). Furthermore, loss of the GAS surface 
hyaluronic acid capsule is also associated with decreased resistance to neutrophil 
phagocytosis and reduced virulence in mice (Moses et al. 1997). Thus, GAS is 
protected from different stages of the innate immune response via coordinated 
expression of multiple virulence factors. This is reflected in the finding that even in 
the presence of cell surface plasmin(ogen), GAS strain NS88.2prp retains 
approximately 80% survival compared with the wild-type parent GAS strain in our 
in vitro neutrophil killing assays. Nevertheless, the ability of GAS to coopt 
plasmin(ogen) correlated to a significant increase in bacterial survival and a decrease 
in association with neutrophils during the early stages of infection in a well-
characterised murine infection model. Inactivation of C3b via cleavage into smaller, 
nonfunctional products as a result of plasmin activation has been described for 
several additional human pathogens including S. aureus (Rooijakkers et al. 2005), 
Bacillus anthracis (Chung et al. 2011), and Borrelia burgdorferi (Grosskinsky et al. 
2009). Recently, a novel plasminogen binding protein, PepO for Streptococcus 
pneumoniae has been shown to mediate C3b degradation upon plasminogen 
activation by uPA (Agarwal et al. 2013). However, to our knowledge, this is the first 
time this potential virulence mechanism has been linked to bacterial survival in vivo. 
The ability of GAS to initiate invasive disease has been shown to be dependent on 
cell surface plasmin acquisition (Sun et al. 2004; Cole et al. 2006; Sanderson-Smith 
et al. 2008), however, few studies of the role of plasminogen in GAS infection have 
looked at the early stages of disease, where the innate immune response is critical. 
Recently, GAS surface-bound plasmin was shown to cleave the cathelicidin 
antimicrobial peptide LL-37 (Hollands et al. 2012). The current study clearly 
demonstrates that, in addition to facilitating tissue degradation and bacterial 
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dissemination, localisation of plasmin at the GAS cell surface via the M protein is 
critical for bacterial survival in the early stages of infection. These data provide new 
insight into the antiphagocytic role of the GAS M protein and add to our 
understanding of how plasmin(ogen) acquisition contributes to virulence of a 
significant human pathogen.  
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presents data generated by co-authors, as outlined on page xi, and will be 
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Martina L. Sanderson-Smith, Yueling Zhang*, Diane Ly*, Deborah Donahue, 
Andrew Hollands, Victor Nizet, Victoria A. Ploplis, Mark J. Walker, Francis J. 
Castellino (2013). A key role for the urokinase plasminogen activator (uPA) in 
invasive group A streptococcal infection. PLoS Pathogens. 9: e1003469. 
*Equal contributions by authors. 
4.1 Abstract 
Activation of human plasminogen to the broad spectrum protease plasmin is 
mediated by either of two physiological activators, uPA and tPA. A role for host 
activators in the pathogenesis of multiple bacterial species has been reported, 
however there is little known about their contribution to GAS virulence. Here, we 
assessed the role of uPA-mediated plasminogen activation in GAS pathogenesis in 
vivo. We show that in the absence of the GAS secreted plasminogen activator 
streptokinase, uPA can facilitate GAS cell surface plasmin acquisition during 
incubation with plasminogen in vitro, or in human plasma ex vivo. Furthermore, 
plasmin-coated GAS were able to mediate a significant increase in the activation of 
the zymogen of uPA (pro-uPA) in human plasma. We next investigated the 
contribution of uPA to invasive GAS disease using a previously undescribed 
transgenic mouse model of infection. We found that humanised plasminogen mice 
deficient in uPA (AlbPLG1/uPA-/-) were less susceptible to GAS infection compared 
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to wild-type mice (AlbPLG1). This observation correlated with a reduced ability of 
GAS to disseminate to internal organs in vivo, and acquire cell surface plasmin ex 
vivo in the absence of uPA. Our findings demonstrate that endogenous uPA plays a 
significant role during GAS infection. We further evaluated the therapeutic potential 
of commercial (amiloride, tranexamic acid, 5-N,N-hexamethylene amiloride; HMA) 
and novel (BB2-50F and BB2-31F) inhibitors directed against uPA activity during 
GAS infection in vivo. Minimum inhibitory concentration (MIC) in vitro data 
indicated antimicrobial potential, however treatment with these inhibitors did not 
correlate with decreased bacterial dissemination, or mice survival in an invasive 
model of GAS disease.  
4.2 Introduction 
uPA is a serine protease activator of plasminogen, the key proenzyme of the 
fibrinolytic system. uPA is synthesised by the kidneys and secreted as a single-chain 
zymogen (pro-uPA) that displays very little intrinsic activity (Pannell and Gurewich 
1987; Kristensen et al. 1991). Plasmin or other proteases subsequently cleave pro-
uPA to form a fully functional HMW two-chain uPA that contains a noncatalytic 
amino-terminal fragment, responsible for mediating binding of uPA to a specific 
high affinity cell surface receptor, uPAR (Vassalli et al. 1985). Plasminogen 
activation can also be facilitated by the other major host activator, tPA, although this 
mechanism is generally restricted to fibrin clots in the vascular injury region due to 
its high binding affinity for fibrin (Kooistra et al. 1994). The physiological role of 
plasmin is widespread and involves degradation of fibrin clots, extracellular matrix 
proteins, and orchestrating the recruitment of immune cells to wound sites. uPA-
mediated plasminogen activation on cellular surfaces leads to increased plasmin 
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formation and localised proteolytic activity, thereby facilitating cell invasion and 
tissue remodeling. The concomitant overexpression of uPA or uPAR has been linked 
to cancer invasion and metastasis (Ossowski and Reich 1983; Duffy et al. 1999; 
Ranson and Andronicos 2003).  
Several lines of evidence suggest a role for uPA and tPA in bacterial pathogenesis 
(Sjobring et al. 1994; Klempner et al. 1995; Yavlovich et al. 2004; Lähteenmäki et 
al. 2005; Magalhaes et al. 2007). Many important pathogens including Borrelia 
burgdorferi (Coleman et al. 1995), Yersina pestis (Sodeinde et al. 1992), 
Haemophilus influenza (Virkola et al. 1996) and Streptococcus pneumoniae 
(Bergmann et al. 2005), recruit human plasminogen to the cell surface, and 
subsequent conversion to plasmin can be mediated by endogenous plasminogen 
activators, leading to bacterial invasion and escape from innate immunity 
(Sanderson-Smith et al. 2012). Plasminogen activation and plasmin acquisition is 
central to the establishment of invasive GAS disease (Sun et al. 2004; Cole et al. 
2006; Sanderson-Smith et al. 2008). The role of secreted streptococcal plasminogen 
activator streptokinase has been well-established during GAS infection, and uPA has 
been shown to mediate plasminogen activation at the GAS cell surface in vitro 
(Berge and Sjobring 1993; Sun et al. 2004). However, the exact contribution of uPA 
to GAS pathogenesis remains unknown.  
Given the potential role of uPA in bacterial disease, manipulation of uPA-mediated 
plasminogen activation may be a promising therapeutic strategy in invasive GAS 
infection. Several commercial inhibitors of uPA and plasminogen activation have 
been shown to be effective as anticancer drugs in animal models including amiloride 
and tranexamic acid (Dunbar et al. 2000; Matthews et al. 2011a; Ding et al. 2012). 
Chapter 4 Investigating the Potential of uPA as a Therapeutic Target in Invasive 
GAS Disease 
Page | 92 
 
Amiloride is a known moderate competitive inhibitor of uPA (Ki = 7 µM) (Matthews 
et al. 2011a), while tranexamic acid targets plasmin(ogen) more effectively than e-
aminocaproic acid, from which it is derived (Markus et al. 1979; Vassalli and Belin 
1987), thereby preventing plasminogen activation and binding of plasmin to fibrin. 
Both these inhibitors are currently approved for clinical use; amiloride as an oral 
potassium-sparing diuretic (Matthews et al. 2011a), and tranexamic acid to prevent 
peri- and post-operative bleeding in humans (Dunn and Goa 1999).  
In order to further explore the role of uPA in GAS disease, we employed a 
humanised plasminogen infection mouse model to investigate the therapeutic 
potential of these drugs to block uPA-mediated plasminogen activation, and 
therefore prevent the development of invasive infection. In addition, we employed a 
derivative of amiloride, hexamethylene amiloride (HMA) (Matthews et al. 2011a), 
and two novel HMA derivatives, BB2-50F (Buckley et al. unpublished) and BB2-
31F (Buckley et al. unpublished) that exhibit enhanced inhibitory effects against the 
proteolytic activity of uPA in vitro compared to HMA. 
4.3 Methods and materials 
4.3.1 Ethics statement 
Plasma samples were collected from healthy volunteers as stated in section 3.3.6.1, 
and animal infection studies complied with regulations as stated in section 2.10.1. 
4.3.2 GAS strains 
This study employed the globally disseminated invasive M1T1 GAS strain 5448 and 
its isogenic mutants, 5448∆ska, and reverse-complemented 5448∆ska (designated 
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5448∆skaRC). Details of GAS strains and culture methods are described in section 
2.1.1.  
4.3.3 Humanised plasminogen uPA-knockout mouse model of GAS infection 
The role of uPA in GAS virulence was assessed in vivo using uPA-deficient 
humanised plasminogen mice as described in section 2.10.2. All survival and 
bacterial dissemination data was generated at the University of Notre Dame by Dr. 
Martina Sanderson-Smith, Dr. Yueling Zhang and Mrs. Debra Donahue (University 
of Notre Dame, Notre Dame), and are detailed in section 2.10. 
4.3.4 Activation of pro-uPA by GAS in human plasma 
The activation of pro-uPA by plasmin-bound GAS in human plasma was assayed 
using a synthetic fluorogenic peptide substrate Z-Gly-Gly-Arg-AMC (Calbiochem). 
Fluorescence in this assay correlates directly with uPA activity due to the high 
specificity of uPA for Z-Gly-Gly-Arg-AMC. Bacterial cultures were harvested at 
mid-logarithmic phase, washed twice in PBS, and resuspended in 50 µL human 
plasma or PBS in duplicate. The cell suspension was transferred to a non-transparent 
96-well flat-bottom plate (Interpath, Heidelberg West, Australia) where an equal 
volume of 1 M Z-Gly-Gly-Arg-AMC was overlayed for a final working 
concentration of 0.5 mM of the fluorogenic substrate and a total reaction volume of 
100 µL per well. Fluorescence emission was recorded immediately at 3 min intervals 
with shaking to resuspend the bacterial cells over 120 min at 37 ºC, using the 
Fluostar Optima (BMG Labtech, Offenburg, Germany). Excitation and emission 
wavelengths were measured at 360 and 440 nm respectively, with multiple gains set 
to detect uPA activity. Wells containing a mixture of GAS and fluorogenic substrate 
in PBS indicted background fluorescence, which was subtracted from each reading 
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before statistical analysis. The initial rate of change in fluorescence.min-1 was 
generated from a linear curve during the first 30 min of the assay, where the 
fluorescence increment at each time-point was plotted against time. The final 
concentration of uPA generated in each assay was determined from a corresponding 
standard curve of known concentrations of uPA incubated in the presence of the 
fluorogenic substrate. 
4.3.3 Treatment of GAS infected mice with amilorde and tranexamic acid 
In order to assess the potential of blocking uPA-mediated plasminogen activation to 
inhibit the development of invasive GAS disease, two commercially available uPA 
inhibitors, amiloride and tranexamic acid, were selected for treatment against GAS 
infection. Cohorts of 10 sex-matched AlbPLG1 mice aged between 8 to 12 weeks old 
were treated with 100 µL of either amiloride (Sigma-Aldrich) at 5, 10 or 20 mg/kg, 
tranexamic acid (Santa Cruz Biotechnology, Dallas, TX) at 20 or 800 mg/kg, or 
0.7% (w/v) saline control via an intraperitoneal (IP) route. Immediately following 
pretreatment, mice were subcutaneously infected with 100 µL of 1 x 109 CFU/mL 
GAS strain 5448. Daily treatment of either drug dose was administered on 
alternating sides of the abdominal cavity, and mice monitored for 10 days. Lesions 
formed at the initial site of infection were also measured daily. 
4.3.4 Determining MIC of novel uPA inhibitors 
The MIC of amiloride, HMA (Sigma-Aldrich), BB2-50F (unpublished) and BB2-
31F (unpublished) was determined against GAS in vitro. uPA inhibitors BB2-50F 
and BB2-31F were developed and provided by Ben Buckley (University of 
Wollongong, Australia). Bacteria were harvested at mid-logarithmic phase, washed 
twice, and transferred to a 96-well plate in duplicate 100 µL aliquots. To produce 
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inhibition profiles, uPA inhibitors in 100% (v/v) DMSO were serially diluted 1:2 
across a 96-well plate starting from a stock concentration of 500 µM. Diluted drug 
samples in 100 µL volumes were then directly transferred into wells already 
containing GAS, and the samples mixed well. The combination of GAS and 
inhibitors was incubated overnight at 37 ºC. Control wells consisted of THBY media 
only. Samples from each well were spot plated onto THYA, and the concentration of 
inhibitor where there was no bacterial growth was determined as the MIC.  
4.3.5 Acute toxicity dose determination 
To determine the possible toxicity of uPA drug inhibitors in AlbPLG1 mice, cohorts 
of 4 age and sex-matched mice were injected IP with 100 µL of HMA, or its novel 
drug analogues, BB2-50F and BB2-31F at 2.5, 5 or 10 mg/kg/day. Alternatively, 10 
or 20% (v/v) DMSO in 0.7% (v/v) saline was administered as a vehicle control. 
Mouse survival was monitored over a 10-day period. Due to the varying solubility of 
the compounds, different solvent vehicles were required; compounds were dissolved 
in 10% (v/v) DMSO/saline (for 2.5 mg/kg toxicity trial), or 20% (v/v) DMSO/saline 
(for 5 and 10 mg/kg toxicity trials). Mice were closely observed twice daily for any 
acute adverse responses. Clinical signs of moribund mice such as impaired mobility, 
prolonged hunched posture, the ability to remain upright, or severe and rapid weight 
loss greater than 20% of initial body weight, resulted in euthanasia.   
4.3.6 Efficacy of novel uPA inhibitors against GAS infection 
The efficacy of uPA inhibitors in controlling invasive GAS pathogenesis was 
initially determined by assessing the bacterial load at the site of infection, and 
dissemination of bacteria in internal organs as described in detail in section 2.10.6. 
Given that the maximum tested drug dose of 10 mg/kg was well tolerated in mice, 
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this dose was considered safe for administration and was therefore selected for the 
GAS challenge study. Cohorts of five AlbPLG1 sex-matched mice aged between 8-
12 weeks were pre-treated with either HMA, BB2-50F or BB2-31F at 10 mg/kg in 
20% (v/v) DMSO/saline, 20% (v/v) DMSO/saline only (vehicle control), or 
erythromycin at 50 mg/kg (positive control) in 10% (v/v) DMSO/saline via an IP 
route. An erythromycin treatment group was included as it is a clinically used 
antibiotic and provides mice with complete protection against invasive GAS 
infection (unpublished). In order to establish a profile examining the effect of these 
compounds on GAS pathogenesis, two endpoints were selected; two and three days 
post-bacterial infection. Mice were subcutaneously infected with approximately 
100µL of 1 x 109 (for two and three day trials), or 100µL of 1 x 107 (three day trial) 
CFU/mL GAS strain 5448 under anaesthesia following pre-treatment with each 
compound. Mice then received daily IP injections of drugs post-bacterial infection 
for the duration of the trial. Alternatively, mice were co-administered with 100µL of 
1 x 109 CFU/mL GAS strain 5448 and HMA, BB2-31F, BB2-50F at 80% of their 
MIC (section 4.4.5) in 20% (v/v) DMSO/saline, 20% (v/v) DMSO/saline only, or 
erythromycin at 50 mg/kg in 10% (v/v) DMSO/saline at a single dose. Mice were 
sacrificed at 48 h post-bacterial infection. In all trials, mouse weight and skin lesion 
size at the site of infection were recorded daily. Mice were sacrificed at end-point, 
and post-sacrifice, skin at the site of initial infection, spleen, liver and blood were 
collected in ice-cold sterile PBS and homogenised as described in 2.10.4. Following 
serial dilution, wells containing blood, homogenised liver and spleen were plated 
onto THYA, while wells containing homogenised skin lesions were plated onto 
HBA in order to differentiate between natural flora and GAS colonies. Bacterial 
colonies were enumerated the following day. 
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4.4 Results 
4.4.1 uPA can mediate cell surface plasmin acquisition by GAS 
The ability of M1T1 GAS strain 5448 to accumulate cell surface plasmin was 
assessed in human plasma as described previously (Cole et al. 2006). As expected, 
following 3 h incubation in human plasma, the M1T1 parental strain 5448 accrued 
significantly higher levels of cell surface plasmin compared to when streptokinase 
was absent (5448∆ska), which was only partially attenuated for plasmin acquisition 
(Figure 4.1A). When streptokinase function was restored, 5448∆skaRC accumulated 
similar levels of plasmin at the surface as wild-type strain 5448 (Figure 4.1A). This 
strongly suggests that in the absence of streptokinase, host activators in plasma can 
contribute to GAS cell surface plasmin acquisition. We therefore incubated GAS 
with purified human plasminogen, uPA or PBS only, or a combination of uPA and 
plasminogen. Both GAS strains 5448 and 5448∆skaRC accumulated plasmin at the 
cell surface when incubated with plasminogen, while minimal plasmin was acquired 
at the cell surface by 5448∆ska, with levels comparable to that of when GAS was 
incubated with uPA or PBS only (Figure 4.1B). Upon co-incubation with 
plasminogen and uPA, GAS strains bound significantly higher levels of plasmin than 
incubation with plasminogen alone (Figure 4.1B). The presence of uPA was 
sufficient for GAS mutant 5448∆skaRC to accumulate cell surface plasmin activity. 
These data demonstrate that host-activator uPA can mediate GAS cell surface 
plasmin acquisition in vitro.  
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Figure 4.1 uPA can facilitate GAS cell surface plasmin acquisition. Wild-type GAS strain 5448 
(black) and its isogenic mutants 5448∆ska (white) and 5448∆skaRC (grey) were incubated in (A) 
human plasma or (B) in the presence of exogenous Glu plasminogen (Glu Plg), uPA or PBS only, or a 
combination of Glu Plg and uPA for 3 h at 37 ºC. Upon incubation in human plasma, the absence of 
streptokinase partially attenuated cell surface plasmin acquisition by GAS. Co-incubation with 
exogenous human Glu Plg and uPA demonstrated that host activator uPA is able to facilitate GAS cell 
surface plasmin acquisition in vitro. Bars indicate mean ± SEM, and data represent two independent 
experiments performed in triplicate (n = 3). Unpaired two-tailed Student’s t-test was used for analysis 
and asterisks indicate statistical significance, **P < 0.005; ***P < 0.001. 
 
4.4.2 Plasmin at the GAS surface can facilitate pro-uPA activation in human 
plasma 
uPA is synthesised as a single polypeptide chain pro-enzyme (pro-uPA) that 
possesses low levels of intrinsic catalytic activity (Pannell and Gurewich 1987). Pro-
uPA is catalysed by plasmin, or other trypsin-specific proteases (but not ska), to 
generate the fully active dual-chain uPA. This reciprocal relationship between 
plasmin, a result of plasminogen activation and pro-uPA activation, acts as a positive 
feedback mechanism that allows for the accumulation of plasmin at the GAS surface. 
We therefore investigated the ability of plasmin bound to the GAS cell surface to 
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activity, thereby enhancing bacterial dissemination. The presence of GAS in human 
plasma resulted in a significant 3-fold enhancement of plasma-derived uPA activity, 
monitored using a uPA-specific fluorescent substrate, compared to the activity in 
plasma alone (Figure 4.2). In the presence of GAS strains 5448, 5448∆ska and 
5448∆skaRC, the initial rate of pro-uPA activation was 10.6±0.928 fluorescence 
units (fu)/min, 9.812±0.957 fu/min and 8.635±1.078 fu/min respectively, whilst the 
rate in plasma alone was 4.921±0.0215 fu/min. By comparison to a uPA activity 
standard curve, the amount of uPA generated by 30 min incubation in plasma was 
0.183±0.035 nM in the presence of 5448, 0.144±0.023 nM in the presence of 
5448∆ska, or 0.166±0.031 nM in the presence of 5448∆skaRC compared to 
0.054±0.018 nM in plasma only. These results show that plasmin accumulated at the 







Figure 4.2 GAS cell surface plasmin facilitates enhanced pro-uPA activation in human plasma. 
In a fluorescence plate assay, human plasma was incubated with or without GAS, and the conversion 
of pro-uPA to uPA was monitored overtime with a uPA-specific fluorogenic substrate Z-Gly-Gly-
Arg-AMC. Plasmin bound to the surface of GAS strains 5448, 5448∆ska and 5448∆skaRC were 
found to enhance pro-uPA cleavage, where greater uPA activity was detected compared to when 
plasma was incubated alone. Background fluorescence containing GAS incubated with PBS only was 
subtracted from all values. Assay is representative of four independent experiments performed in 
duplicate wells.  
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4.4.3 A key role for uPA in a mouse model of GAS infection 
Plasminogen acquisition and activation is a key process in a number of bacterial 
infections (Sanderson-Smith et al. 2012). However, the exact role of host activators 
in GAS pathogenesis remains unclear. Recognising that streptokinase interacts 
specifically with human plasminogen, we assessed the contribution of endogenous 
uPA in humanised plasminogen transgenic mice (Sun et al. 2004). The ability of 
mouse uPA to activate human plasminogen and mediate plasmin acquisition at the 
GAS cell surface was first determined in vitro. As expected, significantly higher 
levels of plasmin accrued at the bacterial surface when GAS was co-incubated with 
human plasminogen and murine uPA than incubation with either plasminogen, or 
murine uPA, or PBS alone (Figure 4.3A). This confirmed the ability of murine uPA 
to facilitate GAS cell surface human plasmin acquisition in the absence of 
streptokinase. We next investigated the survival of mice 10 days post-infection with 
GAS strain 5448 in wild-type (AlbPLG1), or uPA-knockout (AlbPLG1/uPA-/-) mice 
in a humanised plasminogen background. Mortality of uPA-knockout mice was 
significantly lower than wild-type mice following GAS infection (P < 0.01; Figure 
4.3B). Deletion of uPA however, did not completely attenuate bacterial virulence in 
this infection model, which strongly suggests a potential role for streptokinase, and 
potentially the other major host plasminogen activator tPA. Nonetheless, uPA clearly 
plays a central role in GAS virulence in vivo as the absence of both streptokinase and 
uPA significantly increased the survival rate of mice from 20% to 80% (Figure 
4.3B). This was reflected in the reduced ability of GAS to disseminate from the point 
of infection into sterile tissue sites. Following subcutaneous inoculation with GAS 
strain 5448, significantly less bacteria were recovered in the bloodstream and spleen 
of uPA-knockout mice than in wild-type mice 72 h post-infection (Figure 4.3C). 
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Bacterial load at the site of infection was equivalent in both mouse lines, indicating 
that the differences observed in bacterial dissemination was not reflective of the 
ability of GAS to survive at the point of injection (Figure 4.3C). These observations 
correlated with the ability of GAS to accumulate significantly less plasmin at the 
bacterial surface in plasma harvested from AlbPLG1/uPA-/- than AlbPLG1 mice ex 
vivo (Figure 4.3D). These data clearly highlight an important role for uPA in GAS 
virulence in vivo, and demonstrate that uPA-mediated plasmin acquisition is 
associated with bacterial dissemination.  
4.4.4 uPA inhibitors amiloride and tranexamic acid do not inhibit GAS 
pathogenesis 
Given the role of uPA in facilitating plasminogen activation during invasive GAS 
infection in vivo, we next investigated the therapeutic potential of inhibitors targeting 
uPA activity and plasminogen activation to control the development of invasive 
bacterial infection. We selected amiloride and tranexamic acid due to their extensive 
use in humans with minimal adverse effects (Matthews et al. 2011a). In our model, 
AlbPLG1 were infected with GAS strain 5448, given daily IP treatment, and the 
survival rate and lesion size recorded for 10 days. There were no significant 
differences between the survival of mice treated with saline (n = 6-10, depending on 
the cohort of treated mice), and mice treated with amiloride at 5 (n = 6), 10 (n = 8) or 
20 (n = 8) mg/kg, or tranexamic acid at 20 (n = 12), or 800 (n = 10) mg/kg (Figure 
4.4A and C). However, mice treated with 10 mg/kg amiloride showed significantly 
smaller lesion sizes than those of control mice. No other significant differences were 
observed between lesion sizes for any other dose of amiloride or tranexamic acid 
compared to saline control groups (Figure 4.4B and D). 
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Figure 4.3 Host plasminogen activator uPA plays a key role in GAS virulence in vivo. (A) Mouse 
uPA can activate human plasminogen and facilitate plasmin acquisition to the bacterial surfaces of 
5448 (black) and 5448Δska (white). (B) AlbPLG1 mice (n = 10) infected with 5448 (solid line), or 
AlbPLG1/uPA-/- (n = 10) infected with 5448 (dashed line) and 5448Δska (dotted line) were monitored 
10-days post-subcutaneous GAS infection. The survival of uPA-knockout mice was significantly 
increased compared to wild-type mice (P < 0.01). These observations correlated with the ability of 
GAS to disseminate in vivo. (C) Tissues of mice (n = 2) were harvested 72 h post-inoculation with 
GAS strain 5448. In the absence of uPA, bacterial load in the bloodstream and spleen of 
AlbPLG1/uPA-/- (empty circles) was significantly lower than in wild-type AlbPLG1 mice (filled 
circles; P < 0.05). Equivalent bacterial counts were recovered at the site of infection in both mouse 
lines. (D) Significantly lower levels of plasmin was accumulated at the bacterial surfaces of 5448 (P < 
0.001) and 5448Δska (P < 0.05) following incubation in plasma obtained from AlbPLG1/uPA-/- than 
in AlbPLG1. Plasmin acquisition assays are representative of two independent experiments performed 
in triplicate (n = 3). Bars are mean ± SEM, and significance was determined by unpaired two-tailed 
Student’s t-test. Survival data is combined from two independent experiments (n = 20) and analysed 
using log-rank test. Dissemination data was combined from three independent experiments (n = 6). 
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Figure 4.4 Treatment of GAS-infected mice with commercial uPA inhibitors. AlbPLG1 mice 
were intradermally infected with approximately 1 x 109 CFU/mL GAS strain 5448 and given daily 
treatment of amiloride at 5 (■), 10 (▲) or 20 (▼) mg/kg, or tranexamic acid at 20 (■) or 800 (▲) 
mg/kg, or 0.7% (w/v) sterile saline control (●) for 10-days. (A and C) Mice survival rate and (B and 
D) lesion size formed at the focal point of infection were recorded daily following treatment with 
amiloride (n = 6 at 5 mg/kg; n = 8 at 10 mg/kg; n = 8 at 20 mg/kg) or tranexamic acid (n = 12 at 20 
mg/kg; n = 10 at 800 mg/kg). Lesion sizes represent data recorded on day 2 and show mean ± SEM 
from independent experiments. Asterisks indicate statistical significance, **P < 0.01; n.s., non-
significant. 
 
4.4.5 Novel uPA inhibitors have antibacterial properties in vitro 
The finding that treatment with amiloride may decrease lesion size during GAS 
infection suggested the inhibitor may be reducing bacterial burden at the site of 
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infection. To explore this further, we employed the amiloride derivative HMA, 
which has been used extensively in mouse models and shown to be non-toxic at low 
levels (Matthews et al. 2011b). Furthermore, we added to our study the two novel 6-
substituted HMA analogues, BB2-50F and BB2-31F. These compounds exhibit 
approximately 10-fold  enhanced inhibitory activity against the proteolytic activity of 
purified uPA in vitro compared to HMA, and demonstrate high selectivity for uPA 
over other closely related serine ‘off-targets’ (Buckley et al. unpublished).  
Additionally, these compounds are non-toxic against mouse or human cell lines in 
vitro at concentrations at or below 10 µM (Buckley et al. unpublished). Prior to 
assessing the potential therapeutic effect of these inhibitors during GAS infection in 
vivo, the MIC of these compounds, in addition to amiloride, against GAS was 
assessed in vitro. Overnight incubation of GAS strain 5448 with either drug resulted 
in complete growth inhibition of bacteria at 250 µM for HMA and BB2-31F, and at 
32 µM for BB2-50F. Amiloride lacked any antimicrobial activity against GAS. 
These data demonstrate that HMA, BB2-50F and BB2-31F are more potent than 
amiloride, and have antimicrobial effects against GAS in vitro.  
4.4.6 Novel uPA inhibitors are non-toxic in humanised plasminogen mice 
The tolerability of HMA and its novel analogues, BB2-50F and BB2-31F, was 
assessed in AlbPLG1 mice. Mice were administered IP with either drug at 2.5, 5 or 
10 mg/kg/day for up to 10 days. At all three doses, mice showed complete survival 
following treatment (Figure 4.5A). Signs of normal behavior and no adverse 
responses to any treatment including weight loss were observed in mice (Figure 
4.5B-D). The delivery of these drugs in AlbPLG1 mice was therefore deemed safe, 
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Figure 4.5 Survival and weight loss of AlbPLG1 mice during treatment with HMA and 
analogues. Cohorts of four age and sex-matched mice were given IP injections of 10 or 20% (v/v) 
DMSO/saline (●), HMA (■), BB2-50F (▼) or BB2-31F (▲) at varying doses over 10 days. Mice 
were monitored for (A) survival or weight loss during administration of compounds at (B) 2.5 mg/kg, 
(C) 5 mg/kg or (D) 10 mg/kg. Each drug dose was administered until completion of each individual 
trial. Survival curve is representative of all three drug doses. Weight data are presented as mean ± 
SEM (n = 4) of initial body weight. 
 
4.4.7 Novel uPA inhibitors lack systemic antimicrobial effects against GAS in 
vivo 
To investigate the efficacy of uPA inhibitors against the invasive pathogenesis of 
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(positive control), or 20% (v/v) DMSO in saline (vehicle control), followed by 
subcutaneous infection with GAS strain 5448. The mice then received daily IP 
treatment with either drug over 48 or 72 h. No significant difference was observed 
for bacterial dissemination (Figure 4.6), lesion size at the point of infection (Figure 
4.7), or mean weight loss (Figure 4.8), between treated or control mice for all 
endpoints. As expected, erythromycin-treated mice exhibited significantly smaller 
lesions at the site of infection (at 48 h, but not 72 h post-GAS infection), and 
demonstrated minimal weight loss when compared to the other cohorts (Figure 4.7 
and Figure 4.8). To rule out the possibility that a high bacterial inoculum was 
interfering with the functions of these compounds in this highly invasive mouse 
model, we lowered the GAS infection dose two-fold. As observed for mice infected 
with a higher GAS dose, there were no significant differences in bacterial 
dissemination, or the bacterial load at the site of infection 72 h post-infection (Figure 
4.9A). Similarly, there were no significant differences in lesion size (Figure 4.9B), or 
weight loss (Figure 4.9C) for either treatment compared to control mice following a 
low GAS infection dose. Erythromycin-treated mice did not display obvious signs of 
weight loss (Figure 4.9C). These results demonstrate that under the dosing schedule 
and regimen used in this study, administration of HMA and its analogues did not 
delay, or prevent the progression of invasive GAS disease in this humanised 
plasminogen mouse infection model. However, a trend in the reduced lesion size at 
the site of infection following treatment of mice with BB2-31F and BB2-50F, 
particularly following a low GAS infection dose was observed, suggesting that an 
alternative mode of drug delivery should be considered.  
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Figure 4.6 HMA and analogues do not effect the progression of invasive GAS disease in 
AlbPLG1 mice given a high dose of GAS. Cohorts of five age and sex-matched mice were pre-
treated IP with 20% (v/v) DMSO/saline (vehicle control) (●), erythromycin at 50 mg/kg (positive 
control) (■), HMA (▲), BB2-31F (▼), or BB2-50F (♦) at 10 mg/kg. Mice were then subcutaneously 
infected with GAS strain 5448 at 1 x 109 CFU/mL, and received daily treatment for 48 or 72 h post-
infection. Bacterial dissemination was determined in internal organs and in the bloodstream. Data are 
presented as Log10 of colony forming units (CFU), and show mean ± SEM (n = 5). Experiments at 48 
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Figure 4.7 HMA and analogues do not significantly effect lesion size at the site of infection in 
AlbPLG1 mice given a high dose of GAS. Cohorts of five age and sex-matched mice were pre-
treated IP with 20% (v/v) DMSO/saline (vehicle control), erythromycin at 50 mg/kg (positive 
control), HMA, BB2-31F, or BB2-50F at 10 mg/kg. Mice were then subcutaneously infected with 
GAS strain 5448 at 1 x 109 CFU/mL, and received daily treatment for 48 or 72 h post-infection. Data 
show mean lesion size ± SEM (n = 5) at (A) 48 h and (B) 72 h post-GAS infection. Asterisks indicate 














Figure 4.8 HMA and analogues do not effect mouse weight in AlbPLG1 given a high dose of 
GAS. Cohorts of five age and sex-matched mice were pre-treated IP with 20% (v/v) DMSO/saline 
(vehicle control), erythromycin at 50 mg/kg (positive control), HMA, BB2-31F, or BB2-50F at 10 
mg/kg. Mice were then subcutaneously infected with GAS strain 5448 at 1 x 109 CFU/mL, and 
received daily treatment for 48 or 72 h post-infection. Weight data are presented as mean ± SEM (n = 
5) of initial body weight at (A) 48 h and (B) 72 h post-GAS infection. 
A B 48 h infection 72 h infection 
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Figure 4.9 HMA and analogues do not effect the progression of invasive GAS disease in 
AlbPLG1 mice given a low dose of GAS. Cohorts of five mice were subcutaneously infected with 
GAS strain 5448 at approximately 1 x 107 CFU/mL, following pre-treatment with 20% (v/v) 
DMSO/saline (vehicle control) (●), erythromycin at 50 mg/kg (positive control) (■), HMA (▲), BB2-
31F (▼), or BB2-50F (♦) at 10 mg/kg. Mice received daily IP treatment for 72 h. (A) Bacterial counts 
in the skin, liver, spleen and bloodstream, (B) mean lesion size recorded on day 3 post-bacterial 
infection, and (C) mean mice weight were recorded. Bacterial dissemination is presented as Log10 of 
colony forming units (CFU). Data show mean ± SEM (n = 5). Asterisks indicate statistical 
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4.4.8 Co-administration of uPA inhibitors and GAS do not have significant 
effects against bacterial infection in vivo 
It was postulated that the limited effect of the novel uPA inhibitors on systemic GAS 
infection may have been due to drug delivery issues resulting in a reduction in the 
availability or effective concentration at the site of infection. In a pilot study to 
address this, a single dose of the inhibitors were subcutaneously co-administered 
with 1 x 109 CFU/mL GAS inoculum, and mice then euthanised at 48 h. As observed 
with mice receiving daily treatment, co-administration of GAS and uPA inhibitors 
did not affect bacterial dissemination to the liver and spleen, or bacterial load at the 
point of infection after 48 h (Figure 4.10A). However, the presence of GAS in the 
bloodstream of mice treated with BB2-31F and BB2-50F was significantly reduced, 
and complete bacterial clearance was observed in mice treated with HMA. Lesions 
in mice treated with either HMA or erythromycin were not measureable, while a 
trend in reduced lesion sizes was observed in mice treated with BB2-31F and BB2-
50F (Figure 4.10B). No significant differences in weight loss were observed between 
treated and control mice (Figure 4.10C).  
4.5 Discussion 
The recruitment and activation of plasminogen at the bacterial cell surface is critical 
for establishing invasive GAS infection (Sun et al. 2004; Cole et al. 2006; 
Sanderson-Smith et al. 2008). Previous studies have highlighted the importance of 
host plasminogen activators in plasminogen-mediated bacterial invasion and innate 
immune evasion by other pathogens (Lahteenmaki et al. 2001; Sanderson-Smith et 
al. 2012). Using a humanised plasminogen mouse infection model, our study 
establishes a role for uPA, likely acting in synergy with streptokinase, during GAS 
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Figure 4.10 Co-administration of HMA and analogues with GAS strain 5448 did not affect the 
progression of invasive GAS disease. Cohorts of five age and gender-matched AlbPLG1 mice were 
subcutaneously infected at a single dose of 5448 GAS inoculum at 1 x 109 CFU/mL combined with 
20% (v/v) DMSO/saline (control) (●), erythromycin at 50 mg/kg (positive control) (■), HMA (▲), 
BB2-31F (▼), or BB2-50F (♦) at 80% of their MIC. Mice were sacrificed two days post-bacterial 
infection and (A) bacterial dissemination, (B) mean lesion size, and (C) weight loss determined. 
Bacterial dissemination is presented as Log10 of colony forming units (CFU). Data show mean ± SEM 
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infection. The global significance of GAS associated disease necessitates the 
development of safe and effective therapeutics. Given the key role of uPA during 
streptococcal infection, the potential to pharmacologically inhibit uPA activity as a 
means for delaying GAS infection was investigated.  
In the present study, we demonstrate that host uPA significantly increased mice 
mortality during invasive GAS infection. Bacterial counts in the bloodstream and 
spleen were significantly lower in uPA-knockout compared to wild-type mice. This 
correlated with significantly reduced GAS cell surface plasmin acquisition levels in 
plasma from uPA-knockout mice, thereby confirming a role for uPA in plasmin-
mediated dissemination. However, uPA-knockout mice in this model developed 
subcutaneous skin infection even in the absence of bacterial plasminogen activator 
streptokinase. Given the many virulence factors expressed by GAS that contribute to 
GAS survival in mice, this finding was not unexpected (Nizet 2007). 
Streptokinase is one of the best characterised bacterial plasminogen activators, and 
its role in GAS virulence has been extensively studied. Co-administration of GAS 
with human plasminogen considerably increases virulence in subcutaneously 
infected mice, while inactivation of ska significantly reduces virulence (Khil et al. 
2003). Deletion of ska in a humanised skin mouse infection model similarly leads to 
a loss in virulence (Svensson et al. 2002). Sun et al. (2004) later confirmed the 
species specificity of streptokinase for human plasminogen. The present study 
showed that streptokinase-deficient GAS was able to accumulate plasmin at the 
bacterial cell surface following incubation in human plasma, and thus streptokinase 
was not absolutely necessary for plasminogen activation in vivo. This further 
highlights that when streptokinase expression is downregulated during the course of 
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GAS infection, uPA may act as an alternative source for plasmin generation. 
Neutrophils are the first line of innate immune cells to migrate to bacterial infection 
sites, and in addition to macrophages and monocytes, have been shown to express 
uPA and uPAR on the plasma membrane (Plesner et al. 1994; Kumar and Sharma 
2010). The increased expression levels of uPA by these immune cells that circulate 
in abundance during infection are therefore advantageous for plasminogen 
acquisition and activation by GAS. Furthermore, GAS localised plasmin is protected 
from circulating plasmin inhibitors (Sanderson-Smith et al. 2012). Thus, with a high 
concentration of unregulated proteolytic activity at the bacterial cell surface, pro-
uPA activation is enhanced by plasmin accrued at the GAS cell surface, leading to a 
positive feedback mechanism that results in increased uPA production, and 
plasminogen activation by uPA which can both be exploited by GAS. 
The role of uPA is not only limited to its function in proteolysis and fibrinolysis. The 
uPA system also contributes to inflammation and immunity during bacterial 
infection. uPAR is critical for the chemotaxis of neutrophils and monocytes to 
infection sites, while uPA has been linked to potentiating neutrophil activation in 
vitro (Sitrin et al. 1996; Blasi 1997; Blasi and Carmeliet 2002). In pulmonary mouse 
infection models, the deletion of uPA reduced accumulation of inflammatory cells in 
response to intratracheal infection with Pneumocystis carinii, and prevents the 
clearance of bacteria, resulting in uncontrolled infection (Beck et al. 1999; Rijneveld 
et al. 2002). Similar results have been described for the opportunistic fungus 
Cryptococcus neoformans (Gyetko et al. 1996). A later study found that in the 
absence of uPA, phagocytosis, respiratory burst, and degranulation by neutrophils is 
impaired (Gyetko et al. 2004). In another study, antibacterial properties by uPA have 
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been described against staphylococcal infection in a sepsis mouse model (Jin et al. 
2005). Thus, uPA may act as a pro-inflammatory mediator during the course of 
bacterial infection, or promote bacterial dissemination during GAS infection in vivo. 
Given the contribution of uPA to GAS pathogenesis, we attempted to modulate uPA 
activity in vivo to potentially improve host defence against GAS in the humanised 
plasminogen mouse model. We assessed the efficacy of commercial inhibitors 
amiloride and tranexamic acid that target uPA and plasminogen activation 
respectively, and found that treatment of mice with either of these inhibitors at 
increasing doses was not associated with significantly increased mouse survival. 
Whilst amiloride selectively inhibits uPA, and not tPA or other serine protease 
members of the trypsin superfamily, it displays only moderate potency against uPA 
activity (Nienaber et al. 2000; Matthews et al. 2011b). Despite this, treatment with 
amiloride resulted in a reduction in lesion size at the site of infection in AlbPLG1 
mice. We extended this observation with the use of new uPA inhibitors including the 
amiloride derivative HMA, and two previously undescribed novel derivatives of 
HMA, BB2-31F and BB2-50F, that were developed in-house. HMA belongs to a 
family of 6-substituted amiloride, has a reported two-fold higher potency than 
amiloride as a uPA inhibitor, and demonstrates robust anticancer effects in animal 
models (Matthews et al. 2011a; Matthews et al. 2011b). Preliminary data 
demonstrates significantly increased potency against uPA (in nanomolar range) by 
BB2-50F and BB2-31F in vitro (Buckley et al. unpublished). We found that HMA, 
BB2-50F and BB2-31F had antimicrobial activity against GAS in vitro, whilst 
amiloride did not. These compounds therefore displayed dual activity; inhibition of 
uPA proteolytic activity, and an antimicrobial effect against GAS in vitro. However, 
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in our GAS challenge model, targeting uPA-mediated plasminogen activation and 
GAS by these compounds did not significantly diminish bacterial dissemination in 
humanised plasminogen mice following 48 and 72 h post-bacterial infection at a high 
or low (72 h only) infection dose. It may be that daily IP administration of these 
compounds was not sufficient to inhibit uPA activity in this mouse infection model. 
Subsequent to these in vivo studies, detailed analyses of BB2-31F and BB2-50F 
indicated that these particular HMA derivatives have a short metabolic half-life 
when compared to amiloride, which is reported to have a plasma half-life of 
approximately six to nine hours (Vidt 1981). This suggests that low levels of active 
compound reached the point of infection (Buckley, personal communication). We 
therefore investigated an alternative mode of drug delivery via subcutaneously co-
administering GAS and inhibitors at a single dose. While there was no significant 
difference in bacterial dissemination to the liver and spleen in treated versus control 
mice, GAS in the bloodstream of mice treated with BB2-31F and BB2-50F was 
significantly reduced compared to control mice, with complete clearance in HMA-
treated mice observed. Although not significant, lesion sizes were also noticeably 
reduced in mice following co-administration of HMA derivatives and GAS. In all 
trials, erythromycin treatment completely cleared GAS infection within 48 h in the 
bloodstream. While the mechanism of action for erythromycin is well-known, this 
antimicrobial aspect of HMA, BB2-31F and BB2-50F has yet to be explored. 
Furthermore, these compounds are less effective against mouse uPA than human 
uPA in vitro (Buckley et al. unpublished). However, BB2-31F and BB2-50F have 
similar potencies to amiloride against murine uPA (Buckley et al. unpublished), and 
thus may affect the efficacy of these compounds in a mouse model in vivo. Since 
these studies, more stable HMA derivatives with potent uPA inhibitory activity and 
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longer metabolic half-lives have been identified, which may be of interest in future 
studies. Additionally, intravenous administration of these compounds following 
GAS infection would ensure that active compounds were reaching the site of 
infection. To date, mice expressing human uPA have yet to be established. However, 
Lund et al. (2008) have generated a murine inhibitory monoclonal antibody (mU1) 
specifically targeting mouse uPA that exhibits therapeutic potential. Systemic 
administration of recombinant mU1 rescues mice infected with a uPA activity-
dependent bacterial pro-toxin, while its administration in tPA-deficient mice 
successfully impairs uPA-mediated fibrinolysis, as well as delaying skin wound 
healing (Carmeliet et al. 1994; Lund et al. 2008; Jogi et al. 2010). Further testing 
with murine uPA antagonists may therefore better control GAS infection in vivo.  
A functional overlap between uPA and tPA has been suggested in several studies. 
Skin wound healing in uPA- or tPA-deficient mice was found to be indistinguishable 
from the healing of wild-type mice (Lund et al. 2006), and in an earlier study, uPA 
was shown to be capable of fibrin clearance in the absence of tPA in vivo (Bugge et 
al. 1996a). Furthermore, disruption of genes encoding either uPA or tPA, did not 
affect the phenotype of these mice when compared to wild-type mice. These findings 
may therefore reflect the ability of tPA to act as a substitute in the absence of uPA, 
or when uPA-mediated plasminogen activated is inhibited. In the mouse model 
presented in this study, both streptokinase and the other major host activator tPA are 
available as mediators of plasminogen activation, and may therefore provide an 
alternative source for plasminogen activation and acquisition by GAS. Thus, 
therapeutics that target and inactivate these potent plasminogen activators may be 
required to fully control invasive GAS infection.  
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In conclusion, our study reveals for the first time a key role for uPA in invasive GAS 
disease in a newly described uPA-knockout humanised plasminogen mouse infection 
model. Whilst treatment with the selected compounds appeared to have no 
immediate effect on the progression of invasive GAS disease following bacterial 
challenge, compounds that are more potent against murine uPA with improved 
pharmacokinetic properties should be pursued in future studies.  
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This chapter has been submitted for publication and has been formatted accordingly.  
Reference: 
Diane Ly, Deborah Donahue, Mark J Walker, Victoria A Ploplis, Jason D McArthur, 
Marie Ranson, Frank J Castellino, Martina L Sanderson-Smith (2016). 
Characterising the role of tissue-type plasminogen activator in a mouse model of 
Group A streptococcal infection. Submitted to Virulence as a Brief Report (April, 
2016).  
5.1 Abstract 
The glycoprotein plasminogen is central to the human fibrinolytic system, and 
recruitment of its active form plasmin to the bacterial cell surface is critical for 
invasive disease initiation by GAS. A key role for uPA in bacterial dissemination 
was recently reported. However, the contribution of the other major host activator, 
tPA, to GAS pathogenesis remains largely unexplored. Using tPA-deficient 
humanised plasminogen mice, we show that whilst exogenous sources of either 
human or mouse tPA alone were sufficient to mediate human plasminogen activation 
at the bacterial surface, no significant difference in the survival of AlbPLG1 
compared to AlbPLG1/tPA-/- mice was seen 10-days post-infection. Similarly, no 
difference was detected in bacterial dissemination, skin lesion size or the pathology 
of GAS infection in the absence of tPA. These data suggest that host tPA plays a 
limited role in this humanised subcutaneous mouse model of invasive GAS 
infection, and further highlights the importance of its counterpart uPA in invasive 
GAS disease.  
 
 
Chapter 5 Investigating the Role of tPA in a Mouse Model of Invasive GAS Disease 
Page | 120 
 
5.2 Introduction 
One of the central mechanisms of host-GAS invasion is immobilisation of 
plasminogen to the GAS cell surface. The subsequent conversion to plasmin drives 
the unregulated proteolytic destruction of surrounding host-tissue barriers, and thus 
facilitates bacterial dissemination and evasion of the host innate immune response 
that contributes to GAS pathogenesis and the global disease burden (Coleman and 
Benach 1999; Carapetis et al. 2005; Nizet 2007; Walker et al. 2014). 
The secreted GAS plasminogen activator, streptokinase, plays an integral role in 
plasminogen-dependent streptococcal virulence, whilst the contribution of host- 
derived uPA in invasive GAS disease was recently demonstrated using a humanised 
plasminogen uPA-knockout mouse model of GAS disease (Sanderson-Smith et al. 
2013). Whether host plasminogen activator tPA contributes to GAS infection is 
unclear. However, for a number of other highly pathogenic organisms, the activation 
of cell-bound plasminogen can be mediated by host-derived uPA or tPA. Enhanced 
tPA-mediated activation of cell-bound plasminogen has been demonstrated for E. 
coli, Helicobactor pylori, Neisseria meningitides and Group A, C and G 
streptococci, while either uPA- or tPA-mediated plasminogen activation at the 
surfaces of Salmonella typhimurium, Borrelia burgdorferi, Streptococcus 
pneumoniae, Streptococcus agalactiae, and Mycoplasma fermentans promotes 
degradation of ECM components and leads to plasmin-mediated migration through 
endothelial and epithelial cell layers (Kuusela et al. 1992; Yavlovich et al. 2001; 
Lahteenmaki et al. 2005; Magalhaes et al. 2007; Sanderson-Smith et al. 2012).  
Whilst uPA and tPA share the common ability to activate human plasminogen, they 
have distinct protein structures, tissue specificity, and biological activities, which 
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suggests that these host activators may play different roles during bacterial infection 
(Collen 2001). We therefore explored the contribution of tPA during invasive GAS 
disease using a novel mouse model of infection.  
5.3 Methods and materials 
5.3.1 Animals 
The role of tPA in GAS virulence was assessed using humanised plasminogen 
transgenic mice (AlbPLG1) (Sun et al. 2004) and mice deficient in tPA on the same 
genetic background (AlbPLG1/tPA-/-). tPA-knockout mice on a C57BL/6 background 
were constructed by replacing tpa (PLAT) with a neomycin-resistant cassette 
(Carmeliet et al. 1994), and subsequently backcrossed with AlbPLG1 mice to 
generate humanised plasminogen mice depleted in tPA expression. Plasminogen and 
tPA-deficient mouse genotypes were confirmed via PCR of an ear punch as 
described previously (Carmeliet et al. 1994; Sun et al. 2004). In our animal 
experiments, cohorts of eight age and sex-matched mice between 6-10 weeks old 
were intradermally inoculated with approximately 1 x 109 CFU/mL of wild-type 
GAS strain 5448, and their survival monitored over a 10-day period.  
5.3.2 Histology 
Cohorts of five (AlbPLG1/tPA-/-) or four (AlbPLG1) mice were infected with 4 x 109 
CFU/mL of wild-type GAS strain 5448 and after 48 h, lesions at the site of infection 
were excised for histopathology analysis. Following overnight fixing in 4% (w/v) 
PFA, tissues were processed using an ASP200 automated vacuum tissue processor 
(Leica) according to the protocol outlined in Table 5.1. Skin lesions were embedded 
in paraffin blocks using an EG1150 paraffin-embedding station (Leica), and were 
subsequently sectioned at 5 µm onto lysine-coated Snowcoat microscope slides 
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(Leica). Microscope slides were incubated at 65 °C for 20 min prior to staining to 
facilitate adherence of paraffin-embedded tissue sections to the microscope slide. 
Skin lesions were stained with hematoxylin and eosin (H&E) for gross examination, 
Gram’s violet solution for identification of GAS, or probed for fibrin(ogen) via 
immunohistochemistry. 







For H&E staining, sections were manually processed as outlined in Table 5.2. For 
GAS detection, slides were initially stained with crystal violet (1 min), followed by 
iodine (1 min), decolourisation with 95% (v/v) ethanol (30 sec), and counterstained 
with safranin (1 min). GAS (Gram positive bacterium) stained as purple using this 
method. For the detection of fibrin(ogen), the heat induced epitope retrieval (HIER) 
method was utilised. Firstly, tissue sections were deparaffinised (Table 5.3) to 
facilitate optimal tissue staining. Antigen retrieval was performed via incubating 
tissue sections in sodium citrate buffer (Appendix A) for 20 min at 95 °C. Between 
all incubations, slides were washed thrice for 5 min in tris-buffered saline (TBS; 
Appendix A). Endogenous peroxidase activity was quenched by incubating slides 
Solution Time (min) Temperature (°C) 
1. Formalin 5 37 
2. 70% ethanol 10 37 
3. 90% ethanol 10 37 
4. 100% ethanol 20 37 
5. 100% ethanol 20 37 
6. 100% ethanol 30 37 
7. 100% ethanol 45 37 
8. Xylene 20 37 
9. Xylene 30 37 
10. Xylene 45 37 
11. Paraffin 20 65 
12. Paraffin 30 65 
13. Paraffin 45 65 
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with 1% (v/v) H2O2 in PBS for 20 min, followed by blocking overnight with normal 
goat serum (1:5 dilution in TBS with 1% (w/v) BSA; Life Technologies). 
Fibrin(ogen) was probed with rabbit anti-fibrinogen (1 µg/mL in TBS; Abcam) at 4 
°C overnight, followed by HRP-conjugated goat anti-rabbit IgG (1:250 in TBS) for 1 
h. Bound HRP was visualized via 3,3 diaminobenzidine tetrachloride (DAB) staining 
and counterstained with haematoxylin for approximately 1 min. Coverslips were 
mounted onto microscope slides using Safety Mount (Fronine, Riverstone. Australia) 
and sealed with varnish. All stained slides were examined using the Leica Leitz 
DMRB microscope. 












Solution Time (sec) 
1. Xylene 90 
2. Xylene 60 
3. 100% ethanol 90 
4. 100% ethanol 10 
5. Water bath 60 
6. Harris haematoxylin 120 
7. dH2O 120 
8. Acid alcohol 1 
9. dH2O 60 
10. Scotts blueing solution 60 
11. dH2O 60 
12. 1% aqueous eosin 20 
13. 100% ethanol 60 
14. 100% ethanol 45 
15. Xylene 10 
16. Xylene 60 
Solution Time (min) 
1. Xylene (x2) 5 
2. 100% ethanol 5 
3. 95% ethanol 3 
4. 85% ethanol 3 
5. 70% ethanol 3 
6. 50% ethanol 3 
7. dH2O (x2) 5 
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5.4 Results 
5.4.1 Host activator tPA mediates GAS cell surface plasmin acquisition in vitro 
GAS sequesters high levels of cell surface plasmin when incubated in human plasma 
and we have previously demonstrated that this mechanism can be mediated by host 
activator uPA (Sanderson-Smith et al. 2013). The activation of plasminogen bound 
to the GAS cell surface by exogenous tPA was previously shown (Kuusela et al. 
1992). We therefore confirmed the ability of tPA to mediate cell surface plasmin 
acquisition by GAS via incubation in the presence or absence of exogenous tPA. As 
expected, wild-type GAS strain 5448, which expresses the potent plasminogen 
activator streptokinase, accumulated high levels of cell surface plasmin when 
incubated with human Glu-plasminogen (Figure 5.1A). However, in the absence of 
streptokinase, human tPA was able to mediate cell surface plasmin acquisition by 
GAS strain 5448Δska, with levels comparable to that of wild-type GAS strain 5448 
and reverse-complemented ska strain 5448ΔskaRC (Figure 5.1A). In the absence of 
streptokinase, mouse tPA was also able to facilitate plasmin acquisition at the cell 
surface of GAS strain 5448Δska (Figure 5.1B). These results confirm that exogenous 
sources of both human and mouse-derived tPA can facilitate human plasminogen 
activation at the bacterial cell surface in vitro, suggesting a potential role for tPA in 
the development of GAS disease.  
5.4.2 tPA plays a limited role in GAS survival and bacterial dissemination in vivo 
We next investigated whether tPA contributes to invasive GAS disease in vivo using 
humanised plasminogen tPA-knockout mice (AlbPLG1/tPA-/-). Mice were 
intradermally inoculated with 1 x 109 CFU/mL of GAS strain 5448 and their survival  
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Figure 5.1 Host-derived tPA mediates cell surface plasmin acquisition by GAS. GAS strains 5448 
(black), 5448∆ska (white) and 5448ΔskaRC (grey) were incubated for 1 h at 37 °C with either 3 IU 
(A) human or (B) mouse tPA, 0.5 mg/mL Glu-plasminogen (Glu-Plg), tPA and Glu-Plg, or PBS only. 
After removing unbound plasmin(ogen), bacteria were incubated overnight with the plasmin-specific 
chromogenic substrate S-2251, and subsequent plasmin activity levels were measured at 405 nm. Data 
represent three independent experiments performed in triplicate (n = 3). Asterisks indicate statistical 
significance, ***P < 0.001; *P < 0.05. 
 
monitored over 10 days. No significant difference was seen in the survival rates of 
AlbPLG1 versus AlbPLG1/tPA-/- mice, with infection resulting in 50% and 56% 
mortality, respectively (Figure 5.2A). Similarly, no differences were detected in 
bacterial loads in the spleen, liver and blood harvested from AlbPLG1 versus 
AlbPLG1/tPA-/- mice (Figure 5.2B), or the ability of GAS to sequester plasmin at the 
cell surface in plasma obtained from tPA-deficient mice in the absence of 
streptokinase (Figure 5.2C). These results strongly suggest that in this particular 
mouse model of infection, tPA does not significantly contribute to GAS 
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Figure 5.2 tPA does not contribute to disease progression in a mouse model of invasive GAS 
infection. Cohorts of eight aged and sex-matched AlbPLG1 (●) and AlbPLG1/tPA-/- (▪) mice were 
intradermally inoculated with 1 x 109 CFU/mL wild-type GAS strain 5448 and (A) the survival of 
mice monitored over 10 days, or (B) infected with 4 x 109 CFU/mL GAS and the bacterial load 
determined in organs and blood of mice 48-72 h post-infection. (C) GAS cell surface plasmin 
acquisition was performed ex vivo by incubating GAS strains 5448 (black) or 5448Δska (white) in 
plasma from AlbPLG1 or AlbPLG1/tPA-/- mice, or PBS only for 3 h at 37 °C. Survival data represent 
two independent experiments (n = 16), dissemination data represent three independent experiments (n 
= 9) and cell surface plasmin acquisition data represent two independent experiments performed in 
triplicate (n = 2).  
 
5.4.3 Pathology of GAS infection is unaffected by the absence of tPA 
Central to host defence against invading pathogens is the infiltration of immune cells 
to the site of bacterial infection. To further elucidate the impact of tPA in GAS 
disease, the presence of bacteria and histopathological changes at the site of GAS 
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infection were examined. Following infection of mice with wild-type GAS strain 
5448, all excised skin lesions revealed hallmarks of invasive infection including 
severe inflammation of muscle and necrosis of fascia, dermis and epidermis in both 
wild-type and tPA-knockout mice. Both mouse lines displayed an influx of 
infiltrating immune cells, which was most abundant at the boundaries of necrotic 
fascia, but was less evident in GAS-enriched regions. Gram staining confirmed a 
high bacterial load in fascia, and fibrin deposits were comparable in all sections of 
both AlbPLG1 and AlbPLG1/tPA-/- mice (Figure 5.3A). Furthermore, there were no 
significant differences observed in the bacterial load (Figure 3B), or lesion sizes at 
the site of GAS infection of AlbPLG1 compared with AlbPLG1/tPA-/- mice (Figure 
5.3C). 
5.5 Discussion 
GAS is a highly significant human pathogen, and understanding host-pathogen 
interactions is central to the development of potential therapeutics for the treatment 
of severe GAS infection. GAS has evolved to interact with multiple components of 
the host fibrinolytic system, and the ability of GAS to sequester and activate cell-
bound plasminogen is important for bacterial cell migration and invasive disease 
initiation (Sun et al. 2004; Cole et al. 2006; Sanderson-Smith et al. 2008). We 
therefore sought to characterise the role of the eukaryotic plasminogen activator tPA 
in a mouse model of invasive GAS infection. This is the first study to report on the 
contribution of tPA in a mouse model of GAS virulence. Despite being able to 
mediate plasminogen activation at the GAS cell surface in vitro, tPA depletion did 
not significantly alter the pathology of GAS invasive disease following subcutaneous  
 
 
Chapter 5 Investigating the Role of tPA in a Mouse Model of Invasive GAS Disease 













Figure 5.3 Immune cell recruitment and fibrin deposition was unaffected in AlbPLG1/tPA-/- mice 
compared to AlbPLG1. Mice were challenged with 4 x 109 CFU/mL GAS and 48-72 h post-
infection, skin wounds were (A) prepared for histological analysis, (B) enumerated for bacterial load 
or (C) measured for size. Photomicrographs are representative of paraffin-embedded sections from 
five (AlbPLG1/tPA-/-) or four (AlbPLG1) mice stained with Gram’s crystal violet solution, H&E or for 
fibrin deposition. Fibrin deposits were detected using HIER antibody retrieval method, followed by 
labelling with rabbit anti-fibrinogen and HRP-conjugated anti-rabbit, and the reaction visualised via 
DAB staining methods. Numbered arrows indicate the following: 1, streptococci; 2, infiltrating 
inflammatory cells; 3, fibrin deposition. All magnifications are 50x. Images are representative of six 
sections from four (AlbPLG1) or five (AlbPLG/tPA-/-) mice.  
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acquisition in the absence of streptokinase and uPA (Berge and Sjobring 1993; 
Sanderson-Smith et al. 2013). However, mortality and bacterial dissemination did 
not differ between wild-type AlbPLG1 and AlbPLG1/tPA-/- mice following GAS 
infection. Likewise, histological analysis showed no differences in the inflammatory 
response in the absence of tPA at the site of initial GAS skin infection. These data 
indicate that the absence of tPA alone is insufficient to attenuate GAS virulence 
following subcutaneous challenge in this humanised mouse model of infection.  
In studies of other bacterial infections, a dual role has been reported for tPA. In E. 
coli, Klebsiella pneumoniae and Mycobacterium avium infection models, tPA is an 
important factor for the survival of the host. E. coli commonly causes abdominal 
sepsis and urinary tract infections (Barnett and Stephens 1997; Bosscha et al. 1997). 
tPA deficiency during abdominal sepsis is associated with reduced survival and 
increased bacterial dissemination from the primary site of infection in a mouse 
model (Renckens et al. 2006), while Roelofs et al. (2009) reported that bacterial 
clearance by neutrophils in tPA-depleted mice was significantly impaired during 
acute pyelonephritis. Similarly, treatment of mice with high levels of recombinant 
tPA improved host survival and attenuated damage of organs against infection with 
Klebsiella pneumoniae, while recombinant tPA was found to prevent abdominal 
abscess formation in a rat model of secondary peritonitis (Buyne et al. 2008; 
Renckens et al. 2008). Furthermore, bacterial dissemination was found to progress 
faster in the absence of endogenous tPA in a systemic model of Mycobacterium 
avium infection (Sato et al. 2003). In contrast to the aforementioned studies, an 
adverse role has been described for host tPA during sepsis caused by Burkholderia 
pseudomallei, the causative agent for melioidosis. Plasma samples obtained from 
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patients diagnosed with melioidosis have elevated levels of tPA, and a recent study 
found that in a mouse model of sepsis, tPA deficiency resulted in higher survival 
rates, reduced bacterial burden in lung tissue, and attenuated lung injury (Wiersinga 
et al. 2008; Kager et al. 2012). Collectively, these studies clearly demonstrate 
diverse roles for tPA during inflammation and sepsis, whereby it can either enhance 
bacterial invasion or host defence. This duality may result from differences in the 
pathogenic mechanisms employed by the various infectious agents, such as the 
intracellular or extracellular residency of the bacterium (Kager et al. 2012). 
Despite divergence in their basic biological functions, a growing body of evidence 
has shown that uPA and tPA can function as complementary plasminogen activators 
by regulating the formation of plasmin. Previous studies have shown that while tPA 
mediates clot-restricted plasminogen activation and increases the efficiency of fibrin 
clearance, it is not essential for fibrin degradation or skin wound healing (Hoylaerts 
et al. 1982; Bugge et al. 1996a). This supports the observation in the present study 
that extravascular fibrin deposition appears to be equivalent in both wild-type and 
tPA-knockout mice in response to GAS infection. Studies in skin wound healing 
show that mice lacking tPA have reduced thrombolytic potential as well as a slight 
delay in skin wound closure (Carmeliet et al. 1994; Bugge et al. 1996a; Lund et al. 
2006). Similar characteristics were also reflected in uPA-deficient mice (Carmeliet et 
al. 1994). In contrast, uPA and tPA double deficient mice display characteristics akin 
to mice depleted of plasminogen, where higher incidences of spontaneous fibrin 
deposition and in more organs than singly deficient mice were observed, as well as a 
significant impediment in skin wound healing time (Carmeliet et al. 1994; Lund et 
al. 2006). Thus, in the absence of tPA, uPA can produce sufficient fibrinolytic 
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activity to mediate clearance of fibrin deposits from tissues and also support gross 
skin wound healing (Bugge et al. 1996a; Lund et al. 2006). Furthermore, circulating 
plasma kallikrein also activates plasminogen, albeit less efficiently than uPA and 
tPA in vitro (Miles et al. 1983). A role for plasma kallikrein as a plasminogen 
activator during skin wound healing in mice has been identified (Lund et al. 2006). 
In addition to host activators, GAS secretes the potent human-specific plasminogen 
activator streptokinase (Marcum and Kline 1983). The interaction between 
streptokinase and plasminogen is critical for the pathogenesis of GAS and represents 
one of the most well-studied streptococcal virulence mechanisms (Sun et al. 2004; 
McArthur et al. 2012; Cook et al. 2014). Local fibrin formation is essential for GAS 
containment and preventing bacterial spread. The ability of streptokinase to hijack 
the host fibrinolytic system to overcome immune surveillance and barrier functions 
renders streptokinase-dependent plasminogen activation a key process in GAS 
virulence (Sun et al. 2004; Sun et al. 2009). Furthermore, streptokinase-mediated 
plasminogen activation is shielded from circulating scavengers of plasmin, and 
therefore provides an unregulated source of plasmin activity for acquisition by GAS. 
In the mouse model described in this work, both uPA and streptokinase were 
available as mediators of plasminogen activation and plasmin acquisition to the 
bacterial cell surface. Therefore, the limited contribution of tPA in disease 
progression further emphasises the importance of uPA and streptokinase as 
plasminogen activators during GAS virulence. Further, our data highlights the ability 
of eukaryotic plasminogen activators to serve as complementary factors that can 
individually function in the absence of one another. 
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Despite the findings of the current study, we are unable to rule out a role for tPA 
during human infection with GAS. The humanised plasminogen mouse model is the 
most commonly used animal infection model for exploring host-GAS interactions 
and understanding GAS virulence mechanisms. In contrast to the in vivo model used 
in this study, the use of other streptococcal infection mouse models which employ 
alternative routes of bacterial challenge might reveal a role for tPA in GAS 
virulence.  
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GAS is a globally significant, human-restricted bacterial pathogen responsible for 
high rates of morbidity and mortality. GAS is placed amongst the world’s top ten 
human pathogens, and is ranked as the fourth most significant cause of bacterial-
associated deaths (WHO 2005). Uncomplicated throat and skin infections including 
pharyngitis and impetigo are common clinical manifestations of GAS colonisation 
and despite being treatable, the cost of pharyngitis in the USA alone is estimated to 
be an unprecedented $538 million per year (Pfoh et al. 2008). GAS can also cause 
systemic infection, resulting in serious and life-threatening conditions, of which 
STSS and necrotising fasciitis are the major burden of morbidity and mortality 
worldwide (Walker et al. 2014). GAS infections impact countries on a global scale, 
with over 600 million infections reported annually (Carapetis et al. 2005). Thus, 
understanding GAS virulence mechanisms and development of suitable and effective 
treatment to control GAS infection is necessary. Despite intensive research efforts to 
understand the GAS-host relationship, the precise molecular mechanisms of GAS 
virulence and pathogenesis remain elusive. In this study, we employed animal 
models to elucidate the impact of plasmin acquisition by GAS on innate immune 
factors, and characterised the role of host plasminogen activators in invasive GAS 
disease (Figure 6.1). 
Whilst GAS exhibits multiple virulence factors that contribute to complement 
evasion, here we describe for the first time that the acquisition of surface-associated 
host plasmin(ogen) confers GAS protection from neutrophil killing and increased 
GAS survival in vivo. We cannot exactly pinpoint whether it is the contribution of 
plasminogen or active plasmin to these findings. It is likely that a combination of 
both plasminogen at the GAS surface acting as a blocking molecule, and plasmin-
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Figure 6.1 Proposed model for the impact of plasmin(ogen) acquisition on complement-mediated neutrophil killing by GAS in the host. (A) The NS88.2 M protein 
Prp binds plasminogen (plg) at the GAS cell surface which can be activated to plasmin by uPA, tPA, or streptokinase (SK) in vitro. The present study found that (B) 
plasmin at the GAS cell surface partially degraded C3b in vitro, and surface-associated plasminogen acquisition correlated with decreased (C) C3b deposition on the 
bacterial surface and (D) complement-mediated neutrophil killing in vitro. We hypothesise that the reduced bacterial opsonisation is due to either plasmin-mediated 
degradation and/or plasminogen blocking of C3b at the GAS surface. Altogether, in a humanised plasminogen GAS infection mouse model, plasmin(ogen) acquisition by 
GAS paralleled decreased C3b deposition, protection from neutrophil phagocytosis, and increased GAS survival in vivo. This was dependent on the presence of uPA/SK, 
but not tPA. 
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mediated C3b degradation preventing effective opsonisation. Recently it was shown 
that plasminogen binds to C3b (Barthel et al. 2012a). However, active plasmin both 
in fluid-phase and surface-bound, although incompletely cleaving C3b, lead to 
complement inhibition via blocking C3 convertase activity, as also shown for C5. 
Thus, in addition to deactivating complement proteins in plasma, plasmin is also 
capable of blocking all three major complement pathways (Pillemer et al. 1953; 
Barthel et al. 2012a). This highlights the potential for plasmin at the GAS cell 
surface to impact on other complement pathways, and suggests that GAS-generated 
plasmin may be utilised to avoid different stages of complement attack. Degradation 
of other critical complement factors by bacterial-associated plasmin has been 
demonstrated for some pathogens (Ramu et al. 2007), as well as a role for plasmin in 
the infiltration of inflammatory cells to sites of a bacterial infection (Ploplis et al. 
1998; Busuttil et al. 2004). Thus, the consequence of protease activity at the GAS 
surface on other major immune cells including macrophages, and innate immune 
effectors involved in bacterial clearance should be pursued. Expansion of the present 
study in C3-deficient mice on a humanised plasminogen background would also be 
beneficial. Previous data has shown that host defence in C3-deficient mice is 
significantly impaired following infection with Streptococcus agalactiae or 
Streptococcus pneumoniae (Wessels et al. 1995; Circolo et al. 1999). The role of the 
complement system in host defence against GAS infection in vivo is yet to be fully 
explored. 
In addition to the regulatory role of uPA and tPA as activators in fibrinolysis, 
research in the past few decades has focused on the significance of plasminogen 
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activation in thrombolytic therapy (tPA) and cancer invasion (uPA). Only recently 
has the contribution of these activators to bacterial pathogenesis received attention.  
Our study using a uPA-deficient humanised plasminogen mouse model provides 
strong evidence that uPA may serve as an alternative source for plasmin generation 
during the course of GAS infection when streptokinase expression is down-
regulated. Thus we conclude that host uPA significantly contributes to GAS invasive 
infection. Interestingly, Borrerlia burgdorferi, which does not secrete its own 
protease, binds human plasminogen and uPA to the bacterial cell surface as a 
mechanism to facilitate dissemination and localisation of spirochetes to sites of 
vascular injury (Klempner et al. 1995). In our own investigations, we were unable to 
identify any GAS cell surface receptors for uPA (data not shown). During infection 
with S. aureus, PAI-1 levels were inversely related to active uPA levels (Jin et al. 
2005). Investigation of PAI-1 levels in plasma during streptococcal infection, as well 
as the analysis of C3b deposition on the bacterial surface following GAS infection in 
uPA-deficient mice should be considered. 
Given our findings of a role for uPA in GAS virulence, we investigated the selective 
inhibition of plasmin activity to potentially control GAS infection in vivo. Based on 
previous studies, the use of small molecules to block uPA-driven activity in mice has 
exhibited therapeutic potential (Lund et al. 2008; Jogi et al. 2010). We found that in 
a humanised plasminogen mouse model, commercially available and novel uPA 
inhibitors developed in-house lacked systemic effect against GAS infection. 
However, a reduction in lesion size was observed in mice treated with BB2-31F and 
BB2-50F, which displayed antimicrobial activity against GAS in vitro. This suggests 
that an alternative mode of drug delivery, such as an intravenous route, might reveal 
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a significant effect on the development of skin lesions during infection. Identification 
of other compounds, or fine-tuning of the current compounds with improved plasma 
half-life and increased potency against mouse uPA may also be necessary to better 
control GAS infection in this mouse model. Future studies evaluating the candidacy 
of these compounds as antimicrobial treatments against GAS skin infections can be 
performed using the murine tape-stripping superficial skin infection model 
(Kugelberg et al. 2005). This model has successfully identified a topical treatment 
for S. aureus infections (Hu et al. 2010). 
In the mouse model employed in our study, host tPA had a limited role in invasive 
GAS disease. Despite being able to mediate plasminogen activation at the bacterial 
cell surface in the absence of streptokinase and uPA in vitro, tPA depletion did not 
influence the survival of mice, or alter the pathology of invasive GAS disease. This 
suggests that tPA is not predominantly involved in GAS infection in this highly 
invasive humanised plasminogen mouse model, however, a role for tPA in GAS 
virulence cannot be completely dismissed. 
To date, there is no single comprehensive animal model that accurately mimics the 
pathogenesis of any GAS disease (Watson et al. 2016). The mouse model is the most 
utilised in vivo system for the dissection of GAS-host interactions. Components of 
the murine and human fibrinolytic system are largely similar, however, there are 
some differences to be noted, such as a greater resistance to activation by human tPA 
of murine plasminogen than human plasminogen (Lijnen et al. 1994). It is also 
known that the susceptibility to GAS infection varies significantly between mouse 
strains, as a result of differences in host genetic factors (Medina and Lengeling 
2005). tPA is a clot-restricted plasminogen activator, and has a high affinity for 
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fibrin. It may be that the highly invasive, systemic mouse model used in this study 
was not sufficient to assess the contribution of tPA. A previous study has 
demonstrated a role for fibrin clots in host defence against GAS pathogenesis (Sun et 
al. 2004). The formation of a blood clot in either an abrasive or incisional superficial 
skin wound healing model in tPA-knockout mice following GAS infection may 
elucidate a possible role for tPA-mediated plasminogen activation in GAS virulence 
(Dai et al. 2011; Watson et al. 2016). Alternatively, intravenous infection, whereby 
GAS gain direct access to tPA expressing endothelial cells may also provide 
additional insight. Moreover, infection of tPA-knockout mice with a ska-deficient 
GAS strain would address the possibility that the presence of streptokinase may be 
masking the role of tPA. However, in our studies in uPA-knockout mice, there was a 
clear decrease in GAS virulence, even in the presence of ska expression (Sanderson-
Smith et al. 2013). 
uPA and tPA can function as complementary plasminogen activators (Carmeliet et 
al. 1994; Carmeliet and Collen 1996). In the absence of tPA, uPA provides sufficient 
proteolytic activity to facilitate clearance of fibrin deposits and support skin wound 
healing (Miles et al. 1983; Lund et al. 2006). A future endeavor may therefore be to 
challenge doubly deficient plasminogen activator mice with GAS to further elucidate 
the roles of uPA and tPA in GAS pathogenesis. However, these mice demonstrate 
shorter lifespan, reduced fertility and commonly experience rectal prolapse and 
fibrin deposition in multiple organs, which suggests that they would be significantly 
compromised upon GAS infection (Carmeliet et al. 1994). Additionally, a role for a 
third plasminogen activator, plasma kallikrein, in plasminogen activation during skin 
wound healing in mice has been reported (Lund et al. 2006). The role of plasma 
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kallikrein in plasmin-mediated bacterial pathogenesis remains unexplored. Despite 
its poor catalytic efficiency for plasminogen activation when compared to the main 
activators in vitro, its precursor, prekallikrein, circulates at an abundance of 
approximately 20-fold higher than pro-uPA (Colman 1969). Thus, plasma kallikrein 
may contribute to plasmin generation during the initiation of invasive GAS disease.  
The pathological importance of plasminogen activation and acquisition by GAS is 
well-established (Sun et al. 2004; Cole et al. 2006; Sanderson-Smith et al. 2008). 
Bacterially acquired plasmin acts as a key molecule that potentiates and initiates 
systemic bacterial infection. Here, we provide further evidence that GAS sequesters 
host plasmin(ogen) as a protective mechanism to escape from complement-mediated 
neutrophil killing. Furthermore, we show for the first time that host uPA, but not its 
counterpart tPA, significantly contributes to developing invasive GAS infection in a 
humanised plasminogen mouse model. Systemic treatment of GAS-infected mice 
with commercial and newly developed analogue inhibitors of uPA activity however, 
did not alleviate or abolish GAS infection in this mouse model of infection. The use 
of other animal models may address the shortcomings in this study.  Our data fuels 
further knowledge that the ability to capture and/or activate plasminogen not only 
enhances the ability of this bacterium to surmount tissue barriers and facilitate 
invasion, but also provides an opportunity to modulate host defence and increase 
bacterial survival. The present study broadens the scope of research that continues on 
defining the pathogenic mechanisms of GAS, for it is imperative that therapeutic 
strategies are developed in order to improve host defence against the devastating 
impact of this global pathogen. 
 
 
Chapter 7 References 

















Chapter 7 References 
Page | 142 
 
Abdissa, A., D. Asrat, G. Kronvall, B. Shittu, D. Achiko, M. Zeidan, L. K. Yamuah 
and A. Aseffa (2006). High diversity of group A streptococcal emm types among 
healthy schoolchildren in Ethiopia. Clinical Infectious Diseases 42(10): 1362-1367. 
Accardo, P., P. Sanchez-Corral, O. Criado, E. Garcia and S. Rodriguez de Cordoba 
(1996). Binding of human complement component C4b-binding protein (C4BP) to 
Streptococcus pyogenes involves the C4b-binding site. Journal of Immunology 
157(11): 4935-4939. 
Agarwal, V., A. Kuchipudi, M. Fulde, K. Riesbeck, S. Bergmann and A. M. Blom 
(2013). Streptococcus pneumoniae endopeptidase O (PepO) is a multifunctional 
plasminogen- and fibronectin-binding protein, facilitating evasion of innate 
immunity and invasion of host cells. Journal of Biological Chemistry 288(10): 6849-
6863. 
Aisina, R. B. and L. I. Mukhametova (2014). Structure and function of 
plasminogen/plasmin system. Russian Journal of Bioorganic Chemistry 40(6): 590-
605. 
Akesson, P., A. G. Sjoholm and L. Bjorck (1996). Protein SIC, a novel extracellular 
protein of Streptococcus pyogenes interfering with complement function. Journal of 
Biological Chemistry 271(2): 1081-1088. 
Amara, U., M. A. Flierl, D. Rittirsch, A. Klos, H. Chen, B. Acker, U. B. Brückner, 
B. Nilsson, F. Gebhard, J. D. Lambris and M. Huber-Lang (2010). Molecular 
intercommunication between the complement and coagulation systems. Journal of 
Immunology 185(9): 5628-5636. 
Amara, U., D. Rittirsch, M. Flierl, U. Bruckner, A. Klos, F. Gebhard, J. D. Lambris 
and M. Huber-Lang (2008). Interaction between the coagulation and complement 
system. Advances in Experimental Medicine and Biology 632:71-79. 
Andersen, B. R. and J. L. Duncan (1980). Activation of human neutrophil 
metabolism by streptolysin O. Journal of infectious diseases 141(5): 680-685. 
Andreasen, P. A. (2001). Plasminogen activation system. eLS, John Wiley & Sons, 
Ltd. 
Andreasen, P. A., L. Kjoller, L. Christensen and M. J. Duffy (1997). The urokinase-
type plasminogen activator system in cancer metastasis: a review. International 
Journal of Cancer 72(1): 1-22. 
Aziz, R. K. and M. Kotb (2008). Rise and persistence of global M1T1 clone of 
Streptococcus pyogenes. Emerging Infectious Diseases 14(10): 1511-1517. 
Barlow, G. H., C. W. Francis and V. J. Marder (1981). On the conversion of high 
molecular weight urokinase to the low molecular weight form by plasmin. 
Thrombosis Research 23(6): 541-547. 
Barnett, B. J. and D. S. Stephens (1997). Urinary tract infection: an overview. 
American Journal of the Medical Sciences 314(4): 245-249. 
 
Chapter 7 References 
Page | 143 
 
Barthel, D., S. Schindler and P. F. Zipfel (2012a). Plasminogen is a complement 
inhibitor. Journal of Biological Chemistry 287(22): 18831-18842. 
Barthel, D., B. Singh, K. Riesbeck and P. F. Zipfel (2012b). Haemophilus influenzae 
uses the surface protein E to acquire human plasminogen and to evade innate 
immunity. Journal of Immunology 188(1): 379-385. 
Beck, J. M., A. M. Preston and M. R. Gyetko (1999). Urokinase-type plasminogen 
activator in inflammatory cell recruitment and host defense against Pneumocystis 
carinii in mice. Infection and Immunity 67(2): 879-884. 
Berge, A. and U. Sjobring (1993). PAM, a novel plasminogen-binding protein from 
Streptococcus pyogenes. Journal of Biological Chemistry 268(34): 25417-25424. 
Berggard, K., E. Johnsson, F. R. Mooi and G. Lindahl (1997). Bordetella pertussis 
binds the human complement regulator C4BP: role of filamentous hemagglutinin. 
Infection and Immunity 65(9): 3638-3643. 
Berggard, K., E. Johnsson, E. Morfeldt, J. Persson, M. Stalhammar-Carlemalm and 
G. Lindahl (2001). Binding of human C4BP to the hypervariable region of M 
protein: a molecular mechanism of phagocytosis resistance in Streptococcus 
pyogenes. Molecular microbiology 42(2): 539-551. 
Bergmann, S., M. Rohde and S. Hammerschmidt (2004). Glyceraldehyde-3-
phosphate dehydrogenase of Streptococcus pneumoniae is a surface-displayed 
plasminogen-binding protein. Infection and Immunity 72(4): 2416-2419. 
Bergmann, S., M. Rohde, K. T. Preissner and S. Hammerschmidt (2005). The nine 
residue plasminogen-binding motif of the pneumococcal enolase is the major 
cofactor of plasmin-mediated degradation of extracellular matrix, dissolution of 
fibrin and transmigration. Thrombosis and Haemostasis 94(2): 304-311. 
Beutler, B. (2004). Innate immunity: an overview. Molecular Immunology 40(12): 
845-859. 
Bisno, A. L. and D. L. Stevens (1996). Streptococcal infections of skin and soft 
tissues. New England Journal of Medicine 334(4): 240-245. 
Blackmore, T. K., V. A. Fischetti, T. A. Sadlon, H. M. Ward and D. L. Gordon 
(1998). M protein of the group A Streptococcus binds to the seventh short consensus 
repeat of human complement factor H. Infection and Immunity 66(4): 1427-1431. 
Blasi, F. (1997). uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and 
chemotactic highways? Immunology Today 18(9): 415-417. 
Blasi, F. and P. Carmeliet (2002). uPAR: a versatile signalling orchestrator. Nature 
reviews. Molecular Cell Biology 3(12): 932-943. 
Blom, A. M., T. Hallstrom and K. Riesbeck (2009). Complement evasion strategies 
of pathogens-acquisition of inhibitors and beyond. Molecular Immunology 46(14): 
2808-2817. 
 
Chapter 7 References 
Page | 144 
 
Blomback, B., B. Hessel, D. Hogg and L. Therkildsen (1978). A two-step 
fibrinogen-fibrin transition in blood coagulation. Nature 275(5680): 501-505. 
Borregaard, N. and J. B. Cowland (1997). Granules of the human neutrophilic 
polymorphonuclear leukocyte. Blood 89(10): 3503-3521. 
Bosscha, K., K. Reijnders, P. F. Hulstaert, A. Algra and C. van der Werken (1997). 
Prognostic scoring systems to predict outcome in peritonitis and intra-abdominal 
sepsis. British Journal of Surgery 84(11): 1532-1534. 
Boyle, M. D. and R. Lottenberg (1997). Plasminogen activation by invasive human 
pathogens. Thrombosis and Haemostasis 77(1): 1-10. 
Brinkmann, V., U. Reichard, C. Goosmann, B. Fauler, Y. Uhlemann, D. S. Weiss, Y. 
Weinrauch and A. Zychlinsky (2004). Neutrophil extracellular traps kill bacteria. 
Science 303(5663): 1532-1535. 
Brinkmann, V. and A. Zychlinsky (2007). Beneficial suicide: why neutrophils die to 
make NETs. Nature Reviews. Microbiology 5(8): 577-582. 
Buchanan, J. T., A. J. Simpson, R. K. Aziz, G. Y. Liu, S. A. Kristian, M. Kotb, J. 
Feramisco and V. Nizet (2006). DNase expression allows the pathogen group A 
Streptococcus to escape killing in neutrophil extracellular traps. Current biology 
16(4): 396-400. 
Bugge, T. H., M. J. Flick, M. J. Danton, C. C. Daugherty, J. Romer, K. Dano, P. 
Carmeliet, D. Collen and J. L. Degen (1996a). Urokinase-type plasminogen activator 
is effective in fibrin clearance in the absence of its receptor or tissue-type 
plasminogen activator. Proceedings of the National Academy of Sciences of the 
United States of America 93(12): 5899-5904. 
Bugge, T. H., K. W. Kombrinck, M. J. Flick, C. C. Daugherty, M. J. Danton and J. 
L. Degen (1996b). Loss of fibrinogen rescues mice from the pleiotropic effects of 
plasminogen deficiency. Cell 87(4): 709-719. 
Busuttil, S. J., V. A. Ploplis, F. J. Castellino, L. Tang, J. W. Eaton and E. F. Plow 
(2004). A central role for plasminogen in the inflammatory response to biomaterials. 
Journal of Thrombosis and Haemostasis 2(10): 1798-1805. 
Buyne, O. R., R. P. Bleichrodt, H. van Goor, P. E. Verweij and T. Hendriks (2008). 
Plasminogen activator, but not systemic antibiotic therapy, prevents abscess 
formation in an experimental model of secondary peritonitis. British Journal of 
Surgery 95(10): 1287-1293. 
Carapetis, J. R., B. J. Currie and J. D. Mathews (2000). Cumulative incidence of 
rheumatic fever in an endemic region: a guide to the susceptibility of the population? 
Epidemiology and Infection 124(2): 239-244. 
Carapetis, J. R., A. C. Steer, E. K. Mulholland and M. Weber (2005). The global 
burden of group A streptococcal diseases. Lancet Infectious Diseases 5(11): 685-
694. 
 
Chapter 7 References 
Page | 145 
 
Carapetis, J. R., D. R. Wolff and B. J. Currie (1996). Acute rheumatic fever and 
rheumatic heart disease in the top end of Australia's Northern Territory. Medical 
Journal of Australia 164(3): 146-149. 
Carlsson, F., K. Berggard, M. Stalhammar-Carlemalm and G. Lindahl (2003). 
Evasion of phagocytosis through cooperation between two ligand-binding regions in 
Streptococcus pyogenes M protein. Journal of Experimental Medicine 198(7): 1057-
1068. 
Carmeliet, P. and D. Collen (1996). Gene manipulation and transfer of the 
plasminogen and coagulation system in mice. Seminars in Thrombosis and 
Hemostasis 22(6): 525-542. 
Carmeliet, P., L. Schoonjans, L. Kieckens, B. Ream, J. Degen, R. Bronson, R. De 
Vos, J. J. van den Oord, D. Collen and R. C. Mulligan (1994). Physiological 
consequences of loss of plasminogen activator gene function in mice. Nature 
368(6470): 419-424. 
Castellino, F. J. and V. A. Ploplis (2005). Structure and function of the 
plasminogen/plasmin system. Thrombosis and Haemostasis 93(4): 647-654. 
Cesarman-Maus, G. and K. A. Hajjar (2005). Molecular mechanisms of fibrinolysis. 
British Journal of Haematology 129(3): 307-321. 
Chen, C. S., B. Lyons-Giordano, G. S. Lazarus and P. J. Jensen (1993). Differential 
expression of plasminogen activators and their inhibitors in an organotypic skin 
coculture system. Journal of Cell Science 106: 45-53. 
Choby, B. A. (2009). Diagnosis and treatment of streptococcal pharyngitis. 
American Family Physician 79(5): 383-390. 
Christner, R., Z. Li, R. Raeder, A. Podbielski and M. D. Boyle (1997). Identification 
of key gene products required for acquisition of plasmin-like enzymatic activity by 
group A streptococci. Journal of Infectious Diseases 175(5): 1115-1120. 
Chung, M., J. H. Tonry, A. Narayanan, N. P. Manes, R. S. Mackie, B. Gutting, D. V. 
Mukherjee, T. G. Popova, F. Kashanchi, C. L. Bailey and S. G. Popov (2011). 
Bacillus anthracis interacts with plasmin(ogen) to evade C3b-dependent innate 
immunity. PLoS ONE 6(3): e18119. 
Circolo, A., G. Garnier, W. Fukuda, X. Wang, T. Hidvegi, A. J. Szalai, D. E. Briles, 
J. E. Volanakis, R. A. Wetsel and H. R. Colten (1999). Genetic disruption of the 
murine complement C3 promoter region generates deficient mice with extrahepatic 
expression of C3 mRNA. Immunopharmacology 42(1-3): 135-149. 
Cole, J. N., J. D. McArthur, F. C. McKay, M. L. Sanderson-Smith, A. J. Cork, M. 
Ranson, M. Rohde, A. Itzek, H. Sun, D. Ginsburg, M. Kotb, V. Nizet, G. S. 
Chhatwal and M. J. Walker (2006). Trigger for group A streptococcal M1T1 
invasive disease. FASEB Journal 20(10): 1745-1747. 
 
Chapter 7 References 
Page | 146 
 
Coleman, J. L. and J. L. Benach (1999). Use of the plasminogen activation system 
by microorganisms. Journal of Laboratory and Clinical Medicine 134(6): 567-576. 
Coleman, J. L., T. J. Sellati, J. E. Testa, R. R. Kew, M. B. Furie and J. L. Benach 
(1995). Borrelia burgdorferi binds plasminogen, resulting in enhanced penetration of 
endothelial monolayers. Infection and Immunity 63(7): 2478-2484. 
Collen, D. (2001). Ham-Wasserman lecture: role of the plasminogen system in 
fibrin-homeostasis and tissue remodeling. American Society of Hematology: 1-9. 
Collen, D. and H. R. Lijnen (1991). Basic and clinical aspects of fibrinolysis and 
thrombolysis. Blood 78(12): 3114-3124. 
Colman, R. W. (1969). Activation of plasminogen by human plasma kallikrein. 
Biochemical and Biophysical Research Communications 35(2): 273-279. 
Cook, S. M., A. Skora, C. M. Gillen, M. J. Walker and J. D. McArthur (2012). 
Streptokinase variants from Streptococcus pyogenes isolates display altered 
plasminogen activation characteristics - implications for pathogenesis. Molecular 
Microbiology 86(5): 1052-1062. 
Cook, S. M., A. Skora, M. J. Walker, M. L. Sanderson-Smith and J. D. McArthur 
(2014). Site-restricted plasminogen activation mediated by group A streptococcal 
streptokinase variants. Biochemical Journal 458(1): 23-31. 
Cork, A. J., S. Jergic, S. Hammerschmidt, B. Kobe, V. Pancholi, J. L. Benesch, C. V. 
Robinson, N. E. Dixon, J. A. Aquilina and M. J. Walker (2009). Defining the 
structural basis of human plasminogen binding by streptococcal surface enolase. 
Journal of Biological Chemistry 284(25): 17129-17137. 
Cork, A. J., S. Jergic, S. Hammerschmidt, B. Kobe, V. Pancholi, J. L. P. Benesch, C. 
V. Robinson, N. E. Dixon, J. A. Aquilina and M. J. Walker (2009). Defining the 
structural basis of human plasminogen binding by streptococcal surface enolase. 
Journal of Biological Chemistry 284(25): 17129-17137. 
Correia, M. L. and W. G. Haynes (2006). A role for plasminogen activator inhibitor-
1 in obesity: from pie to PAI? Arteriosclerosis, Thrombosis, and Vascular Biology 
26(10): 2183-2185. 
Cunningham, M. W. (2000). Pathogenesis of group A streptococcal infections. 
Clinical Microbiology Reviews 13(3): 470-511. 
D'Costa, S. S. and M. D. Boyle (1998). Interaction of a group A Streptococcus 
within human plasma results in assembly of a surface plasminogen activator that 
contributes to occupancy of surface plasmin-binding structures. Microbial 
Pathogenesis 24(6): 341-349. 
Dai, T., G. B. Kharkwal, M. Tanaka, Y. Y. Huang, V. J. Bil de Arce and M. R. 
Hamblin (2011). Animal models of external traumatic wound infections. Virulence 
2(4): 296-315. 
 
Chapter 7 References 
Page | 147 
 
De Oliveira, D. M., R. H. Law, D. Ly, S. M. Cook, A. J. Quek, J. D. McArthur, J. C. 
Whisstock and M. L. Sanderson-Smith (2015). Preferential acquisition and 
activation of plasminogen glycoform II by PAM positive group A streptococcal 
Isolates. Biochemistry 54(25): 3960-3968. 
Degen, J. L., T. H. Bugge and J. D. Goguen (2007). Fibrin and fibrinolysis in 
infection and host defense. Journal of Thrombosis and Haemostasis 5(Suppl 1): 24-
31. 
Del Rosso, M., G. Fibbi, M. Pucci, F. Margheri and S. Serrati (2008). The 
plasminogen activation system in inflammation. Frontiers in Bioscience 13: 4667-
4686. 
Delvaeye, M. and E. M. Conway (2009). Coagulation and innate immune responses: 
can we view them separately? Blood 114(12): 2367-2374. 
Dey, N., D. J. McMillan, P. J. Yarwood, R. M. Joshi, R. Kumar, M. F. Good, K. S. 
Sriprakash and H. Vohra (2005). High diversity of group A Streptococcal emm types 
in an Indian community: the need to tailor multivalent vaccines. Clinical Infectious 
Diseases 40(1): 46-51. 
Ding, Y., H. Zhang, Z. Zhou, M. Zhong, Q. Chen, X. Wang and Z. Zhu (2012). u-PA 
inhibitor amiloride suppresses peritoneal metastasis in gastric cancer. World Journal 
of Surgical Oncology 10: 270. 
Dobrovolsky, A. B. and E. V. Titaeva (2002). The fibrinolysis system: regulation of 
activity and physiologic functions of its main components. Biochemistry 67(1): 99-
108. 
Duffy, M. J., T. M. Maguire, E. W. McDermott and N. O'Higgins (1999). Urokinase 
plasminogen activator: a prognostic marker in multiple types of cancer. Journal of 
Surgical Oncology 71(2): 130-135. 
Dunbar, S. D., D. L. Ornstein and L. R. Zacharski (2000). Cancer treatment with 
inhibitors of urokinase-type plasminogen activator and plasmin. Expert Opinion on 
Investigational Drugs 9(9): 2085-2092. 
Dunn, C. J. and K. L. Goa (1999). Tranexamic acid: a review of its use in surgery 
and other indications. Drugs 57(6): 1005-1032. 
Ellis, N. M., D. K. Kurahara, H. Vohra, A. Mascaro-Blanco, G. Erdem, E. E. 
Adderson, L. G. Veasy, J. A. Stoner, E. Tam, H. R. Hill, K. Yamaga and M. W. 
Cunningham (2010). Priming the immune system for heart disease: a perspective on 
group A streptococci. Journal of Infectious Diseases 202(7): 1059-1067. 
Ellis, V., M. F. Scully and V. V. Kakkar (1989). Plasminogen activation initiated by 
single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. 
Journal of Biological Chemistry 264(4): 2185-2188. 
 
Chapter 7 References 
Page | 148 
 
Ermert, D., J. Shaughnessy, T. Joeris, J. Kaplan, C. J. Pang, E. A. Kurt-Jones, P. A. 
Rice, S. Ram and A. M. Blom (2015). Virulence of group a streptococci is enhanced 
by human complement inhibitors. PLoS pathogens 11(7): e1005043. 
Facklam, R. (2002). What happened to the streptococci: overview of taxonomic and 
nomenclature changes. Clinical microbiology reviews 15(4): 613-630. 
Fischetti, V. A. (1989). Streptococcal M protein: molecular design and biological 
behavior. Clinical Microbiology Reviews 2(3): 285-314. 
Flick, M. J., X. Du, D. P. Witte, M. Jirouskova, D. A. Soloviev, S. J. Busuttil, E. F. 
Plow and J. L. Degen (2004). Leukocyte engagement of fibrin(ogen) via the integrin 
receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. 
Journal of Clinical Investigation 113(11): 1596-1606. 
Frick, I. M., P. Akesson, M. Rasmussen, A. Schmidtchen and L. Bjorck (2003). SIC, 
a secreted protein of Streptococcus pyogenes that inactivates antibacterial peptides. 
Journal of Biological Chemistry 278(19): 16561-16566. 
Fuchs, T. A., U. Abed, C. Goosmann, R. Hurwitz, I. Schulze, V. Wahn, Y. 
Weinrauch, V. Brinkmann and A. Zychlinsky (2007). Novel cell death program 
leads to neutrophil extracellular traps. Journal of Cell Biology 176(2): 231-241. 
Fuhrman, B. (2012). The urokinase system in the pathogenesis of atherosclerosis. 
Atherosclerosis 222(1): 8-14. 
Georgousakis, M. M., D. J. McMillan, M. R. Batzloff and K. S. Sriprakash (2009). 
Moving forward: a mucosal vaccine against group A Streptococcus. Expert Review 
of Vaccines 8(6): 747-760. 
Gong, Y., E. Hart, A. Shchurin and J. Hoover-Plow (2008). Inflammatory 
macrophage migration requires MMP-9 activation by plasminogen in mice. Journal 
of Clinical Investigation 118(9): 3012-3024. 
Goto, H. and Y. Kawaoka (1998). A novel mechanism for the acquisition of 
virulence by a human influenza A virus. Proceedings of the National Academy of 
Sciences of the United States of America 95(17): 10224-10228. 
Gotze, O. and H. J. Muller-Eberhard (1971). The C3-activator system: an alternate 
pathway of complement activation. Journal of Experimental Medicine 134(3): 90-
108. 
Green, R. J., D. C. Dafoe and T. A. Raffin (1996). Necrotizing fasciitis. Chest 
110(1): 219-229. 
Grosskinsky, S., M. Schott, C. Brenner, S. J. Cutler, P. Kraiczy, M. M. Simon, P. F. 
Zipfel and R. Wallich (2009). Borrelia recurrentis employs a novel multifunctional 
surface protein with anti-complement, anti-opsonic and invasive potential to escape 
innate immunity. PLoS ONE 4(3): e4858. 
 
Chapter 7 References 
Page | 149 
 
Guilherme, L. and J. Kalil (2010). Rheumatic fever and rheumatic heart disease: 
cellular mechanisms leading autoimmune reactivity and disease. Journal of Clinical 
Immunology 30(1): 17-23. 
Guo, Y., J. Li, E. Hagstrom and T. Ny (2008). Protective effects of plasmin(ogen) in 
a mouse model of Staphylococcus aureus-induced arthritis. Arthritis and 
Rheumatism 58(3): 764-772. 
Gurewich, V., R. Pannell, S. Louie, P. Kelley, R. L. Suddith and R. Greenlee (1984). 
Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase 
(pro-urokinase). A study in vitro and in two animal species. Journal of Clinical 
Investigation 73(6): 1731-1739. 
Gyetko, M. R., D. Aizenberg and L. Mayo-Bond (2004). Urokinase-deficient and 
urokinase receptor-deficient mice have impaired neutrophil antimicrobial activation 
in vitro. Journal of Leukocyte Biology 76(3): 648-656. 
Gyetko, M. R., G. H. Chen, R. A. McDonald, R. Goodman, G. B. Huffnagle, C. C. 
Wilkinson, J. A. Fuller and G. B. Toews (1996). Urokinase is required for the 
pulmonary inflammatory response to Cryptococcus neoformans. A murine 
transgenic model. Journal of Clinical Investigation 97(8): 1818-1826. 
Hajjar, K. A., P. C. Harpel, E. A. Jaffe and R. L. Nachman (1986). Binding of 
plasminogen to cultured human endothelial cells. Journal of Biological Chemistry 
261(25): 11656-11662. 
Hassell, M., P. Fagan, P. Carson and B. J. Currie (2004). Streptococcal necrotising 
fasciitis from diverse strains of Streptococcus pyogenes in tropical northern 
Australia: case series and comparison with the literature. BMC Infectious Diseases 
4(1): 60. 
Henningham, A., T. C. Barnett, P. G. Maamary and M. J. Walker (2012). 
Pathogenesis of group A streptococcal infections. Discovery Medicine 13(72): 329-
342. 
Hidalgo-Grass, C., M. Dan-Goor, A. Maly, Y. Eran, L. A. Kwinn, V. Nizet, M. 
Ravins, J. Jaffe, A. Peyser, A. E. Moses and E. Hanski (2004). Effect of a bacterial 
pheromone peptide on host chemokine degradation in group A streptococcal 
necrotising soft-tissue infections. Lancet 363(9410): 696-703. 
Hoe, N. P., R. M. Ireland, F. R. DeLeo, B. B. Gowen, D. W. Dorward, J. M. Voyich, 
M. Liu, E. H. Burns, Jr., D. M. Culnan, A. Bretscher and J. M. Musser (2002). 
Insight into the molecular basis of pathogen abundance: group A Streptococcus 
inhibitor of complement inhibits bacterial adherence and internalization into human 
cells. Proceedings of the National Academy of Sciences of the United States of 
America 99(11): 7646-7651. 
Hollands, A., D. Gonzalez, E. Leire, C. Donald, R. L. Gallo, M. Sanderson-Smith, P. 
C. Dorrestein and V. Nizet (2012). A bacterial pathogen co-opts host plasmin to 
 
Chapter 7 References 
Page | 150 
 
resist killing by cathelicidin antimicrobial peptides. Journal of Biological Chemistry 
287(49): 40891-40897. 
Hollands, A., M. A. Pence, A. M. Timmer, S. R. Osvath, L. Turnbull, C. B. 
Whitchurch, M. J. Walker and V. Nizet (2010). Genetic switch to hypervirulence 
reduces colonization phenotypes of the globally disseminated group A Streptococcus 
M1T1 clone. Journal of Infectious Diseases 202(1): 11-19. 
Honda-Ogawa, M., T. Ogawa, Y. Terao, T. Sumitomo, M. Nakata, K. Ikebe, Y. 
Maeda and S. Kawabata (2013). Cysteine proteinase from Streptococcus pyogenes 
enables evasion of innate immunity via degradation of complement factors. The 
Journal of Biological Chemistry 288(22): 15854-15864. 
Hoylaerts, M., D. C. Rijken, H. R. Lijnen and D. Collen (1982). Kinetics of the 
activation of plasminogen by human tissue plasminogen activator. Role of fibrin. 
Journal of Biological Chemistry 257(6): 2912-2919. 
Hu, Y., A. Shamaei-Tousi, Y. Liu and A. Coates (2010). A new approach for the 
discovery of antibiotics by targeting non-multiplying bacteria: a novel topical 
antibiotic for staphylococcal infections. PLoS One 5(7): e11818. 
Huang, Y. Y., M. E. Bach, H. P. Lipp, M. Zhuo, D. P. Wolfer, R. D. Hawkins, L. 
Schoonjans, E. R. Kandel, J. M. Godfraind, R. Mulligan, D. Collen and P. Carmeliet 
(1996). Mice lacking the gene encoding tissue-type plasminogen activator show a 
selective interference with late-phase long-term potentiation in both Schaffer 
collateral and mossy fiber pathways. Proceedings of the National Academy of 
Sciences of the United States of America 93(16): 8699-8704. 
Hynes, W. (2004). Virulence factors of the group A streptococci and genes that 
regulate their expression. Frontiers in Bioscience 9: 3399-3433. 
Innings, A., M. Krabbe, M. Ullberg and B. Herrmann (2005). Identification of 43 
Streptococcus species by pyrosequencing analysis of the rnpB gene. Journal of 
Clinical Microbiology 43(12): 5983-5991. 
Irigoyen, J. P., P. Munoz-Canoves, L. Montero, M. Koziczak and Y. Nagamine 
(1999). The plasminogen activator system: biology and regulation. Cellular and 
Molecular Life Sciences 56(1-2): 104-132. 
Jacks-Weis, J., Y. Kim and P. P. Cleary (1982). Restricted deposition of C3 on M+ 
group A streptococci: correlation with resistance to phagocytosis. Journal of 
Immunology 128(4): 1897-1902. 
Jarva, H., T. S. Jokiranta, R. Wurzner and S. Meri (2003). Complement resistance 
mechanisms of streptococci. Molecular Immunology 40(2-4): 95-107. 
Jeng, A., V. Sakota, Z. Li, V. Datta, B. Beall and V. Nizet (2003). Molecular genetic 
analysis of a group A Streptococcus operon encoding serum opacity factor and a 
novel fibronectin-binding protein, SfbX. Journal of Bacteriology 185(4): 1208-1217. 
 
Chapter 7 References 
Page | 151 
 
Ji, Y., L. McLandsborough, A. Kondagunta and P. P. Cleary (1996). C5a peptidase 
alters clearance and trafficking of group A streptococci by infected mice. Infection 
and Immunity 64(2): 503-510. 
Jin, H., Y. P. Song, G. Boel, J. Kochar and V. Pancholi (2005). Group A 
streptococcal surface GAPDH, SDH, recognizes uPAR/CD87 as its receptor on the 
human pharyngeal cell and mediates bacterial adherence to host cells. Journal of 
Molecular Biology 350(1): 27-41. 
Jin, T., M. Bokarewa and A. Tarkowski (2005). Urokinase-type plasminogen 
activator, an endogenous antibiotic. Journal of Infectious Diseases 192(3): 429-437. 
Jogi, A., B. Rono, I. K. Lund, B. S. Nielsen, M. Ploug, G. Hoyer-Hansen, J. Romer 
and L. R. Lund (2010). Neutralisation of uPA with a monoclonal antibody reduces 
plasmin formation and delays skin wound healing in tPA-deficient mice. PLoS One 
5(9): e12746. 
Johansson, L., P. Thulin, D. E. Low and A. Norrby-Teglund (2010). Getting under 
the skin: the immunopathogenesis of Streptococcus pyogenes deep tissue infections. 
Clinical Infectious Diseases 51(1): 58-65. 
Kagawa, T. F., M. R. O'Connell, P. Mouat, M. Paoli, P. W. O'Toole and J. C. 
Cooney (2009). Model for substrate interactions in C5a peptidase from 
Streptococcus pyogenes: A 1.9 Å crystal structure of the active form of ScpA. 
Journal of Molecular Biology 386(3): 754-772. 
Kager, L. M., W. J. Wiersinga, J. J. Roelofs, J. C. Meijers, M. Levi, C. Van't Veer 
and T. van der Poll (2012). Endogenous tissue-type plasminogen activator impairs 
host defense during severe experimental Gram-negative sepsis (melioidosis). Critical 
Care Medicine 40(7): 2168-2175. 
Kasai, S., H. Arimura, M. Nishida and T. Suyama (1985). Primary structure of 
single-chain pro-urokinase. Journal of Biological Chemistry 260(22): 2382-2389. 
Kaul, R., A. McGeer, D. E. Low, K. Green and B. Schwartz (1997). Population-
based surveillance for group A streptococcal necrotizing fasciitis: clinical features, 
prognostic indicators, and microbiologic analysis of seventy-seven cases. Ontario 
Group A Streptococcal Study. American Journal of Medicine 103(1): 18-24. 
Khil, J., M. Im, A. Heath, U. Ringdahl, L. Mundada, N. Cary Engleberg and W. P. 
Fay (2003). Plasminogen enhances virulence of group A streptococci by 
streptokinase-dependent and streptokinase-independent mechanisms. Journal of 
Infectious Diseases 188(4): 497-505. 
Kihlberg, B. M., J. Cooney, M. G. Caparon, A. Olsen and L. Bjorck (1995). 
Biological properties of a Streptococcus pyogenes mutant generated by Tn916 
insertion in mga. Microbial Pathogenesis 19(5): 299-315. 
Klempner, M. S., R. Noring, M. P. Epstein, B. McCloud, R. Hu, S. A. Limentani and 
R. A. Rogers (1995). Binding of human plasminogen and urokinase-type 
 
Chapter 7 References 
Page | 152 
 
plasminogen activator to the Lyme disease spirochete, Borrelia burgdorferi. Journal 
of Infectious Diseases 171(5): 1258-1265. 
Knaust, A., M. V. Weber, S. Hammerschmidt, S. Bergmann, M. Frosch and O. 
Kurzai (2007). Cytosolic proteins contribute to surface plasminogen recruitment of 
Neisseria meningitidis. Journal of Bacteriology 189(8): 3246-3255. 
Knudsen, B. S., R. L. Silverstein, L. L. Leung, P. C. Harpel and R. L. Nachman 
(1986). Binding of plasminogen to extracellular matrix. Journal of Biological 
Chemistry 261(23): 10765-10771. 
Koenigs, A., C. Hammerschmidt, B. L. Jutras, D. Pogoryelov, D. Barthel, C. Skerka, 
D. Kugelstadt, R. Wallich, B. Stevenson, P. F. Zipfel and P. Kraiczy (2013). BBA70 
of Borrelia burgdorferi is a novel plasminogen-binding protein. Journal of 
Biological Chemistry 288(35): 25229-25243. 
Kolev, K. and R. Machovich (2003). Molecular and cellular modulation of 
fibrinolysis. Thrombosis and Haemostasis 89(4): 610-621. 
Kolev, M., G. Le Friec and C. Kemper (2014). Complement--tapping into new sites 
and effector systems. Nature Reviews. Immunology 14(12): 811-820. 
Kooistra, T., Y. Schrauwen, J. Arts and J. J. Emeis (1994). Regulation of 
endothelial-cell t-pa synthesis and release. International Journal of Hematology 
59(4): 233-255. 
Kraiczy, P. and R. Wurzner (2006). Complement escape of human pathogenic 
bacteria by acquisition of complement regulators. Molecular Immunology 43(1-2): 
31-44. 
Kristensen, P., J. Eriksen and K. Dano (1991). Localization of urokinase-type 
plasminogen activator messenger RNA in the normal mouse by in situ hybridization. 
Journal Of Histochemistry and Cytochemistry 39(3): 341-349. 
Kugelberg, E., T. Norstrom, T. K. Petersen, T. Duvold, D. I. Andersson and D. 
Hughes (2005). Establishment of a superficial skin infection model in mice by using 
Staphylococcus aureus and Streptococcus pyogenes. Antimicrobial agents and 
Chemotherapy 49(8): 3435-3441. 
Kumar, V. and A. Sharma (2010). Neutrophils: cinderella of innate immune system. 
International Immunopharmacology 10(11): 1325-1334. 
Kunert, A., J. Losse, C. Gruszin, M. Huhn, K. Kaendler, S. Mikkat, D. Volke, R. 
Hoffmann, T. S. Jokiranta, H. Seeberger, U. Moellmann, J. Hellwage and P. F. 
Zipfel (2007). Immune evasion of the human pathogen Pseudomonas aeruginosa: 
Elongation factor Tuf is a factor H and plasminogen binding protein. Journal of 
Immunology 179(5): 2979-2988. 
Kuusela, P. and O. Saksela (1990). Binding and activation of plasminogen at the 
surface of Staphylococcus aureus. Increase in affinity after conversion to the Lys 
form of the ligand. European Journal of Biochemistry 193(3): 759-765. 
 
Chapter 7 References 
Page | 153 
 
Kuusela, P., M. Ullberg, O. Saksela and G. Kronvall (1992). Tissue-type 
plasminogen activator-mediated activation of plasminogen on the surface of group 
A, C, and G streptococci. Infection and Immunity 60(1): 196-201. 
Kwinn, L. A. and V. Nizet (2007). How group A Streptococcus circumvents host 
phagocyte defenses. Future Microbiology 2(1): 75-84. 
Lachmann, P. J., M. K. Pangburn and R. G. Oldroyd (1982). Breakdown of C3 after 
complement activation. Identification of a new fragment C3g, using monoclonal 
antibodies. Journal of Experimental Medicine 156(1): 205-216. 
Lähteenmäki, K., S. Edelman and T. K. Korhonen (2005). Bacterial metastasis: the 
host plasminogen system in bacterial invasion. TRENDS in Microbiology 13(2): 79-
85. 
Lähteenmäki, K., P. Kuusela and T. K. Korhonen (2000). Plasminogen activation in 
degradation and penetration of extracellular matrices and basement membranes by 
invasive bacteria. Methods 21(2): 125-132. 
Lähteenmäki, K., P. Kuusela and T. K. Korhonen (2001). Bacterial plasminogen 
activators and receptors. FEMS Microbiology Reviews 25(5): 531-552. 
Lamagni, T. L., J. Darenberg, B. Luca-Harari, T. Siljander, A. Efstratiou, B. 
Henriques-Normark, J. Vuopio-Varkila, A. Bouvet, R. Creti, K. Ekelund, M. Koliou, 
R. R. Reinert, A. Stathi, L. Strakova, V. Ungureanu, C. Schalen and A. Jasir (2008). 
Epidemiology of severe Streptococcus pyogenes disease in Europe. Journal of 
Clinical Microbiology 46(7): 2359-2367. 
Lambris, J. D., D. Ricklin and B. V. Geisbrecht (2008). Complement evasion by 
human pathogens. Nature reviews. Microbiology 6(2): 132-142. 
Law, R. H., D. Abu-Ssaydeh and J. C. Whisstock (2013). New insights into the 
structure and function of the plasminogen/plasmin system. Current Opinion in 
Structural Biology 23(6): 836-841. 
Leavell, K. J., M. W. Peterson and T. J. Gross (1996). The role of fibrin degradation 
products in neutrophil recruitment to the lung. American Journal of Respiratory Cell 
and Molecular Biology 14(1): 53-60. 
Lee, J. A., B. J. Cochran, S. Lobov and M. Ranson (2011). Forty years later and the 
role of plasminogen activator inhibitor type 2/SERPINB2 is still an enigma. 
Seminars in Thrombosis and Hemostasis 37(4): 395-407. 
Lee, J. A., J. J. Yerbury, N. Farrawell, R. F. Shearer, P. Constantinescu, D. M. 
Hatters, W. A. Schroder, A. Suhrbier, M. R. Wilson, D. N. Saunders and M. Ranson 
(2015). SerpinB2 (PAI-2) modulates proteostasis via binding misfolded proteins and 
promotion of cytoprotective inclusion formation. PLoS One 10(6): e0130136. 
Lemarchant, S., F. Docagne, E. Emery, D. Vivien, C. Ali and M. Rubio (2012). tPA 
in the injured central nervous system: different scenarios starring the same actor? 
Neuropharmacology 62(2): 749-756. 
 
Chapter 7 References 
Page | 154 
 
Levin, E. G. (1983). Latent tissue plasminogen activator produced by human 
endothelial cells in culture: evidence for an enzyme-inhibitor complex. Proceedings 
of the National Academy of Sciences of the United States of America 80(22): 6804-
6808. 
Li, Z., V. A. Ploplis, E. L. French and M. D. Boyle (1999). Interaction between 
group A streptococci and the plasmin(ogen) system promotes virulence in a mouse 
skin infection model. Journal of Infectious Diseases 179(4): 907-914. 
Lijnen, H. R. and D. Collen (1988). Mechanisms of plasminogen activation by 
mammalian plasminogen activators. Enzyme 40(2-3): 90-96. 
Lijnen, H. R. and D. Collen (1995). Mechanisms of physiological fibrinolysis. 
Bailliere's Clinical Haematology 8(2): 277-290. 
Lijnen, H. R., B. van Hoef, V. Beelen and D. Collen (1994). Characterisation of the 
murine plasma fibrinolytic system. European Journal of Biochemistry 224(3): 863-
871. 
Lijnen, H. R., B. Van Hoef, L. Nelles and D. Collen (1990). Plasminogen activation 
with single-chain urokinase-type plasminogen activator (scu-PA). Studies with 
active site mutagenized plasminogen (Ser740→Ala) and plasmin-resistant scu-PA 
(Lys158→Glu). Journal of Biological Chemistry 265(9): 5232-5236. 
Lin, A., J. A. Loughman, B. H. Zinselmeyer, M. J. Miller and M. G. Caparon (2009). 
Streptolysin S inhibits neutrophil recruitment during the early stages of 
Streptococcus pyogenes infection. Infection and Immunity 77(11): 5190-5201. 
Longstaff, C. and P. J. Gaffney (1991). Serpin-serine protease binding kinetics: alpha 
2-antiplasmin as a model inhibitor. Biochemistry 30(4): 979-986. 
Lottenberg, R., L. E. DesJardin, H. Wang and M. D. Boyle (1992). Streptokinase-
producing streptococci grown in human plasma acquire unregulated cell-associated 
plasmin activity. Journal of Infectious Diseases 166(2): 436-440. 
Lottenberg, R., D. Minning-Wenz and M. D. Boyle (1994). Capturing host 
plasmin(ogen): a common mechanism for invasive pathogens? Trends in 
Microbiology 2(1): 20-24. 
Lund, I. K., A. Jogi, B. Rono, M. G. Rasch, L. R. Lund, K. Almholt, H. Gardsvoll, 
N. Behrendt, J. Romer and G. Hoyer-Hansen (2008). Antibody-mediated targeting of 
the urokinase-type plasminogen activator proteolytic function neutralizes fibrinolysis 
in vivo. Journal of Biological Chemistry 283(47): 32506-32515. 
Lund, L. R., K. A. Green, A. A. Stoop, M. Ploug, K. Almholt, J. Lilla, B. S. Nielsen, 
I. J. Christensen, C. S. Craik, Z. Werb, K. Dano and J. Romer (2006). Plasminogen 
activation independent of uPA and tPA maintains wound healing in gene-deficient 
mice. EMBO journal 25(12): 2686-2697. 
Lynskey, N. N., R. A. Lawrenson and S. Sriskandan (2011). New understandings in 
Streptococcus pyogenes. Current Opinion in Infectious Diseases 24(3): 196-202. 
 
Chapter 7 References 
Page | 155 
 
Magalhaes, V., I. Veiga-Malta, M. R. Almeida, M. Baptista, A. Ribeiro, P. Trieu-
Cuot and P. Ferreira (2007). Interaction with human plasminogen system turns on 
proteolytic activity in Streptococcus agalactiae and enhances its virulence in a 
mouse model. Microbes and Infection 9(11): 1276-1284. 
Marcum, J. A. and D. L. Kline (1983). Species specificity of streptokinase. 
Comparative Biochemistry and Physiology. B, Comparative Biochemistry 75(3): 
389-394. 
Markus, G., R. L. Priore and F. C. Wissler (1979). The binding of tranexamic acid to 
native (Glu) and modified (Lys) human plasminogen and its effect on conformation. 
Journal of Biological Chemistry 254(4): 1211-1216. 
Matta, S. K., S. Agarwal and R. Bhatnagar (2010). Surface localised and 
extracellular glyceraldehyde-3-phosphate dehydrogenase of Bacillus anthracis is a 
plasminogen binding protein. Biochimica et biophysica acta 1804(11): 2111-2120. 
Matthews, H., M. Ranson and M. J. Kelso (2011a). Anti-tumour/metastasis effects of 
the potassium-sparing diuretic amiloride: an orally active anti-cancer drug waiting 
for its call-of-duty? International Journal of Cancer 129(9): 2051-2061. 
Matthews, H., M. Ranson, J. D. Tyndall and M. J. Kelso (2011b). Synthesis and 
preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type 
plasminogen activator (uPA). Bioorganic and Medicinal Chemistry Letters 21(22): 
6760-6766. 
McArthur, J. D., S. M. Cook, C. Venturini and M. J. Walker (2012). The role of 
streptokinase as a virulence determinant of Streptococcus pyogenes - potential for 
therapeutic targeting. Current drug targets 13(3): 297-307. 
McArthur, J. D., F. C. McKay, V. Ramachandran, P. Shyam, A. J. Cork, M. L. 
Sanderson-Smith, J. N. Cole, U. Ringdahl, U. Sjobring, M. Ranson and M. J. Walker 
(2008). Allelic variants of streptokinase from Streptococcus pyogenes display 
functional differences in plasminogen activation. FASEB Journal 22(9): 3146-3153. 
McDonald, M., B. J. Currie and J. R. Carapetis (2004). Acute rheumatic fever: a 
chink in the chain that links the heart to the throat? Lancet Infectious Diseases 4(4): 
240-245. 
McKay, F. C., J. D. McArthur, M. L. Sanderson-Smith, S. Gardam, B. J. Currie, K. 
S. Sriprakash, P. K. Fagan, R. J. Towers, M. R. Batzloff, G. S. Chhatwal, M. Ranson 
and M. J. Walker (2004). Plasminogen binding by group A streptococcal isolates 
from a region of hyperendemicity for streptococcal skin infection and a high 
incidence of invasive infection. Infection and Immunity 72(1): 364-370. 
McMillan, D. J., P. A. Dreze, T. Vu, D. E. Bessen, J. Guglielmini, A. C. Steer, J. R. 
Carapetis, L. Van Melderen, K. S. Sriprakash and P. R. Smeesters (2013). Updated 
model of group A Streptococcus M proteins based on a comprehensive worldwide 
study. Clinical Microbiology and Infection 19(5): 222-229. 
 
Chapter 7 References 
Page | 156 
 
Medina, E. (2004). Models of group A streptococcal diseases: a review of current 
status. Drug Discovery Today: Disease Models 1(1): 65-71. 
Medina, E. and A. Lengeling (2005). Genetic regulation of host responses to group 
A streptococcus in mice. Briefings in Functional Genomics and Proteomics 4(3): 
248-257. 
Mekkawy, A. H., M. H. Pourgholami and D. L. Morris (2014). Involvement of 
urokinase-type plasminogen activator system in cancer: an overview. Medicinal 
Research Reviews 34(5): 918-956. 
Miles, L. A., M. H. Ginsberg, J. G. White and E. F. Plow (1986). Plasminogen 
interacts with human platelets through two distinct mechanisms. Journal of Clinical 
Investigation 77(6): 2001-2009. 
Miles, L. A., J. S. Greengard and J. H. Griffin (1983). A comparison of the abilities 
of plasma kallikrein, beta-Factor XIIa, Factor XIa and urokinase to activate 
plasminogen. Thrombosis Research 29(4): 407-417. 
Moses, A. E., M. R. Wessels, K. Zalcman, S. Alberti, S. Natanson-Yaron, T. Menes 
and E. Hanski (1997). Relative contributions of hyaluronic acid capsule and M 
protein to virulence in a mucoid strain of the group A Streptococcus. Infection and 
Immunity 65(1): 64-71. 
Muller-Eberhard, H. J. (1986). The membrane attack complex of complement. 
Annual Review of Immunology 4: 503-528. 
Murphy, G., R. Ward, J. Gavrilovic and S. Atkinson (1992). Physiological 
mechanisms for metalloproteinase activation. Matrix 1: 224-230. 
Navarini, A. A., K. S. Lang, A. Verschoor, M. Recher, A. S. Zinkernagel, V. Nizet, 
B. Odermatt, H. Hengartner and R. M. Zinkernagel (2009). Innate immune-induced 
depletion of bone marrow neutrophils aggravates systemic bacterial infections. 
Proceedings of the National Academy of Sciences of the United States of America 
106(17): 7107-7112. 
Nelson, D. C., J. Garbe and M. Collin (2011). Cysteine proteinase SpeB from 
Streptococcus pyogenes - a potent modifier of immunologically important host and 
bacterial proteins. Biological Chemistry 392(12): 1077-1088. 
Nienaber, V., J. Wang, D. Davidson and J. Henkin (2000). Re-engineering of human 
urokinase provides a system for structure-based drug design at high resolution and 
reveals a novel structural subsite. Journal of Biological Chemistry 275(10): 7239-
7248. 
Nienaber, V. L., S. L. Young, J. J. Birktoft, D. L. Higgins and L. J. Berliner (1992). 
Conformational similarities between one-chain and two-chain tissue plasminogen 
activator (t-PA): implications to the activation mechanism on one-chain t-PA. 
Biochemistry 31(15): 3852-3861. 
 
Chapter 7 References 
Page | 157 
 
Nizet, V. (2007). Understanding how leading bacterial pathogens subvert innate 
immunity to reveal novel therapeutic targets. Journal of Allergy and Clinical 
Immunology 120(1): 13-22. 
O'Loughlin, R. E., A. Roberson, P. R. Cieslak, R. Lynfield, K. Gershman, A. Craig, 
B. A. Albanese, M. M. Farley, N. L. Barrett, N. L. Spina, B. Beall, L. H. Harrison, 
A. Reingold and C. Van Beneden (2007). The epidemiology of invasive group A 
streptococcal infection and potential vaccine implications: United States, 2000-2004. 
Clinical infectious diseases 45(7): 853-862. 
Ogston, D. (1980). Biochemistry of the plasmin system. Journal of Clinical 
Pathology. Supplement 14(5-9. 
Okumura, C. Y. and V. Nizet (2014). Subterfuge and sabotage: evasion of host 
innate defenses by invasive gram-positive bacterial pathogens. Annual Review of 
Microbiology 68(439-458. 
Oliver, M. A., J. M. Rojo, S. Rodriguez de Cordoba and S. Alberti (2008). Binding 
of complement regulatory proteins to group A Streptococcus. Vaccine (26)Suppl 8: 
I75-178. 
Olsen, R. J., S. A. Shelburne and J. M. Musser (2009). Molecular mechanisms 
underlying group A streptococcal pathogenesis. Cellular microbiology 11(1): 1-12. 
Ossowski, L. and E. Reich (1983). Antibodies to plasminogen activator inhibit 
human tumor metastasis. Cell 35(3): 611-619. 
Pancholi, V. and V. A. Fischetti (1998). α-Enolase, a Novel Strong Plasmin(ogen) 
Binding Protein on the Surface of Pathogenic Streptococci. Journal of Biological 
Chemistry 273(23): 14503-14515. 
Pancholi, V., P. Fontan and H. Jin (2003). Plasminogen-mediated group A 
streptococcal adherence to and pericellular invasion of human pharyngeal cells. 
Microbial Pathogenesis 35(6): 293-303. 
Pangburn, M. K., V. P. Ferreira and C. Cortes (2008). Discrimination between host 
and pathogens by the complement system. Vaccine (26)Suppl 8: I15-121. 
Pannell, R. and V. Gurewich (1987). Activation of plasminogen by single-chain 
urokinase or by two-chain urokinase - a demonstration that single-chain urokinase 
has a low catalytic activity (pro-urokinase). Blood 69(1): 22-26. 
Parry, M. A., X. C. Zhang and I. Bode (2000). Molecular mechanisms of 
plasminogen activation: bacterial cofactors provide clues. Trends in Biochemical 
Sciences 25(2): 53-59. 
Passali, D., M. Lauriello, G. C. Passali, F. M. Passali and L. Bellussi (2007). Group 
A streptococcus and its antibiotic resistance. Acta otorhinolaryngologica Italica 
27(1): 27-32. 
 
Chapter 7 References 
Page | 158 
 
Peetermans, M., T. Vanassche, L. Liesenborghs, R. H. Lijnen and P. Verhamme 
(2015). Bacterial pathogens activate plasminogen to breach tissue barriers and 
escape from innate immunity. Critical Reviews in Microbiology 1-17. 
Peng, Q., K. Li, S. H. Sacks and W. Zhou (2009). The role of anaphylatoxins C3a 
and C5a in regulating innate and adaptive immune responses. Inflammation and 
Allergy Drug Targets 8(3): 236-246. 
Perez-Casal, J., N. Okada, M. G. Caparon and J. R. Scott (1995). Role of the 
conserved C-repeat region of the M protein of Streptococcus pyogenes. Molecular 
Microbiology 15(5): 907-916. 
Petersen, L. C., L. R. Lund, L. S. Nielsen, K. Dano and L. Skriver (1988). One-chain 
urokinase-type plasminogen activator from human sarcoma cells is a proenzyme 
with little or no intrinsic activity. Journal of Biological Chemistry 263(23): 11189-
11195. 
Pfoh, E., M. R. Wessels, D. Goldmann and G. M. Lee (2008). Burden and economic 
cost of group A streptococcal pharyngitis. Pediatrics 121(2): 229-234. 
Phillips, G. N., Jr., P. F. Flicker, C. Cohen, B. N. Manjula and V. A. Fischetti 
(1981). Streptococcal M protein: alpha-helical coiled-coil structure and arrangement 
on the cell surface. Proceedings of the National Academy of Sciences of the United 
States of America 78(8): 4689-4693. 
Pillemer, L., O. D. Ratnoff, L. Blum and I. H. Lepow (1953). The inactivation of 
complement and its components by plasmin. Journal of Experimental Medicine 
97(4): 573-589. 
Plesner, T., M. Ploug, V. Ellis, E. Ronne, G. Hoyer-Hansen, M. Wittrup, T. L. 
Pedersen, T. Tscherning, K. Dano and N. E. Hansen (1994). The receptor for 
urokinase-type plasminogen activator and urokinase is translocated from two distinct 
intracellular compartments to the plasma membrane on stimulation of human 
neutrophils. Blood 83(3): 808-815. 
Ploplis, V. A., E. L. French, P. Carmeliet, D. Collen and E. F. Plow (1998). 
Plasminogen deficiency differentially affects recruitment of inflammatory cell 
populations in mice. Blood 91(6): 2005-2009. 
Plow, E. F., T. Herren, A. Redlitz, L. A. Miles and J. L. Hoover-Plow (1995). The 
cell biology of the plasminogen system. FASEB Journal 9(10): 939-945. 
Potempa, J., E. Korzus and J. Travis (1994). The serpin superfamily of proteinase 
inhibitors: structure, function, and regulation. Journal of Biological Chemistry 
269(23): 15957-15960. 
Potempa, M. and J. Potempa (2012). Protease-dependent mechanisms of 
complement evasion by bacterial pathogens. Biological chemistry 393(9): 873-888. 
Ramos-Kichik, V., R. Mondragon-Flores, M. Mondragon-Castelan, S. Gonzalez-
Pozos, S. Muniz-Hernandez, O. Rojas-Espinosa, R. Chacon-Salinas, S. Estrada-Parra 
 
Chapter 7 References 
Page | 159 
 
and I. Estrada-Garcia (2009). Neutrophil extracellular traps are induced by 
Mycobacterium tuberculosis. Tuberculosis 89(1): 29-37. 
Ramu, P., R. Tanskanen, M. Holmberg, K. Lähteenmäki, T. K. Korhonen and S. 
Meri (2007). The surface protease PgtE of Salmonella enterica affects complement 
activity by proteolytically cleaving C3b, C4b and C5. FEBS letters 581(9): 1716-
1720. 
Ranby, M. (1982). Studies on the kinetics of plasminogen activation by tissue 
plasminogen activator. Biochimica et biophysica acta 704(3): 461-469. 
Ranson, M. and N. M. Andronicos (2003). Plasminogen binding and cancer: 
promises and pitfalls. Frontiers in Bioscience 8: s294-304. 
Raum, D., D. Marcus, C. A. Alper, R. Levey, P. D. Taylor and T. E. Starzl (1980). 
Synthesis of human plasminogen by the liver. Science 208(4447): 1036-1037. 
Reddy, K. N. and G. Markus (1972). Mechanism of activation of human 
plasminogen by streptokinase. Presence of active center in streptokinase-
plasminogen complex. Journal of Biological Chemistry 247(6): 1683-1691. 
Relf, W. A., D. R. Martin and K. S. Sriprakash (1992). Identification of sequence 
types among the M-nontypeable group A streptococci. Journal of Clinical 
Microbiology 30(12): 3190-3194. 
Renckens, R., J. J. Roelofs, S. Florquin, A. F. de Vos, J. M. Pater, H. R. Lijnen, P. 
Carmeliet, C. van 't Veer and T. van der Poll (2006). Endogenous tissue-type 
plasminogen activator is protective during Escherichia coli-induced abdominal 
sepsis in mice. Journal of Immunology 177(2): 1189-1196. 
Renckens, R., J. J. Roelofs, M. E. Stegenga, S. Florquin, M. Levi, P. Carmeliet, C. 
Van't Veer and T. van der Poll (2008). Transgenic tissue-type plasminogen activator 
expression improves host defense during Klebsiella pneumonia. Journal of 
Thrombosis and Haemostasis 6(4): 660-668. 
Rezcallah, M. S., M. D. Boyle and D. D. Sledjeski (2004). Mouse skin passage of 
Streptococcus pyogenes results in increased streptokinase expression and activity. 
Microbiology 150(Pt 2): 365-371. 
Riccio, A., G. Grimaldi, P. Verde, G. Sebastio, S. Boast and F. Blasi (1985). The 
human urokinase-plasminogen activator gene and its promoter. Nucleic Acids 
Research 13(8): 2759-2771. 
Rijken, D. C. (1995). Plasminogen activators and plasminogen activator inhibitors: 
biochemical aspects. Bailliere's Clinical Haematology 8(2): 291-312. 
Rijken, D. C. and H. R. Lijnen (2009). New insights into the molecular mechanisms 
of the fibrinolytic system. Journal of Thrombosis and Haemostasis 7(1): 4-13. 
 
Chapter 7 References 
Page | 160 
 
Rijneveld, A. W., M. Levi, S. Florquin, P. Speelman, P. Carmeliet and T. van Der 
Poll (2002). Urokinase receptor is necessary for adequate host defense against 
pneumococcal pneumonia. Journal of Immunology 168(7): 3507-3511. 
Roelofs, J. J., K. M. Rouschop, G. J. Teske, G. T. Wagenaar, N. Claessen, J. J. 
Weening, T. van der Poll and S. Florquin (2009). Endogenous tissue-type 
plasminogen activator is protective during ascending urinary tract infection. 
Nephrology, Dialysis, Transplantation 24(3): 801-808. 
Rojas, M., I. Labrador, J. L. Concepcion, E. Aldana and L. Avilan (2008). 
Characteristics of plasminogen binding to Trypanosoma cruzi epimastigotes. Acta 
Tropica 107(1): 54-58. 
Romer, J., T. H. Bugge, C. Pyke, L. R. Lund, M. J. Flick, J. L. Degen and K. Dano 
(1996). Impaired wound healing in mice with a disrupted plasminogen gene. Nature 
Medicine 2(3): 287-292. 
Rooijakkers, S. H. and J. A. van Strijp (2007). Bacterial complement evasion. 
Molecular Immunology 44(1-3): 23-32. 
Rooijakkers, S. H., W. J. van Wamel, M. Ruyken, K. P. van Kessel and J. A. van 
Strijp (2005). Anti-opsonic properties of staphylokinase. Microbes and Infection 
7(3): 476-484. 
Ryan, T. J., L. Lai and A. B. Malik (1992). Plasmin generation induces neutrophil 
aggregation: dependence on the catalytic and lysine binding sites. Journal of 
Cellular Physiology 151(2): 255-261. 
Saksela, O. (1985). Plasminogen activation and regulation of pericellular proteolysis. 
Biochimica et biophysica acta 823(1): 35-65. 
Saksela, O. and D. B. Rifkin (1988). Cell-associated plasminogen activation: 
regulation and physiological functions. Annual Review of Cell Biology 4: 93-126. 
Sanderson-Smith, M., D. M. De Oliveira, J. Guglielmini, D. J. McMillan, T. Vu, J. 
K. Holien, A. Henningham, A. C. Steer, D. E. Bessen, J. B. Dale, N. Curtis, B. W. 
Beall, M. J. Walker, M. W. Parker, J. R. Carapetis, L. Van Melderen, K. S. 
Sriprakash and P. R. Smeesters (2014). A systematic and functional classification of 
Streptococcus pyogenes that serves as a new tool for molecular typing and vaccine 
development. Journal of Infectious Diseases 210(8): 1325-1338. 
Sanderson-Smith, M. L., D. M. De Oliveira, M. Ranson and J. D. McArthur (2012). 
Bacterial plasminogen receptors: mediators of a multifaceted relationship. Journal of 
Biomedicine and Biotechnology 2012(272148. 
Sanderson-Smith, M. L., K. Dinkla, J. N. Cole, A. J. Cork, P. G. Maamary, J. D. 
McArthur, G. S. Chhatwal and M. J. Walker (2008). M protein-mediated 
plasminogen binding is essential for the virulence of an invasive Streptococcus 
pyogenes isolate. FASEB Journal 22(8): 2715-2722. 
 
Chapter 7 References 
Page | 161 
 
Sanderson-Smith, M. L., M. Dowton, M. Ranson and M. J. Walker (2007). The 
plasminogen-binding group A streptococcal M protein-related protein Prp binds 
plasminogen via arginine and histidine residues. Journal of Bacteriology 189(4): 
1435-1440. 
Sanderson-Smith, M. L., M. J. Walker and M. Ranson (2006). The maintenance of 
high affinity plasminogen binding by group A streptococcal plasminogen-binding 
M-like protein is mediated by arginine and histidine residues within the a1 and a2 
repeat domains. Journal of Biological Chemistry 281(36): 25965-25971. 
Sanderson-Smith, M. L., Y. Zhang, D. Ly, D. Donahue, A. Hollands, V. Nizet, M. 
Ranson, V. A. Ploplis, M. J. Walker and F. J. Castellino (2013). A key role for the 
urokinase plasminogen activator (uPA) in invasive group A streptococcal infection. 
PLoS Pathogens 9(7): e1003469. 
Sato, J., J. Schorey, V. A. Ploplis, E. Haalboom, L. Krahule and F. J. Castellino 
(2003). The fibrinolytic system in dissemination and matrix protein deposition 
during a mycobacterium infection. American Journal of Pathology 163(2): 517-531. 
Schaiff, W. T. and P. R. Eisenberg (1997). Direct induction of complement 
activation by pharmacologic activation of plasminogen. Coronary Artery Disease 
8:9-18. 
Schmitt, M., L. Goretzki, F. Janicke, J. Calvete, M. Eulitz, H. Kobayashi, N. 
Chucholowski and H. Graeff (1991). Biological and clinical relevance of the 
urokinase-type plasminogen activator (uPA) in breast cancer. Biomedica biochimica 
acta 50(4-6): 731-741. 
Schneider, M. C., R. M. Exley, S. Ram, R. B. Sim and C. M. Tang (2007). 
Interactions between Neisseria meningitidis and the complement system. Trends in 
Microbiology 15(5): 233-240. 
Schuster, V., B. Hugle and K. Tefs (2007). Plasminogen deficiency. Journal of 
Thrombosis and Haemostasis 5(12): 2315-2322. 
Schwartz, B., R. R. Facklam and R. F. Breiman (1990). Changing epidemiology of 
group A streptococcal infection in the USA. Lancet 336(8724): 1167-1171. 
Seya, T. and S. Nagasawa (1985). Limited proteolysis of complement protein C3b 
by regulatory enzyme C3b inactivator: isolation and characterisation of a 
biologically active fragment, C3d,g. Journal of Biochemistry 97(1): 373-382. 
Siemens, N., N. Patenge, J. Otto, T. Fiedler and B. Kreikemeyer (2011). 
Streptococcus pyogenes M49 plasminogen/plasmin binding facilitates keratinocyte 
invasion via integrin-integrin-linked kinase (ILK) pathways and protects from 
macrophage killing. Journal of Biological Chemistry 286(24): 21612-21622. 
Simonsen, S. M., E. R. van Orman, B. E. Hatch, S. S. Jones, L. H. Gren, K. T. 
Hegmann and J. L. Lyon (2006). Cellulitis incidence in a defined population. 
Epidemiology and Infection 134(2): 293-299. 
 
Chapter 7 References 
Page | 162 
 
Sitrin, R. G., R. F. Todd, 3rd, E. Albrecht and M. R. Gyetko (1996). The urokinase 
receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes. 
Journal of Clinical Investigation 97(8): 1942-1951. 
Sjobring, U., G. Pohl and A. Olsen (1994). Plasminogen, absorbed by Escherichia 
coli expressing curli or by Salmonella enteritidis expressing thin aggregative 
fimbriae, can be activated by simultaneously captured tissue-type plasminogen 
activator (t-PA). Molecular Microbiology 14(3): 443-452. 
Smeesters, P. R., P. A. Dreze, D. Perez-Morga, D. Biarent, L. Van Melderen and A. 
Vergison (2010). Group A Streptococcus virulence and host factors in two toddlers 
with rheumatic fever following toxic shock syndrome. International Journal of 
Infectious Diseases 14(5): e403-409. 
Smeesters, P. R., D. J. McMillan, K. S. Sriprakash and M. M. Georgousakis (2009). 
Differences among group A Streptococcus epidemiological landscapes: 
consequences for M protein-based vaccines? Expert Review of Vaccines 8(12): 1705-
1720. 
Smeesters, P. R., A. Vergison, D. Campos, E. de Aguiar, V. Y. Miendje Deyi and L. 
Van Melderen (2006). Differences between Belgian and Brazilian group A 
Streptococcus epidemiologic landscape. PLoS One 1: e10. 
Sodeinde, O. A., Y. V. Subrahmanyam, K. Stark, T. Quan, Y. Bao and J. D. Goguen 
(1992). A surface protease and the invasive character of plague. Science 258(5084): 
1004-1007. 
Staali, L., M. Morgelin, L. Bjorck and H. Tapper (2003). Streptococcus pyogenes 
expressing M and M-like surface proteins are phagocytosed but survive inside 
human neutrophils. Cellular Microbiology 5(4): 253-265. 
Stevens, D. L., M. H. Tanner, J. Winship, R. Swarts, K. M. Ries, P. M. Schlievert 
and E. Kaplan (1989). Severe group A streptococcal infections associated with a 
toxic shock-like syndrome and scarlet fever toxin A. New England Journal of 
Medicine 321(1): 1-7. 
Sumby, P., A. R. Whitney, E. A. Graviss, F. R. DeLeo and J. M. Musser (2006). 
Genome-wide analysis of group a streptococci reveals a mutation that modulates 
global phenotype and disease specificity. PLoS Pathogens 2(1): e5. 
Sun, H. (2006). The interaction between pathogens and the host coagulation system. 
Physiology 21: 281-288. 
Sun, H., U. Ringdahl, J. W. Homeister, W. P. Fay, N. C. Engleberg, A. Y. Yang, L. 
S. Rozek, X. Wang, U. Sjobring and D. Ginsburg (2004). Plasminogen is a critical 
host pathogenicity factor for group A streptococcal infection. Science 305(5688): 
1283-1286. 
Sun, H., X. Wang, J. L. Degen and D. Ginsburg (2009). Reduced thrombin 
generation increases host susceptibility to group A streptococcal infection. Blood 
113(6): 1358-1364. 
 
Chapter 7 References 
Page | 163 
 
Svensson, M. D., U. Sjobring and D. E. Bessen (1999). Selective distribution of a 
high-affinity plasminogen-binding site among group A streptococci associated with 
impetigo. Infection and immunity 67(8): 3915-3920. 
Svensson, M. D., U. Sjobring, F. Luo and D. E. Bessen (2002). Roles of the 
plasminogen activator streptokinase and the plasminogen-associated M protein in an 
experimental model for streptococcal impetigo. Microbiology 148(Pt 12): 3933-
3945. 
Takada, Y. and A. Takada (1989). Evidence for the formation of a trimolecular 
complex between streptokinase, plasminogen and fibrinogen. Thrombosis Research 
53(4): 409-415. 
Tate, K. M., D. L. Higgins, W. E. Holmes, M. E. Winkler, H. L. Heyneker and G. A. 
Vehar (1987). Functional-role of proteolytic cleavage at arginine-275 of human-
tissue plasminogen-activator as assessed by site-directed mutagenesis. Biochemistry 
26(2): 338-343. 
Teesalu, T., A. Kulla, A. Simisker, V. Siren, D. A. Lawrence, T. Asser and A. 
Vaheri (2004). Tissue plasminogen activator and neuroserpin are widely expressed 
in the human central nervous system. Thrombosis and Haemostasis 92(2): 358-368. 
Terao, Y., Y. Mori, M. Yamaguchi, Y. Shimizu, K. Ooe, S. Hamada and S. 
Kawabata (2008). Group A streptococcal cysteine protease degrades C3 (C3b) and 
contributes to evasion of innate immunity. Journal of Biological Chemistry 283(10): 
6253-6260. 
Terao, Y., M. Yamaguchi, S. Hamada and S. Kawabata (2006). Multifunctional 
glyceraldehyde-3-phosphate dehydrogenase of Streptococcus pyogenes is essential 
for evasion from neutrophils. Journal of Biological Chemistry 281(20): 14215-
14223. 
Thern, A., L. Stenberg, B. Dahlback and G. Lindahl (1995). Ig-binding surface 
proteins of Streptococcus pyogenes also bind human C4b-binding protein (C4BP), a 
regulatory component of the complement system. Journal of immunology 154(1): 
375-386. 
Tsao, N., W. H. Tsai, Y. S. Lin, W. J. Chuang, C. H. Wang and C. F. Kuo (2006). 
Streptococcal pyrogenic exotoxin B cleaves properdin and inhibits complement-
mediated opsonophagocytosis. Biochemical and Biophysical Research 
Communications 339(3): 779-784. 
Tsatsaronis, J. A., D. Ly, A. Pupovac, O. Goldmann, M. Rohde, J. M. Taylor, M. J. 
Walker, E. Medina and M. L. Sanderson-Smith (2015). Group A Streptococcus 
modulates host inflammation by manipulating polymorphonuclear leukocyte cell 
death responses. Journal of Innate Immunity 7(6): 612-622. 
Turvey, S. E. and D. H. Broide (2010). Innate immunity. Journal of Allergy And 
Clinical Immunology 125(2 Suppl 2): S24-32. 
 
Chapter 7 References 
Page | 164 
 
Ulisse, S., E. Baldini, S. Sorrenti and M. D'Armiento (2009). The urokinase 
plasminogen activator system: a target for anti-cancer therapy. Current Cancer Drug 
Targets 9(1): 32-71. 
Valery, P. C., M. Wenitong, V. Clements, M. Sheel, D. McMillan, J. Stirling, K. S. 
Sriprakash, M. Batzloff, R. Vohra and J. S. McCarthy (2008). Skin infections among 
Indigenous Australians in an urban setting in far North Queensland. Epidemiology 
and Infection 136(8): 1103-1108. 
Vassalli, J. D., D. Baccino and D. Belin (1985). A cellular binding site for the Mr 
55,000 form of the human plasminogen activator, urokinase. Journal of Cell Biology 
100(1): 86-92. 
Vassalli, J. D. and D. Belin (1987). Amiloride selectively inhibits the urokinase-type 
plasminogen activator. FEBS letters 214(1): 187-191. 
Vassalli, J. D., A. P. Sappino and D. Belin (1991). The plasminogen 
activator/plasmin system. Journal of Clinical Investigation 88(4): 1067-1072. 
Vassalli, J. D., A. Wohlwend and D. Belin (1992). Urokinase-catalyzed plasminogen 
activation at the monocyte/macrophage cell surface: a localised and regulated 
proteolytic system. Current Topics in Microbiology and Immunology 181: 65-86. 
Verheijen, J. H., M. P. Caspers, G. T. Chang, G. A. de Munk, P. H. Pouwels and B. 
E. Enger-Valk (1986). Involvement of finger domain and kringle 2 domain of tissue-
type plasminogen activator in fibrin binding and stimulation of activity by fibrin. 
EMBO journal 5(13): 3525-3530. 
Vidt, D. G. (1981). Mechanism of action, pharmacokinetics, adverse effects, and 
therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic. 
Pharmacotherapy 1(3): 179-187. 
Virkola, R., K. Lähteenmäki , T. Eberhard, P. Kuusela, L. van Alphen, M. Ullberg 
and T. K. Korhonen (1996). Interaction of Haemophilus influenzae with the 
mammalian extracellular matrix. Journal of Infectious Diseases 173(5): 1137-1147. 
Vitali, L. A., C. Zampaloni, M. Prenna and S. Ripa (2002). PCR M typing: a new 
method for rapid typing of group a streptococci. Journal of Clinical Microbiology 
40(2): 679-681. 
von Pawel-Rammingen, U., B. P. Johansson, H. Tapper and L. Bjorck (2002). 
Streptococcus pyogenes and phagocytic killing. Nature Medicine 8(10): 1044-1045. 
Walker, M. J., T. C. Barnett, J. D. McArthur, J. N. Cole, C. M. Gillen, A. 
Henningham, K. S. Sriprakash, M. L. Sanderson-Smith and V. Nizet (2014). Disease 
manifestations and pathogenic mechanisms of group a Streptococcus. Clinical 
Microbiology Reviews 27(2): 264-301. 
Walker, M. J., A. Hollands, M. L. Sanderson-Smith, J. N. Cole, J. K. Kirk, A. 
Henningham, J. D. McArthur, K. Dinkla, R. K. Aziz, R. G. Kansal, A. J. Simpson, J. 
T. Buchanan, G. S. Chhatwal, M. Kotb and V. Nizet (2007). DNase Sda1 provides 
 
Chapter 7 References 
Page | 165 
 
selection pressure for a switch to invasive group A streptococcal infection. Nature 
Medicine 13(8): 981-985. 
Walker, M. J., J. D. McArthur, F. McKay and M. Ranson (2005). Is plasminogen 
deployed as a Streptococcus pyogenes virulence factor? Trends in Microbiology 
13(7): 308-313. 
Wang, H., R. Lottenberg and M. D. Boyle (1995a). Analysis of the interaction of 
group A streptococci with fibrinogen, streptokinase and plasminogen. Microbial 
Pathogenesis 18(3): 153-166. 
Wang, H., R. Lottenberg and M. D. Boyle (1995b). A role for fibrinogen in the 
streptokinase-dependent acquisition of plasmin(ogen) by group A streptococci. 
Journal of Infectious Diseases 171(1): 85-92. 
Wang, X., X. Lin, J. A. Loy, J. Tang and X. C. Zhang (1998). Crystal structure of the 
catalytic domain of human plasmin complexed with streptokinase. Science 
281(5383): 1662-1665. 
Watson, M., M. Neely and M. Caparon (2016). Animal Models of Streptococcus 
pyogenes Infection. Streptococcus pyogenes: Basic Biology to Clinical 
Manifestations. Oklahoma City, University of Oklahoma Health Sciences Center. 
Wessels, M. R. (2011). Clinical practice. Streptococcal pharyngitis. New England 
Journal of Medicine 364(7): 648-655. 
Wessels, M. R., P. Butko, M. Ma, H. B. Warren, A. L. Lage and M. C. Carroll 
(1995). Studies of group B streptococcal infection in mice deficient in complement 
component C3 or C4 demonstrate an essential role for complement in both innate 
and acquired immunity. Proceedings of the National Academy of Sciences of the 
United States of America 92(25): 11490-11494. 
Wexler, D. E. and P. P. Cleary (1985). Purification and characteristics of the 
streptococcal chemotactic factor inactivator. Infection and Immunity 50(3): 757-764. 
WHO (2005). The current evidence for the burden of group A streptococcal diseases. 
WHO report. WHO, Geneva, Switzerland. 
Wiersinga, W. J., J. C. Meijers, M. Levi, C. Van 't Veer, N. P. Day, S. J. Peacock 
and T. van der Poll (2008). Activation of coagulation with concurrent impairment of 
anticoagulant mechanisms correlates with a poor outcome in severe melioidosis. 
Journal of Thrombosis and Haemostasis 6(1): 32-39. 
Winram, S. B. and R. Lottenberg (1996). The plasmin-binding protein Plr of group 
A streptococci is identified as glyceraldehyde-3-phosphate dehydrogenase. 
Microbiology 142(Pt 8): 2311-2320. 
Winram, S. B. and R. Lottenberg (1998). Site-directed mutagenesis of streptococcal 
plasmin receptor protein (Plr) identifies the C-terminal Lys334 as essential for 
plasmin binding, but mutation of the plr gene does not reduce plasmin binding to 
group A streptococci. Microbiology 144 ( Pt 8): 2025-2035. 
 
Chapter 7 References 
Page | 166 
 
Wistedt, A. C., U. Ringdahl, W. Muller-Esterl and U. Sjobring (1995). Identification 
of a plasminogen-binding motif in PAM, a bacterial surface protein. Molecular 
Microbiology 18(3): 569-578. 
Wong, S. S. and K. Y. Yuen (2012). Streptococcus pyogenes and re-emergence of 
scarlet fever as a public health problem. Emerging Microbes and Infections 1(7): e2. 
Wooster, D. G., R. Maruvada, A. M. Blom and N. V. Prasadarao (2006). 
Logarithmic phase Escherichia coli K1 efficiently avoids serum killing by 
promoting C4BP-mediated C3b and C4b degradation. Immunology 117(4): 482-493. 
Yavlovich, A., A. A. R. Higazi and S. Rottem (2001). Plasminogen binding and 
activation by Mycoplasma fermentans. Infection and Immunity 69(4): 1977-1982. 
Yavlovich, A., A. Katzenell, M. Tarshis, A. A. R. Higazi and S. Rottem (2004). 
Mycoplasma fermentans binds to and invades HeLa cells: involvement of 
plasminogen and urokinase. Infection and Immunity 72(9): 5004-5011. 
Zinkernagel, A. S., A. M. Timmer, M. A. Pence, J. B. Locke, J. T. Buchanan, C. E. 
Turner, I. Mishalian, S. Sriskandan, E. Hanski and V. Nizet (2008). The IL-8 
protease SpyCEP/ScpC of group A Streptococcus promotes resistance to neutrophil 
killing. Cell Host and Microbe 4(2): 170-178. 
Zipfel, P. F., J. Hellwage, M. A. Friese, G. Hegasy, S. T. Jokiranta and S. Meri 
(1999). Factor H and disease: a complement regulator affects vital body functions. 
Molecular Immunology 36(4-5): 241-248. 
 
 
Chapter 8 Appendices 
Page | 167 
 
 










Chapter 8 Appendices 
Page | 168 
 
Appendix A: Media, Buffers and Solutions 
Nutrient and growth media 
 Todd-Hewitt broth (THBY) 
Todd Hewitt broth 10 g/L 
Yeast extract 1% (w/v) 
 Todd-Hewitt agar (THYA) 
THY  
Agar  15 g/L 
 Lysogeny-Broth (LB) 
 Tryptone  10 g/L 
 Yeast extract 5 g/L 
 NaCl 10 g/L 
 LB agar 
 LB  
 Agar 15 g/L 
All media was made up to the desired volume in distilled H20. 
Agarose gel electrophoresis 
 1X Tris-acetate-EDTA buffer 
 Tris-base 40 mM 
 Glaciel acetic acid 20 mM 
 EDTA (pH 8.0) 1 mM 
 1 % agarose gel 
 1X TAE buffer 100 mL 
 Agarose LE analytical grade 1% (w/v) 
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 DNA loading dye 
 Bromophenol blue 0.005% (w/v) 
 Glycerol 75% (v/v) 
 1X TAE buffer (pH 8.0) 25% (v/v) 
 Ethidium bromide staining solution 
 Ethidium bromide 1 µg/mL  
SDS-PAGE gel electrophoresis 
 2X Protein cracking buffer 
 Tris-HCl (pH 6.8) 90 mM 
 Glycerol 20% (v/v) 
 SDS 2% (w/v) 
 Bromophenol blue  0.02% (w/v) 
 1X SDS-PAGE running buffer 
 Tris-HCl 25 mM 
 SDS 0.1% (w/v) 
 Glycine 190 mM 
 Coomassie Blue rapid stain 
 Coomassie™ Blue R-250 0.2% (w/v) 
 Glacial acetic acid 10% (v/v) 
 Methanol 40% (v/v) 
 Rapid destain 
Glacial acetic acid 10% (v/v) 
Methanol 40% (v/v) 
 10 % resolving gel 
40 % acrylamide/bis solution (37.5:1) 1.25 mL 
1.5 M Tris-HCl (pH 6.8) 1.25 mL 
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10 % SDS 50 µL 
Distilled H2O 2.4 mL 
N, N, N’, N’ – tetramethylethylenediamine 25 µL 
10 % ammonium persulphate 25 µL 
Components were added in the order as listed above.  
 4 % stacking gel 
40 % acrylamide/bis solution (37.5:1) 225 µL 
0.5 M Tris-HCl (pH 6.8) 600 µL 
10 % SDS 25 µL 
Distilled H2O 1.6 mL 
N, N, N’, N’ – tetramethylethylenediamine 12.5 µL 
10 % ammonium persulphate 12.5 µL 
Components were added in the order as listed above.  
Western transfer  
 Transfer buffer 
Tris-base 23 mM 
Glycine 190 mM 
Methanol 20% (v/v) 
 Developing solution 
Tris-base (pH 7.6) 100 mM 
3,3’-diaminobenzadine tetrahydrochloride hydrate (DAB) 1.4 mM 
Hydrogen peroxide 0.06% (w/v) 
 1X Phosphate buffered saline (PBS) pH 7.4 
NaCl 135 mM (w/v) 
Na2HPO4 10 mM (w/v) 
KCl 2.7 mL (w/v) 
KH2PO4 1.75 mM (w/v) 
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 1X PBS Tween20 (PBST) 
PBS  
Tween-20 0.05% (v/v) 
Enzyme-linked immunosorbent assay (ELISA) 
 Coating buffer 
PBS (pH 8.5) 100 mL 
NaCO3 0.1 M 
 Washing buffer 
PBS 
Tween-20 0.05% (v/v) 
 Blocking buffer 
PBS 
Bovine serum albumin 1% (w/v) 
 Citrate buffer 
Na2HPO4 8 mM 
Adjusted to pH 5.0 with solid citric acid. 
 Substrate solution 
Citrate buffer 50 µL/well 
o-phenylenediamine 0.4% (w/v) 
Hydrogen peroxide 0.4% (v/v) 
Neutrophil phagocytosis assay 
 RPMI 1640 media 
[+] L-glutamine 25 mM 
[+] HEPES 25 mM 
 Trypan blue solution 
NaCl 0.81% (w/v) 
K2HPO4 0.06% (w/v) 
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Histology 
 Sodium citrate buffer pH 6.0 
Tri-sodium citrate (dehydrate) 10 mM 
Tween-20 0.05% (v/v) 
 Tris-buffered saline (TBS) 
Tris 50 mM 
NaCl 13.8 mM 
Tween-20 0.05% (v/v) 
KCl 0.27 mM 
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Figure 8.1 Characterisation of homozygous humanised plasminogen mice. (A) Streptokinase-
mediated plasminogen activation and (B) cell surface plasmin acquisition by NS88.2 in plasma 
collected from AlbPLG+/- (heterozygous; n = 1) and AlbPLG1+/+ (homozygous; n = 2) mice. 
Streptokinase-mediated plasminogen activation data represent the mean ± SD of duplicate assays. 
Cell surface plasmin acquisition data represent the mean ± SEM of two independent experiments 
performed in triplicate. (C) Cohorts of 10 age and sex-matched AlbPLG1+/- or AlbPLG1+/+ mice were 
subcutaneously infected with NS88.2 and the survival monitored over a 10-day period. Asterisks 
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